<?xml version="1.0" encoding="UTF-8"?>
<abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <coredata>
    <prism:url>http://api.elsevier.com/content/abstract/scopus_id/84997859186</prism:url>
    <dc:identifier>SCOPUS_ID:84997859186</dc:identifier>
    <eid>2-s2.0-84997859186</eid>
    <prism:doi>10.1177/2045125314540297</prism:doi>
    <dc:title>The role of long-acting injectable antipsychotics in schizophrenia: A critical appraisal</dc:title>
    <prism:aggregationType>Journal</prism:aggregationType>
    <srctype>j</srctype>
    <citedby-count>3</citedby-count>
    <prism:publicationName>Therapeutic Advances in Psychopharmacology</prism:publicationName>
    <source-id>21100787110</source-id>
    <prism:issn>20451261</prism:issn>
    <prism:volume>4</prism:volume>
    <prism:issueIdentifier>5</prism:issueIdentifier>
    <prism:startingPage>198</prism:startingPage>
    <prism:endingPage>219</prism:endingPage>
    <prism:pageRange>198-219</prism:pageRange>
    <prism:coverDate>2014-01-01</prism:coverDate>
    <dc:creator>
      <author auid="16240939700" seq="1">
        <ce:initials>S.</ce:initials>
        <ce:indexed-name>Brissos S.</ce:indexed-name>
        <ce:surname>Brissos</ce:surname>
        <ce:given-name>Sofia</ce:given-name>
        <preferred-name> <ce:initials>S.</ce:initials> <ce:indexed-name>Brissos S.</ce:indexed-name> <ce:surname>Brissos</ce:surname> <ce:given-name>Sofia</ce:given-name> </preferred-name>
        <author-url>http://api.elsevier.com/content/author/author_id/16240939700</author-url>
        <affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/117758958" id="117758958"/>
      </author>
    </dc:creator>
    <dc:description>
      <abstract original="y" xml:lang="eng"> <ce:para>Despite their widespread use, long-acting injectable (LAI) antipsychotics (APs) are often regarded with some negativity because of the assumption of punishment, control and insufficient evolution towards psychosocial development of patients. However, LAI APs have proved effective in schizophrenia and other severe psychotic disorders because they assure stable blood levels, leading to a reduction of the risk of relapse. Therapeutic opportunities have also arisen after introduction of newer, second-generation LAI APs in recent years. Newer LAI APs are more readily dosed optimally, may be better tolerated and are better suited to integrated rehabilitation programmes. This review outlines the older and newer LAI APs available for the treatment of schizophrenia, with considerations of past and present pharmacological and therapeutic issues. Traditional, evidence-based approaches to systematic reviews and randomized clinical trials are of limited utility in this area so this paper's blending of experimental trials with observational research is particularly appropriate and effective. © 2014, SAGE Publications. All rights reserved.</ce:para> </abstract>
    </dc:description>
    <intid>84997859186</intid>
    <link href="http://api.elsevier.com/content/abstract/scopus_id/84997859186" rel="self"/>
    <link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=84997859186&amp;origin=inward" rel="scopus"/>
    <link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=84997859186&amp;origin=inward" rel="scopus-citedby"/>
  </coredata>
  <affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/117758958" id="117758958">
    <affilname>Psychiatrist</affilname>
    <affiliation-city>Lisbon</affiliation-city>
    <affiliation-country>Portugal</affiliation-country>
  </affiliation>
  <affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60028884" id="60028884">
    <affilname>South London and Maudsley NHS Foundation Trust</affilname>
    <affiliation-city>Beckenham Kent</affiliation-city>
    <affiliation-country>United Kingdom</affiliation-country>
  </affiliation>
  <affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60008561" id="60008561">
    <affilname>Hospital Universitario Dr. Peset</affilname>
    <affiliation-city>Valencia</affiliation-city>
    <affiliation-country>Spain</affiliation-country>
  </affiliation>
  <affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60033267" id="60033267">
    <affilname>Hospital Universitario Virgen del Rocio</affilname>
    <affiliation-city>Sevilla</affiliation-city>
    <affiliation-country>Spain</affiliation-country>
  </affiliation>
  <authors>
    <author auid="16240939700" seq="1">
      <ce:initials>S.</ce:initials>
      <ce:indexed-name>Brissos S.</ce:indexed-name>
      <ce:surname>Brissos</ce:surname>
      <ce:given-name>Sofia</ce:given-name>
      <preferred-name> <ce:initials>S.</ce:initials> <ce:indexed-name>Brissos S.</ce:indexed-name> <ce:surname>Brissos</ce:surname> <ce:given-name>Sofia</ce:given-name> </preferred-name>
      <author-url>http://api.elsevier.com/content/author/author_id/16240939700</author-url>
      <affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/117758958" id="117758958"/>
    </author>
    <author auid="36633645300" seq="2">
      <ce:initials>M.R.</ce:initials>
      <ce:indexed-name>Veguilla M.R.</ce:indexed-name>
      <ce:surname>Veguilla</ce:surname>
      <ce:given-name>Miguel Ruiz</ce:given-name>
      <preferred-name> <ce:initials>M.R.</ce:initials> <ce:indexed-name>Veguilla M.</ce:indexed-name> <ce:surname>Veguilla</ce:surname> <ce:given-name>Miguel Ruiz</ce:given-name> </preferred-name>
      <author-url>http://api.elsevier.com/content/author/author_id/36633645300</author-url>
      <affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60033267" id="60033267"/>
    </author>
    <author auid="55574206575" seq="3">
      <ce:initials>D.</ce:initials>
      <ce:indexed-name>Taylor D.</ce:indexed-name>
      <ce:surname>Taylor</ce:surname>
      <ce:given-name>David</ce:given-name>
      <preferred-name> <ce:initials>D.</ce:initials> <ce:indexed-name>Taylor D.</ce:indexed-name> <ce:surname>Taylor</ce:surname> <ce:given-name>David</ce:given-name> </preferred-name>
      <author-url>http://api.elsevier.com/content/author/author_id/55574206575</author-url>
      <affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60028884" id="60028884"/>
    </author>
    <author auid="12760426100" seq="4">
      <ce:initials>V.</ce:initials>
      <ce:indexed-name>Balanza-Martinez V.</ce:indexed-name>
      <ce:surname>Balanzá-Martinez</ce:surname>
      <ce:given-name>Vicent</ce:given-name>
      <preferred-name> <ce:initials>V.</ce:initials> <ce:indexed-name>Balanzá-Martinez V.</ce:indexed-name> <ce:surname>Balanzá-Martinez</ce:surname> <ce:given-name>Vicent</ce:given-name> </preferred-name>
      <author-url>http://api.elsevier.com/content/author/author_id/12760426100</author-url>
      <affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60008561" id="60008561"/>
    </author>
  </authors>
  <language xml:lang="eng"/>
  <authkeywords>
    <author-keyword>adherence</author-keyword>
    <author-keyword>atypical</author-keyword>
    <author-keyword>clinical trial</author-keyword>
    <author-keyword>depot</author-keyword>
    <author-keyword>history</author-keyword>
    <author-keyword>long-acting injections</author-keyword>
    <author-keyword>pharmacology</author-keyword>
    <author-keyword>treatment</author-keyword>
    <author-keyword>typical</author-keyword>
  </authkeywords>
  <idxterms/>
  <subject-areas>
    <subject-area abbrev="PHAR" code="3001">Pharmacology, Toxicology and Pharmaceutics (miscellaneous)</subject-area>
    <subject-area abbrev="PSYC" code="3201">Psychology (miscellaneous)</subject-area>
  </subject-areas>
  <item xmlns="">
    <ait:process-info>
      <ait:date-delivered day="26" month="12" timestamp="2016-12-26T03:29:03.000003+00:00" year="2016"/>
      <ait:date-sort day="01" month="01" year="2014"/>
      <ait:status stage="S300" state="update" type="core"/>
    </ait:process-info>
    <bibrecord>
      <item-info>
        <copyright type="Elsevier">Copyright 2016 Elsevier B.V., All rights reserved.</copyright>
        <itemidlist> <ce:doi>10.1177/2045125314540297</ce:doi> <itemid idtype="PUI">402673237</itemid> <itemid idtype="ARCSA2">20150002673238</itemid> <itemid idtype="CAR-ID">657493469</itemid> <itemid idtype="SCP">84997859186</itemid> <itemid idtype="SGR">84997859186</itemid> </itemidlist>
        <history> <date-created day="29" month="10" timestamp="BST 17:53:00" year="2016"/> </history>
        <dbcollection>ARCSA2</dbcollection>
        <dbcollection>ElsevierApibase</dbcollection>
      </item-info>
      <head>
        <citation-info>
          <citation-type code="re"/>
          <citation-language language="English" xml:lang="eng"/>
          <abstract-language language="English" xml:lang="eng"/>
          <author-keywords> <author-keyword>adherence</author-keyword> <author-keyword>atypical</author-keyword> <author-keyword>clinical trial</author-keyword> <author-keyword>depot</author-keyword> <author-keyword>history</author-keyword> <author-keyword>long-acting injections</author-keyword> <author-keyword>pharmacology</author-keyword> <author-keyword>treatment</author-keyword> <author-keyword>typical</author-keyword> </author-keywords>
        </citation-info>
        <citation-title>
          <titletext language="English" original="y" xml:lang="eng">The role of long-acting injectable antipsychotics in schizophrenia: A critical appraisal</titletext>
        </citation-title>
        <author-group>
          <author auid="16240939700" seq="1" type="auth"> <ce:initials>S.</ce:initials> <ce:indexed-name>Brissos S.</ce:indexed-name> <ce:surname>Brissos</ce:surname> <ce:given-name>Sofia</ce:given-name> <preferred-name> <ce:initials>S.</ce:initials> <ce:indexed-name>Brissos S.</ce:indexed-name> <ce:surname>Brissos</ce:surname> <ce:given-name>Sofia</ce:given-name> </preferred-name> </author>
          <affiliation afid="117758958" country="prt" dptid="117759593">
            <organization>Psychiatrist</organization>
            <organization>Lisbon's Psychiatric Hospitalar Centre</organization>
            <address-part>Rua Conde de Redondo, nº 8 3º dt.</address-part>
            <city-group>Lisbon, 1150</city-group>
            <country>Portugal</country>
          </affiliation>
        </author-group>
        <author-group>
          <author auid="36633645300" seq="2" type="auth"> <ce:initials>M.R.</ce:initials> <ce:indexed-name>Veguilla M.R.</ce:indexed-name> <ce:surname>Veguilla</ce:surname> <ce:given-name>Miguel Ruiz</ce:given-name> <preferred-name> <ce:initials>M.R.</ce:initials> <ce:indexed-name>Veguilla M.</ce:indexed-name> <ce:surname>Veguilla</ce:surname> <ce:given-name>Miguel Ruiz</ce:given-name> </preferred-name> </author>
          <affiliation afid="60033267" country="esp" dptid="113340859">
            <organization>Grupo Psicosis y Neurodesarrollo</organization>
            <organization>Instituto de Biomedicina de Sevilla (IBIS)</organization>
            <organization>Hospital Universitario Virgen del Rocio /CSIC/Universidad de Sevilla</organization>
            <organization>Unidad de Hospitalizacion de Salud Mental</organization>
            <city-group>Sevilla</city-group>
            <country>Spain</country>
          </affiliation>
        </author-group>
        <author-group>
          <author auid="55574206575" seq="3" type="auth"> <ce:initials>D.</ce:initials> <ce:indexed-name>Taylor D.</ce:indexed-name> <ce:surname>Taylor</ce:surname> <ce:given-name>David</ce:given-name> <preferred-name> <ce:initials>D.</ce:initials> <ce:indexed-name>Taylor D.</ce:indexed-name> <ce:surname>Taylor</ce:surname> <ce:given-name>David</ce:given-name> </preferred-name> </author>
          <affiliation afid="60028884" country="gbr" dptid="105937209">
            <organization>South London and Maudsley NHS Foundation Trust</organization>
            <organization>Pharmacy Department</organization>
            <organization>Maudsley Hospital</organization>
            <organization>Denmark Hill</organization>
            <city-group>London</city-group>
            <country>United Kingdom</country>
          </affiliation>
        </author-group>
        <author-group>
          <author auid="12760426100" seq="4" type="auth"> <ce:initials>V.</ce:initials> <ce:indexed-name>Balanza-Martinez V.</ce:indexed-name> <ce:surname>Balanzá-Martinez</ce:surname> <ce:given-name>Vicent</ce:given-name> <preferred-name> <ce:initials>V.</ce:initials> <ce:indexed-name>Balanzá-Martinez V.</ce:indexed-name> <ce:surname>Balanzá-Martinez</ce:surname> <ce:given-name>Vicent</ce:given-name> </preferred-name> </author>
          <affiliation afid="60008561" country="esp" dptid="117759703">
            <organization>Catarroja Mental Health Unit</organization>
            <organization>University Hospital Doctor Peset</organization>
            <organization>FISABIO</organization>
            <organization>Section of Psychiatry</organization>
            <organization>University of Valencia</organization>
            <organization>CIBERSAM</organization>
            <city-group>Valencia</city-group>
            <country>Spain</country>
          </affiliation>
        </author-group>
        <abstracts>
          <abstract original="y" xml:lang="eng"> <ce:para>Despite their widespread use, long-acting injectable (LAI) antipsychotics (APs) are often regarded with some negativity because of the assumption of punishment, control and insufficient evolution towards psychosocial development of patients. However, LAI APs have proved effective in schizophrenia and other severe psychotic disorders because they assure stable blood levels, leading to a reduction of the risk of relapse. Therapeutic opportunities have also arisen after introduction of newer, second-generation LAI APs in recent years. Newer LAI APs are more readily dosed optimally, may be better tolerated and are better suited to integrated rehabilitation programmes. This review outlines the older and newer LAI APs available for the treatment of schizophrenia, with considerations of past and present pharmacological and therapeutic issues. Traditional, evidence-based approaches to systematic reviews and randomized clinical trials are of limited utility in this area so this paper's blending of experimental trials with observational research is particularly appropriate and effective. © 2014, SAGE Publications. All rights reserved.</ce:para> </abstract>
        </abstracts>
        <source srcid="21100787110" type="j">
          <sourcetitle>Therapeutic Advances in Psychopharmacology</sourcetitle>
          <sourcetitle-abbrev>Ther. Adv. Psychopharmacol.</sourcetitle-abbrev>
          <issn type="electronic">20451261</issn>
          <issn type="print">20451253</issn>
          <volisspag> <voliss issue="5" volume="4"/> <pagerange first="198" last="219"/> </volisspag>
          <publicationyear first="2014"/>
          <publicationdate> <year>2014</year> <date-text>October 2014</date-text> </publicationdate>
        </source>
        <enhancement>
          <classificationgroup>
            <classifications type="ASJC"> <classification>3001</classification> <classification>3201</classification> </classifications>
            <classifications type="SUBJABBR">
              <classification>PHAR</classification>
              <classification>PSYC</classification>
            </classifications>
          </classificationgroup>
        </enhancement>
      </head>
      <tail>
        <bibliography refcount="196"> <reference id="1"> <ref-info> <ref-title> <ref-titletext>The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84877010165</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>E.</ce:initials> <ce:indexed-name>Achilla E.</ce:indexed-name> <ce:surname>Achilla</ce:surname> </author> <author seq="2"> <ce:initials>P.</ce:initials> <ce:indexed-name>McCrone P.</ce:indexed-name> <ce:surname>McCrone</ce:surname> </author> </ref-authors> <ref-sourcetitle>Appl Health Econ Health Policy</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="11"/> <pagerange first="95" last="106"/> </ref-volisspag> </ref-info> <ref-fulltext>Achilla E. McCrone P. (2013) The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations. Appl Health Econ Health Policy 11: 95–106</ref-fulltext> </reference> <reference id="2"> <ref-info> <ref-title> <ref-titletext>Systematic meta-review of depot antipsychotic drugs for people with schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0034776721</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>C.</ce:initials> <ce:indexed-name>Adams C.</ce:indexed-name> <ce:surname>Adams</ce:surname> </author> <author seq="2"> <ce:initials>M.</ce:initials> <ce:indexed-name>Fenton M.</ce:indexed-name> <ce:surname>Fenton</ce:surname> </author> <author seq="3"> <ce:initials>S.</ce:initials> <ce:indexed-name>Quairashi S.</ce:indexed-name> <ce:surname>Quairashi</ce:surname> </author> <author seq="4"> <ce:initials>A.</ce:initials> <ce:indexed-name>David A.</ce:indexed-name> <ce:surname>David</ce:surname> </author> </ref-authors> <ref-sourcetitle>Br J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2001"/> <ref-volisspag> <voliss volume="179"/> <pagerange first="290" last="299"/> </ref-volisspag> </ref-info> <ref-fulltext>Adams C. Fenton M. Quairashi S. David A. (2001) Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 179: 290–299.</ref-fulltext> </reference> <reference id="3"> <ref-info> <ref-title> <ref-titletext>Update on the use of MR for assessment and diagnosis of psychiatric diseases</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">77950397233</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>N.</ce:initials> <ce:indexed-name>Agarwal N.</ce:indexed-name> <ce:surname>Agarwal</ce:surname> </author> <author seq="2"> <ce:initials>J.</ce:initials> <ce:indexed-name>Port J.</ce:indexed-name> <ce:surname>Port</ce:surname> </author> <author seq="3"> <ce:initials>M.</ce:initials> <ce:indexed-name>Bazzocchi M.</ce:indexed-name> <ce:surname>Bazzocchi</ce:surname> </author> <author seq="4"> <ce:initials>P.</ce:initials> <ce:indexed-name>Renshaw P.</ce:indexed-name> <ce:surname>Renshaw</ce:surname> </author> </ref-authors> <ref-sourcetitle>Radiology</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <voliss volume="255"/> <pagerange first="23" last="41"/> </ref-volisspag> </ref-info> <ref-fulltext>Agarwal N. Port J. Bazzocchi M. Renshaw P. (2010) Update on the use of MR for assessment and diagnosis of psychiatric diseases. Radiology 255: 23–41.</ref-fulltext> </reference> <reference id="4"> <ref-info> <ref-title> <ref-titletext>Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">77956575798</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>O.</ce:initials> <ce:indexed-name>Agid O.</ce:indexed-name> <ce:surname>Agid</ce:surname> </author> <author seq="2"> <ce:initials>G.</ce:initials> <ce:indexed-name>Foussias G.</ce:indexed-name> <ce:surname>Foussias</ce:surname> </author> <author seq="3"> <ce:initials>G.</ce:initials> <ce:indexed-name>Remington G.</ce:indexed-name> <ce:surname>Remington</ce:surname> </author> </ref-authors> <ref-sourcetitle>Expert Opin Pharmacother</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <voliss volume="11"/> <pagerange first="2301" last="2317"/> </ref-volisspag> </ref-info> <ref-fulltext>Agid O. Foussias G. Remington G. (2010) Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacother 11: 2301–2317.</ref-fulltext> </reference> <reference id="5"> <ref-info> <ref-title> <ref-titletext>Relapse in schizophrenia: costs, clinical outcomes and quality of life</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">1842866942</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>S.</ce:initials> <ce:indexed-name>Almond S.</ce:indexed-name> <ce:surname>Almond</ce:surname> </author> <author seq="2"> <ce:initials>M.</ce:initials> <ce:indexed-name>Knapp M.</ce:indexed-name> <ce:surname>Knapp</ce:surname> </author> <author seq="3"> <ce:initials>C.</ce:initials> <ce:indexed-name>Francois C.</ce:indexed-name> <ce:surname>Francois</ce:surname> </author> <author seq="4"> <ce:initials>M.</ce:initials> <ce:indexed-name>Toumi M.</ce:indexed-name> <ce:surname>Toumi</ce:surname> </author> <author seq="5"> <ce:initials>T.</ce:initials> <ce:indexed-name>Brugha T.</ce:indexed-name> <ce:surname>Brugha</ce:surname> </author> </ref-authors> <ref-sourcetitle>Br J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2004"/> <ref-volisspag> <voliss volume="184"/> <pagerange first="346" last="351"/> </ref-volisspag> </ref-info> <ref-fulltext>Almond S. Knapp M. Francois C. Toumi M. Brugha T. (2004) Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 184: 346–351.</ref-fulltext> </reference> <reference id="6"> <ref-info> <ref-title> <ref-titletext>Rethinking the role of long-acting atypical antipsychotics in the community setting</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84867015675</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>A.</ce:initials> <ce:indexed-name>Altamura A.</ce:indexed-name> <ce:surname>Altamura</ce:surname> </author> <author seq="2"> <ce:initials>E.</ce:initials> <ce:indexed-name>Aguglia E.</ce:indexed-name> <ce:surname>Aguglia</ce:surname> </author> <author seq="3"> <ce:initials>M.</ce:initials> <ce:indexed-name>Bassi M.</ce:indexed-name> <ce:surname>Bassi</ce:surname> </author> <author seq="4"> <ce:initials>F.</ce:initials> <ce:indexed-name>Bogetto F.</ce:indexed-name> <ce:surname>Bogetto</ce:surname> </author> <author seq="5"> <ce:initials>L.</ce:initials> <ce:indexed-name>Cappellari L.</ce:indexed-name> <ce:surname>Cappellari</ce:surname> </author> <author seq="6"> <ce:initials>S.</ce:initials> <ce:indexed-name>De Giorgi S.</ce:indexed-name> <ce:surname>De Giorgi</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Int Clin Psychopharmacol</ref-sourcetitle> <ref-publicationyear first="2012"/> <ref-volisspag> <voliss volume="27"/> <pagerange first="336" last="349"/> </ref-volisspag> </ref-info> <ref-fulltext>Altamura A. Aguglia E. Bassi M. Bogetto F. Cappellari L. De Giorgi S. et al. (2012) Rethinking the role of long-acting atypical antipsychotics in the community setting. Int Clin Psychopharmacol 27: 336–349.</ref-fulltext> </reference> <reference id="7"> <ref-info> <ref-title> <ref-titletext>Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">44949155699</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Alvarez-Jimenez M.</ce:indexed-name> <ce:surname>Alvarez-Jiménez</ce:surname> </author> <author seq="2"> <ce:initials>C.</ce:initials> <ce:indexed-name>Gonzalez-Blanch C.</ce:indexed-name> <ce:surname>González-Blanch</ce:surname> </author> <author seq="3"> <ce:initials>B.</ce:initials> <ce:indexed-name>Crespo-Facorro B.</ce:indexed-name> <ce:surname>Crespo-Facorro</ce:surname> </author> <author seq="4"> <ce:initials>S.</ce:initials> <ce:indexed-name>Hetrick S.</ce:indexed-name> <ce:surname>Hetrick</ce:surname> </author> <author seq="5"> <ce:initials>J.</ce:initials> <ce:indexed-name>Rodriguez-Sanchez J.</ce:indexed-name> <ce:surname>Rodríguez-Sánchez</ce:surname> </author> <author seq="6"> <ce:initials>R.</ce:initials> <ce:indexed-name>Perez-Iglesias R.</ce:indexed-name> <ce:surname>Pérez-Iglesias</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>CNS Drugs</ref-sourcetitle> <ref-publicationyear first="2008"/> <ref-volisspag> <voliss volume="22"/> <pagerange first="547" last="562"/> </ref-volisspag> </ref-info> <ref-fulltext>Alvarez-Jiménez M. González-Blanch C. Crespo-Facorro B. Hetrick S. Rodríguez-Sánchez J. Pérez-Iglesias R. et al. (2008) Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 22: 547–562.</ref-fulltext> </reference> <reference id="8"> <ref-info> <ref-title> <ref-titletext>Remission in schizophrenia: proposed criteria and rationale for consensus</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">14844334624</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>N.</ce:initials> <ce:indexed-name>Andreasen N.</ce:indexed-name> <ce:surname>Andreasen</ce:surname> </author> <author seq="2"> <ce:initials>W.</ce:initials> <ce:indexed-name>Carpenter W.</ce:indexed-name> <ce:surname>Carpenter</ce:surname> <ce:suffix>Jr.</ce:suffix> </author> <author seq="3"> <ce:initials>J.</ce:initials> <ce:indexed-name>Kane J.</ce:indexed-name> <ce:surname>Kane</ce:surname> </author> <author seq="4"> <ce:initials>R.</ce:initials> <ce:indexed-name>Lasser R.</ce:indexed-name> <ce:surname>Lasser</ce:surname> </author> <author seq="5"> <ce:initials>S.</ce:initials> <ce:indexed-name>Marder S.</ce:indexed-name> <ce:surname>Marder</ce:surname> </author> <author seq="6"> <ce:initials>D.</ce:initials> <ce:indexed-name>Weinburger D.</ce:indexed-name> <ce:surname>Weinburger</ce:surname> </author> </ref-authors> <ref-sourcetitle>Am J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2005"/> <ref-volisspag> <voliss volume="162"/> <pagerange first="441" last="449"/> </ref-volisspag> </ref-info> <ref-fulltext>Andreasen N. Carpenter W. Jr. Kane J. Lasser R. Marder S. Weinburger D. (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162: 441–449.</ref-fulltext> </reference> <reference id="9"> <ref-info> <ref-title> <ref-titletext>Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">34548560603</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>Y.</ce:initials> <ce:indexed-name>Bai Y.</ce:indexed-name> <ce:surname>Bai</ce:surname> </author> <author seq="2"> <ce:initials>T.</ce:initials> <ce:indexed-name>Ting Chen T.</ce:indexed-name> <ce:surname>Ting Chen</ce:surname> </author> <author seq="3"> <ce:initials>J.</ce:initials> <ce:indexed-name>Chen J.</ce:indexed-name> <ce:surname>Chen</ce:surname> </author> <author seq="4"> <ce:initials>W.</ce:initials> <ce:indexed-name>Chang W.</ce:indexed-name> <ce:surname>Chang</ce:surname> </author> <author seq="5"> <ce:initials>B.</ce:initials> <ce:indexed-name>Wu B.</ce:indexed-name> <ce:surname>Wu</ce:surname> </author> <author seq="6"> <ce:initials>C.</ce:initials> <ce:indexed-name>Hung C.</ce:indexed-name> <ce:surname>Hung</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="2007"/> <ref-volisspag> <voliss volume="68"/> <pagerange first="1218" last="1225"/> </ref-volisspag> </ref-info> <ref-fulltext>Bai Y. Ting Chen T. Chen J. Chang W. Wu B. Hung C. et al. (2007) Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry 68: 1218–1225.</ref-fulltext> </reference> <reference id="10"> <ref-info> <ref-title> <ref-titletext>Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">80052438410</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>G.</ce:initials> <ce:indexed-name>Bartzokis G.</ce:indexed-name> <ce:surname>Bartzokis</ce:surname> </author> <author seq="2"> <ce:initials>P.</ce:initials> <ce:indexed-name>Lu P.</ce:indexed-name> <ce:surname>Lu</ce:surname> </author> <author seq="3"> <ce:initials>P.</ce:initials> <ce:indexed-name>Amar P.</ce:indexed-name> <ce:surname>Amar</ce:surname> </author> <author seq="4"> <ce:initials>E.</ce:initials> <ce:indexed-name>Raven E.</ce:indexed-name> <ce:surname>Raven</ce:surname> </author> <author seq="5"> <ce:initials>N.</ce:initials> <ce:indexed-name>Detore N.</ce:indexed-name> <ce:surname>Detore</ce:surname> </author> <author seq="6"> <ce:initials>L.</ce:initials> <ce:indexed-name>Altshuler L.</ce:indexed-name> <ce:surname>Altshuler</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Schizophr Res</ref-sourcetitle> <ref-publicationyear first="2011"/> <ref-volisspag> <voliss volume="132"/> <pagerange first="35" last="41"/> </ref-volisspag> </ref-info> <ref-fulltext>Bartzokis G. Lu P. Amar P. Raven E. Detore N. Altshuler L. et al. (2011) Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. Schizophr Res 132: 35–41.</ref-fulltext> </reference> <reference id="11"> <ref-info> <ref-title> <ref-titletext>Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84865322948</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>G.</ce:initials> <ce:indexed-name>Bartzokis G.</ce:indexed-name> <ce:surname>Bartzokis</ce:surname> </author> <author seq="2"> <ce:initials>P.</ce:initials> <ce:indexed-name>Lu P.</ce:indexed-name> <ce:surname>Lu</ce:surname> </author> <author seq="3"> <ce:initials>E.</ce:initials> <ce:indexed-name>Raven E.</ce:indexed-name> <ce:surname>Raven</ce:surname> </author> <author seq="4"> <ce:initials>C.</ce:initials> <ce:indexed-name>Amar C.</ce:indexed-name> <ce:surname>Amar</ce:surname> </author> <author seq="5"> <ce:initials>N.</ce:initials> <ce:indexed-name>Detore N.</ce:indexed-name> <ce:surname>Detore</ce:surname> </author> <author seq="6"> <ce:initials>A.</ce:initials> <ce:indexed-name>Couvrette A.</ce:indexed-name> <ce:surname>Couvrette</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Schizophr Res</ref-sourcetitle> <ref-publicationyear first="2012"/> <ref-volisspag> <voliss volume="140"/> <pagerange first="122" last="128"/> </ref-volisspag> </ref-info> <ref-fulltext>Bartzokis G. Lu P. Raven E. Amar C. Detore N. Couvrette A. et al. (2012) Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia. Schizophr Res 140: 122–128.</ref-fulltext> </reference> <reference id="12"> <ref-info> <ref-title> <ref-titletext>Early intervention in psychosis. The critical period hypothesis</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0031807922</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Birchwood M.</ce:indexed-name> <ce:surname>Birchwood</ce:surname> </author> <author seq="2"> <ce:initials>P.</ce:initials> <ce:indexed-name>Todd P.</ce:indexed-name> <ce:surname>Todd</ce:surname> </author> <author seq="3"> <ce:initials>C.</ce:initials> <ce:indexed-name>Jackson C.</ce:indexed-name> <ce:surname>Jackson</ce:surname> </author> </ref-authors> <ref-sourcetitle>Br J Psychiatry Suppl</ref-sourcetitle> <ref-publicationyear first="1998"/> <ref-volisspag> <voliss volume="172"/> <pagerange first="53" last="59"/> </ref-volisspag> </ref-info> <ref-fulltext>Birchwood M. Todd P. Jackson C. (1998) Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl 172: 53–59.</ref-fulltext> </reference> <reference id="13"> <ref-info> <ref-title> <ref-titletext>Antipsychotic prophylaxis is needed sfter remission from a first episode psychotic episode in schizophrenia patients: results from an aborted randomised trial</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">79955753989</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>G.</ce:initials> <ce:indexed-name>Boonstra G.</ce:indexed-name> <ce:surname>Boonstra</ce:surname> </author> <author seq="2"> <ce:initials>H.</ce:initials> <ce:indexed-name>Burger H.</ce:indexed-name> <ce:surname>Burger</ce:surname> </author> <author seq="3"> <ce:initials>D.</ce:initials> <ce:indexed-name>Grobbee D.</ce:indexed-name> <ce:surname>Grobbee</ce:surname> </author> <author seq="4"> <ce:initials>R.</ce:initials> <ce:indexed-name>Kahn R.</ce:indexed-name> <ce:surname>Kahn</ce:surname> </author> </ref-authors> <ref-sourcetitle>Int J Psychiatry Clin Pract</ref-sourcetitle> <ref-publicationyear first="2011"/> <ref-volisspag> <voliss volume="15"/> <pagerange first="128" last="134"/> </ref-volisspag> </ref-info> <ref-fulltext>Boonstra G. Burger H. Grobbee D. Kahn R. (2011) Antipsychotic prophylaxis is needed sfter remission from a first episode psychotic episode in schizophrenia patients: results from an aborted randomised trial. Int J Psychiatry Clin Pract 15: 128–134.</ref-fulltext> </reference> <reference id="14"> <ref-info> <ref-title> <ref-titletext>Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">79957977497</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>S.</ce:initials> <ce:indexed-name>Brissos S.</ce:indexed-name> <ce:surname>Brissos</ce:surname> </author> <author seq="2"> <ce:initials>V.</ce:initials> <ce:indexed-name>Dias V.</ce:indexed-name> <ce:surname>Dias</ce:surname> </author> <author seq="3"> <ce:initials>V.</ce:initials> <ce:indexed-name>Balanza-Martinez V.</ce:indexed-name> <ce:surname>Balanzá-Martinez</ce:surname> </author> <author seq="4"> <ce:initials>A.</ce:initials> <ce:indexed-name>Carita A.</ce:indexed-name> <ce:surname>Carita</ce:surname> </author> <author seq="5"> <ce:initials>M.</ce:initials> <ce:indexed-name>Figueira M.</ce:indexed-name> <ce:surname>Figueira</ce:surname> </author> </ref-authors> <ref-sourcetitle>Schizophr Res</ref-sourcetitle> <ref-publicationyear first="2011"/> <ref-volisspag> <voliss volume="129"/> <pagerange first="133" last="136"/> </ref-volisspag> </ref-info> <ref-fulltext>Brissos S. Dias V. Balanzá-Martinez V. Carita A. Figueira M. (2011) Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance. Schizophr Res 129: 133–136.</ref-fulltext> </reference> <reference id="15"> <ref-info> <ref-title> <ref-titletext>Proton magnetic resonance spectroscopy and illness stage in schizophrenia–a systematic review and meta-analysis</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">79951682529</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>S.</ce:initials> <ce:indexed-name>Brugger S.</ce:indexed-name> <ce:surname>Brugger</ce:surname> </author> <author seq="2"> <ce:initials>J.</ce:initials> <ce:indexed-name>Davis J.</ce:indexed-name> <ce:surname>Davis</ce:surname> </author> <author seq="3"> <ce:initials>S.</ce:initials> <ce:indexed-name>Leucht S.</ce:indexed-name> <ce:surname>Leucht</ce:surname> </author> <author seq="4"> <ce:initials>J.</ce:initials> <ce:indexed-name>Stone J.</ce:indexed-name> <ce:surname>Stone</ce:surname> </author> </ref-authors> <ref-sourcetitle>Biol Psychiatry</ref-sourcetitle> <ref-publicationyear first="2011"/> <ref-volisspag> <voliss volume="69"/> <pagerange first="495" last="503"/> </ref-volisspag> </ref-info> <ref-fulltext>Brugger S. Davis J. Leucht S. Stone J. (2011) Proton magnetic resonance spectroscopy and illness stage in schizophrenia–a systematic review and meta-analysis. Biol Psychiatry 69: 495–503.</ref-fulltext> </reference> <reference id="16"> <ref-info> <ref-title> <ref-titletext>Clinical practice guidelines. Treatment of schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">33645458077</itemid> </refd-itemidlist> <ref-authors> <collaboration seq="1"> <ce:indexed-name>Canadian Psychiatric Association</ce:indexed-name> <ce:text>Canadian Psychiatric Association</ce:text> </collaboration> </ref-authors> <ref-sourcetitle>Can J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2005"/> <ref-volisspag> <voliss issue="13" volume="50"/> <pagerange first="7" last="57"/> </ref-volisspag> </ref-info> <ref-fulltext>Canadian Psychiatric Association (2005) Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry 50(13 Suppl. 1): 7–57.</ref-fulltext> </reference> <reference id="17"> <ref-info> <ref-title> <ref-titletext>Opinions of French patients with schizophrenia regarding injectable medication</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84863222170</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>F.</ce:initials> <ce:indexed-name>Caroli F.</ce:indexed-name> <ce:surname>Caroli</ce:surname> </author> <author seq="2"> <ce:initials>P.</ce:initials> <ce:indexed-name>Raymondet P.</ce:indexed-name> <ce:surname>Raymondet</ce:surname> </author> <author seq="3"> <ce:initials>I.</ce:initials> <ce:indexed-name>Izard I.</ce:indexed-name> <ce:surname>Izard</ce:surname> </author> <author seq="4"> <ce:initials>J.</ce:initials> <ce:indexed-name>Plas J.</ce:indexed-name> <ce:surname>Plas</ce:surname> </author> <author seq="5"> <ce:initials>B.</ce:initials> <ce:indexed-name>Gall B.</ce:indexed-name> <ce:surname>Gall</ce:surname> </author> <author seq="6"> <ce:initials>A.</ce:initials> <ce:indexed-name>Delgado A.</ce:indexed-name> <ce:surname>Delgado</ce:surname> </author> </ref-authors> <ref-sourcetitle>Patient Prefer Adherence</ref-sourcetitle> <ref-publicationyear first="2011"/> <ref-volisspag> <voliss volume="5"/> <pagerange first="165" last="171"/> </ref-volisspag> </ref-info> <ref-fulltext>Caroli F. Raymondet P. Izard I. Plas J. Gall B. Delgado A. (2011) Opinions of French patients with schizophrenia regarding injectable medication. Patient Prefer Adherence 5: 165–171.</ref-fulltext> </reference> <reference id="18"> <ref-info> <ref-title> <ref-titletext>Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0028856570</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>A.</ce:initials> <ce:indexed-name>Chatterjee A.</ce:indexed-name> <ce:surname>Chatterjee</ce:surname> </author> <author seq="2"> <ce:initials>M.</ce:initials> <ce:indexed-name>Chakos M.</ce:indexed-name> <ce:surname>Chakos</ce:surname> </author> <author seq="3"> <ce:initials>A.</ce:initials> <ce:indexed-name>Koreen A.</ce:indexed-name> <ce:surname>Koreen</ce:surname> </author> <author seq="4"> <ce:initials>S.</ce:initials> <ce:indexed-name>Geisler S.</ce:indexed-name> <ce:surname>Geisler</ce:surname> </author> <author seq="5"> <ce:initials>B.</ce:initials> <ce:indexed-name>Sheitman B.</ce:indexed-name> <ce:surname>Sheitman</ce:surname> </author> <author seq="6"> <ce:initials>M.</ce:initials> <ce:indexed-name>Woerner M.</ce:indexed-name> <ce:surname>Woerner</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Am J Psychiatry</ref-sourcetitle> <ref-publicationyear first="1995"/> <ref-volisspag> <voliss volume="152"/> <pagerange first="1724" last="1729"/> </ref-volisspag> </ref-info> <ref-fulltext>Chatterjee A. Chakos M. Koreen A. Geisler S. Sheitman B. Woerner M. et al. (1995) Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 152: 1724–1729.</ref-fulltext> </reference> <reference id="19"> <ref-info> <ref-title> <ref-titletext>Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: random controlled trial</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84859002685</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>E.</ce:initials> <ce:indexed-name>Chen E.</ce:indexed-name> <ce:surname>Chen</ce:surname> </author> <author seq="2"> <ce:initials>C.</ce:initials> <ce:indexed-name>Hui C.</ce:indexed-name> <ce:surname>Hui</ce:surname> </author> <author seq="3"> <ce:initials>M.</ce:initials> <ce:indexed-name>Lam M.</ce:indexed-name> <ce:surname>Lam</ce:surname> </author> <author seq="4"> <ce:initials>C.</ce:initials> <ce:indexed-name>Chiu C.</ce:indexed-name> <ce:surname>Chiu</ce:surname> </author> <author seq="5"> <ce:initials>C.</ce:initials> <ce:indexed-name>Law C.</ce:indexed-name> <ce:surname>Law</ce:surname> </author> <author seq="6"> <ce:initials>D.</ce:initials> <ce:indexed-name>Chung D.</ce:indexed-name> <ce:surname>Chung</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>BMJ</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <voliss volume="19"/> <pagerange first="c4024"/> </ref-volisspag> </ref-info> <ref-fulltext>Chen E. Hui C. Lam M. Chiu C. Law C. Chung D. et al. (2010) Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: random controlled trial. BMJ 19: c4024.</ref-fulltext> </reference> <reference id="20"> <ref-info> <ref-title> <ref-titletext>Neuroleptic–induced supersensitivity psychosis: clinical and pharmacologic characteristics</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0018835477</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>G.</ce:initials> <ce:indexed-name>Chouinard G.</ce:indexed-name> <ce:surname>Chouinard</ce:surname> </author> <author seq="2"> <ce:initials>B.</ce:initials> <ce:indexed-name>Jones B.</ce:indexed-name> <ce:surname>Jones</ce:surname> </author> </ref-authors> <ref-sourcetitle>Am J Psychiatry</ref-sourcetitle> <ref-publicationyear first="1980"/> <ref-volisspag> <voliss volume="137"/> <pagerange first="16" last="21"/> </ref-volisspag> </ref-info> <ref-fulltext>Chouinard G. Jones B. (1980) Neuroleptic–induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 137: 16–21.</ref-fulltext> </reference> <reference id="21"> <ref-info> <ref-title> <ref-titletext>Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">9644257391</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>P.</ce:initials> <ce:indexed-name>Chue P.</ce:indexed-name> <ce:surname>Chue</ce:surname> </author> <author seq="2"> <ce:initials>M.</ce:initials> <ce:indexed-name>Eerdekens M.</ce:indexed-name> <ce:surname>Eerdekens</ce:surname> </author> <author seq="3"> <ce:initials>I.</ce:initials> <ce:indexed-name>Augustyns I.</ce:indexed-name> <ce:surname>Augustyns</ce:surname> </author> <author seq="4"> <ce:initials>B.</ce:initials> <ce:indexed-name>Lachaux B.</ce:indexed-name> <ce:surname>Lachaux</ce:surname> </author> <author seq="5"> <ce:initials>P.</ce:initials> <ce:indexed-name>Molcan P.</ce:indexed-name> <ce:surname>Molcan</ce:surname> </author> <author seq="6"> <ce:initials>L.</ce:initials> <ce:indexed-name>Eriksson L.</ce:indexed-name> <ce:surname>Eriksson</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Eur Neuropsychopharmacol</ref-sourcetitle> <ref-publicationyear first="2005"/> <ref-volisspag> <voliss volume="15"/> <pagerange first="111" last="117"/> </ref-volisspag> </ref-info> <ref-fulltext>Chue P. Eerdekens M. Augustyns I. Lachaux B. Molcan P. Eriksson L. et al. (2005a) Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 15: 111–117.</ref-fulltext> </reference> <reference id="22"> <ref-info> <ref-title> <ref-titletext>Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">33644826441</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>P.</ce:initials> <ce:indexed-name>Chue P.</ce:indexed-name> <ce:surname>Chue</ce:surname> </author> <author seq="2"> <ce:initials>B.</ce:initials> <ce:indexed-name>Heeg B.</ce:indexed-name> <ce:surname>Heeg</ce:surname> </author> <author seq="3"> <ce:initials>E.</ce:initials> <ce:indexed-name>Buskens E.</ce:indexed-name> <ce:surname>Buskens</ce:surname> </author> <author seq="4"> <ce:initials>B.</ce:initials> <ce:indexed-name>van Hout B.</ce:indexed-name> <ce:surname>van Hout</ce:surname> </author> </ref-authors> <ref-sourcetitle>Pharmacoeconomics</ref-sourcetitle> <ref-publicationyear first="2005"/> <ref-volisspag> <pagerange first="62" last="74"/> </ref-volisspag> <ref-text>23(</ref-text> </ref-info> <ref-fulltext>Chue P. Heeg B. Buskens E. van Hout B. (2005b) Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics 23(Suppl. 1): 62–74.</ref-fulltext> </reference> <reference id="23"> <ref-info> <ref-title> <ref-titletext>Medication adherence of individuals with a first episode of psychosis</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0036789677</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>E.</ce:initials> <ce:indexed-name>Coldham E.</ce:indexed-name> <ce:surname>Coldham</ce:surname> </author> <author seq="2"> <ce:initials>J.</ce:initials> <ce:indexed-name>Addington J.</ce:indexed-name> <ce:surname>Addington</ce:surname> </author> <author seq="3"> <ce:initials>D.</ce:initials> <ce:indexed-name>Addington D.</ce:indexed-name> <ce:surname>Addington</ce:surname> </author> </ref-authors> <ref-sourcetitle>Acta Psychiatr Scand</ref-sourcetitle> <ref-publicationyear first="2002"/> <ref-volisspag> <voliss volume="106"/> <pagerange first="286" last="290"/> </ref-volisspag> </ref-info> <ref-fulltext>Coldham E. Addington J. Addington D. (2002) Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 106: 286–290.</ref-fulltext> </reference> <reference id="24"> <ref-info> <ref-title> <ref-titletext>Rehospitalization risk with second-generation and depot antipsychotics</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0038341023</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>R.</ce:initials> <ce:indexed-name>Conley R.</ce:indexed-name> <ce:surname>Conley</ce:surname> </author> <author seq="2"> <ce:initials>D.</ce:initials> <ce:indexed-name>Kelly D.</ce:indexed-name> <ce:surname>Kelly</ce:surname> </author> <author seq="3"> <ce:initials>R.</ce:initials> <ce:indexed-name>Love R.</ce:indexed-name> <ce:surname>Love</ce:surname> </author> <author seq="4"> <ce:initials>R.</ce:initials> <ce:indexed-name>McMahon R.</ce:indexed-name> <ce:surname>McMahon</ce:surname> </author> </ref-authors> <ref-sourcetitle>Ann Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="2003"/> <ref-volisspag> <voliss volume="15"/> <pagerange first="23" last="31"/> </ref-volisspag> </ref-info> <ref-fulltext>Conley R. Kelly D. Love R. McMahon R. (2003) Rehospitalization risk with second-generation and depot antipsychotics. Ann Clin Psychiatry 15: 23–31.</ref-fulltext> </reference> <reference id="25"> <ref-info> <ref-title> <ref-titletext>Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">80052149754</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>C.</ce:initials> <ce:indexed-name>Correll C.</ce:indexed-name> <ce:surname>Correll</ce:surname> </author> <author seq="2"> <ce:initials>T.</ce:initials> <ce:indexed-name>Kishimoto T.</ce:indexed-name> <ce:surname>Kishimoto</ce:surname> </author> <author seq="3"> <ce:initials>J.</ce:initials> <ce:indexed-name>Kane J.</ce:indexed-name> <ce:surname>Kane</ce:surname> </author> </ref-authors> <ref-sourcetitle>Dialogues Clin Neurosci</ref-sourcetitle> <ref-publicationyear first="2011"/> <ref-volisspag> <voliss volume="13"/> <pagerange first="155" last="172"/> </ref-volisspag> </ref-info> <ref-fulltext>Correll C. Kishimoto T. Kane J. (2011) Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. Dialogues Clin Neurosci 13: 155–172.</ref-fulltext> </reference> <reference id="26"> <ref-info> <ref-title> <ref-titletext>Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84861831352</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>N.</ce:initials> <ce:indexed-name>Covell N.</ce:indexed-name> <ce:surname>Covell</ce:surname> </author> <author seq="2"> <ce:initials>J.</ce:initials> <ce:indexed-name>McEvoy J.</ce:indexed-name> <ce:surname>McEvoy</ce:surname> </author> <author seq="3"> <ce:initials>N.</ce:initials> <ce:indexed-name>Schooler N.</ce:indexed-name> <ce:surname>Schooler</ce:surname> </author> <author seq="4"> <ce:initials>T.</ce:initials> <ce:indexed-name>Stroup T.</ce:indexed-name> <ce:surname>Stroup</ce:surname> </author> <author seq="5"> <ce:initials>C.</ce:initials> <ce:indexed-name>Jackson C.</ce:indexed-name> <ce:surname>Jackson</ce:surname> </author> <author seq="6"> <ce:initials>I.</ce:initials> <ce:indexed-name>Rojas I.</ce:indexed-name> <ce:surname>Rojas</ce:surname> </author> <collaboration seq="1"> <ce:indexed-name>Schizophrenia Trials Network</ce:indexed-name> <ce:text>Schizophrenia Trials Network</ce:text> </collaboration> <et-al/> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="2012"/> <ref-volisspag> <voliss volume="73"/> <pagerange first="669" last="675"/> </ref-volisspag> </ref-info> <ref-fulltext>Covell N. McEvoy J. Schooler N. Stroup T. Jackson C. Rojas I.; Schizophrenia Trials Network et al. (2012) Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. J Clin Psychiatry 73: 669–675.</ref-fulltext> </reference> <reference id="27"> <ref-info> <ref-title> <ref-titletext>Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0035988550</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>N.</ce:initials> <ce:indexed-name>Covell N.</ce:indexed-name> <ce:surname>Covell</ce:surname> </author> <author seq="2"> <ce:initials>C.</ce:initials> <ce:indexed-name>Jackson C.</ce:indexed-name> <ce:surname>Jackson</ce:surname> </author> <author seq="3"> <ce:initials>A.</ce:initials> <ce:indexed-name>Evans A.</ce:indexed-name> <ce:surname>Evans</ce:surname> </author> <author seq="4"> <ce:initials>S.</ce:initials> <ce:indexed-name>Essock S.</ce:indexed-name> <ce:surname>Essock</ce:surname> </author> </ref-authors> <ref-sourcetitle>Schizophr Bull</ref-sourcetitle> <ref-publicationyear first="2002"/> <ref-volisspag> <voliss volume="28"/> <pagerange first="17" last="29"/> </ref-volisspag> </ref-info> <ref-fulltext>Covell N. Jackson C. Evans A. Essock S. (2002) Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 28: 17–29.</ref-fulltext> </reference> <reference id="28"> <ref-info> <ref-title> <ref-titletext>A randomised controlled trial of prophylactic neuroleptic treatment</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0022668286</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>T.</ce:initials> <ce:indexed-name>Crow T.</ce:indexed-name> <ce:surname>Crow</ce:surname> </author> <author seq="2"> <ce:initials>J.</ce:initials> <ce:indexed-name>MacMillan J.</ce:indexed-name> <ce:surname>MacMillan</ce:surname> </author> <author seq="3"> <ce:initials>A.</ce:initials> <ce:indexed-name>Johnson A.</ce:indexed-name> <ce:surname>Johnson</ce:surname> </author> <author seq="4"> <ce:initials>E.</ce:initials> <ce:indexed-name>Johnstone E.</ce:indexed-name> <ce:surname>Johnstone</ce:surname> </author> </ref-authors> <ref-sourcetitle>Br J Psychiatry</ref-sourcetitle> <ref-publicationyear first="1986"/> <ref-volisspag> <voliss volume="148"/> <pagerange first="120" last="127"/> </ref-volisspag> </ref-info> <ref-fulltext>Crow T. MacMillan J. Johnson A. Johnstone E. (1986) A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 148: 120–127.</ref-fulltext> </reference> <reference id="29"> <ref-info> <ref-title> <ref-titletext>Safety and efficacy review of inhaled loxapine for treatment of agitation</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84876397913</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>G.</ce:initials> <ce:indexed-name>Currier G.</ce:indexed-name> <ce:surname>Currier</ce:surname> </author> <author seq="2"> <ce:initials>P.</ce:initials> <ce:indexed-name>Walsh P.</ce:indexed-name> <ce:surname>Walsh</ce:surname> </author> </ref-authors> <ref-sourcetitle>Clin Schizophr Relat Psychoses</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="7"/> <pagerange first="25" last="32"/> </ref-volisspag> </ref-info> <ref-fulltext>Currier G. Walsh P. (2013) Safety and efficacy review of inhaled loxapine for treatment of agitation. Clin Schizophr Relat Psychoses 7: 25–32.</ref-fulltext> </reference> <reference id="30"> <ref-info> <ref-title> <ref-titletext>Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0018346351</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>S.</ce:initials> <ce:indexed-name>Curry S.</ce:indexed-name> <ce:surname>Curry</ce:surname> </author> <author seq="2"> <ce:initials>R.</ce:initials> <ce:indexed-name>Whelpton R.</ce:indexed-name> <ce:surname>Whelpton</ce:surname> </author> <author seq="3"> <ce:initials>P.</ce:initials> <ce:indexed-name>de Schepper P.</ce:indexed-name> <ce:surname>de Schepper</ce:surname> </author> <author seq="4"> <ce:initials>S.</ce:initials> <ce:indexed-name>Vranckx S.</ce:indexed-name> <ce:surname>Vranckx</ce:surname> </author> <author seq="5"> <ce:initials>A.</ce:initials> <ce:indexed-name>Schiff A.</ce:indexed-name> <ce:surname>Schiff</ce:surname> </author> </ref-authors> <ref-sourcetitle>Br J Clin Pharmacol</ref-sourcetitle> <ref-publicationyear first="1979"/> <ref-volisspag> <voliss volume="7"/> <pagerange first="325" last="331"/> </ref-volisspag> </ref-info> <ref-fulltext>Curry S. Whelpton R. de Schepper P. Vranckx S. Schiff A. (1979) Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. Br J Clin Pharmacol 7: 325–331.</ref-fulltext> </reference> <reference id="31"> <ref-info> <ref-title> <ref-titletext>The use of depot medications in the treatment of schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">75749132020</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Davis J.</ce:indexed-name> <ce:surname>Davis</ce:surname> </author> </ref-authors> <ref-sourcetitle>Am J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <voliss volume="167"/> <pagerange first="125" last="126"/> </ref-volisspag> </ref-info> <ref-fulltext>Davis J. (2010) The use of depot medications in the treatment of schizophrenia. Am J Psychiatry 167: 125–126.</ref-fulltext> </reference> <reference id="32"> <ref-info> <ref-title> <ref-titletext>Depot antipsychotic drugs. Place in therapy</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0028336845</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Davis J.</ce:indexed-name> <ce:surname>Davis</ce:surname> </author> <author seq="2"> <ce:initials>L.</ce:initials> <ce:indexed-name>Matalon L.</ce:indexed-name> <ce:surname>Matalon</ce:surname> </author> <author seq="3"> <ce:initials>M.</ce:initials> <ce:indexed-name>Watanabe M.</ce:indexed-name> <ce:surname>Watanabe</ce:surname> </author> <author seq="4"> <ce:initials>L.</ce:initials> <ce:indexed-name>Blake L.</ce:indexed-name> <ce:surname>Blake</ce:surname> </author> <author seq="5"> <ce:initials>L.</ce:initials> <ce:indexed-name>Matalon L.</ce:indexed-name> <ce:surname>Matalon</ce:surname> </author> </ref-authors> <ref-sourcetitle>Drugs</ref-sourcetitle> <ref-publicationyear first="1994"/> <ref-volisspag> <voliss volume="47"/> <pagerange first="741" last="773"/> </ref-volisspag> </ref-info> <ref-fulltext>Davis J. Matalon L. Watanabe M. Blake L. Matalon L. (1994) Depot antipsychotic drugs. Place in therapy. Drugs 47: 741–773.</ref-fulltext> </reference> <reference id="33"> <ref-info> <ref-title> <ref-titletext>Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">70350167140</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>De la Gandara J.</ce:indexed-name> <ce:surname>De la Gándara</ce:surname> </author> <author seq="2"> <ce:initials>L.</ce:initials> <ce:indexed-name>San Molina L.</ce:indexed-name> <ce:surname>San Molina</ce:surname> </author> <author seq="3"> <ce:initials>G.</ce:initials> <ce:indexed-name>Rubio G.</ce:indexed-name> <ce:surname>Rubio</ce:surname> </author> <author seq="4"> <ce:initials>A.</ce:initials> <ce:indexed-name>Rodriguez-Morales A.</ce:indexed-name> <ce:surname>Rodriguez-Morales</ce:surname> </author> <author seq="5"> <ce:initials>R.</ce:initials> <ce:indexed-name>Hidalgo Borrajo R.</ce:indexed-name> <ce:surname>Hidalgo Borrajo</ce:surname> </author> <author seq="6"> <ce:initials>J.</ce:initials> <ce:indexed-name>Buron J.</ce:indexed-name> <ce:surname>Burón</ce:surname> </author> </ref-authors> <ref-sourcetitle>Expert Rev Neurother</ref-sourcetitle> <ref-publicationyear first="2009"/> <ref-volisspag> <voliss volume="9"/> <pagerange first="1463" last="1474"/> </ref-volisspag> </ref-info> <ref-fulltext>De la Gándara J. San Molina L. Rubio G. Rodriguez-Morales A Hidalgo Borrajo R. Burón J. (2009) Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study. Expert Rev Neurother 9: 1463–1474.</ref-fulltext> </reference> <reference id="34"> <ref-info> <ref-title> <ref-titletext>History and therapeutic rationale of long acting antipsychotics</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84894031270</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>A.</ce:initials> <ce:indexed-name>De Risio A.</ce:indexed-name> <ce:surname>De Risio</ce:surname> </author> <author seq="2"> <ce:initials>A.</ce:initials> <ce:indexed-name>Lang A.</ce:indexed-name> <ce:surname>Lang</ce:surname> </author> </ref-authors> <ref-sourcetitle>Curr Clin Pharmacol</ref-sourcetitle> <ref-publicationyear first="2014"/> <ref-volisspag> <voliss volume="9"/> <pagerange first="39" last="52"/> </ref-volisspag> </ref-info> <ref-fulltext>De Risio A. Lang A. (2014) History and therapeutic rationale of long acting antipsychotics. Curr Clin Pharmacol 9: 39–52.</ref-fulltext> </reference> <reference id="35"> <ref-info> <ref-title> <ref-titletext>The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0021270101</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>S.</ce:initials> <ce:indexed-name>Dencker S.</ce:indexed-name> <ce:surname>Dencker</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="1984"/> <ref-volisspag> <voliss volume="45"/> <pagerange first="22" last="27"/> </ref-volisspag> </ref-info> <ref-fulltext>Dencker S. (1984) The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective. J Clin Psychiatry 45: 22–27.</ref-fulltext> </reference> <reference id="36"> <ref-info> <ref-title> <ref-titletext>The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0015170072</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Denham J.</ce:indexed-name> <ce:surname>Denham</ce:surname> </author> <author seq="2"> <ce:initials>L.</ce:initials> <ce:indexed-name>Adamson L.</ce:indexed-name> <ce:surname>Adamson</ce:surname> </author> </ref-authors> <ref-sourcetitle>Acta Psychiatr Scand</ref-sourcetitle> <ref-publicationyear first="1971"/> <ref-volisspag> <voliss volume="47"/> <pagerange first="420" last="430"/> </ref-volisspag> </ref-info> <ref-fulltext>Denham J. Adamson L. (1971) The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients. Acta Psychiatr Scand 47: 420–430.</ref-fulltext> </reference> <reference id="37"> <ref-info> <ref-title> <ref-titletext>Fluphenazine decanoate vs oral antipsychotics: a comparison of their effectiveness in the treatment of schizophrenia as measured by a reduction in hospital readmissions</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0017915299</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>R.</ce:initials> <ce:indexed-name>Devito R.</ce:indexed-name> <ce:surname>Devito</ce:surname> </author> <author seq="2"> <ce:initials>L.</ce:initials> <ce:indexed-name>Brink L.</ce:indexed-name> <ce:surname>Brink</ce:surname> </author> <author seq="3"> <ce:initials>C.</ce:initials> <ce:indexed-name>Sloan C.</ce:indexed-name> <ce:surname>Sloan</ce:surname> </author> <author seq="4"> <ce:initials>F.</ce:initials> <ce:indexed-name>Jolliff F.</ce:indexed-name> <ce:surname>Jolliff</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="1978"/> <ref-volisspag> <voliss volume="39"/> <pagerange first="26" last="34"/> </ref-volisspag> </ref-info> <ref-fulltext>Devito R. Brink L. Sloan C. Jolliff F. (1978) Fluphenazine decanoate vs oral antipsychotics: a comparison of their effectiveness in the treatment of schizophrenia as measured by a reduction in hospital readmissions. J Clin Psychiatry 39: 26–34.</ref-fulltext> </reference> <reference id="38"> <ref-info> <ref-title> <ref-titletext>Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84876136063</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>T.</ce:initials> <ce:indexed-name>Dilla T.</ce:indexed-name> <ce:surname>Dilla</ce:surname> </author> <author seq="2"> <ce:initials>A.</ce:initials> <ce:indexed-name>Ciudad A.</ce:indexed-name> <ce:surname>Ciudad</ce:surname> </author> <author seq="3"> <ce:initials>M.</ce:initials> <ce:indexed-name>Alvarez M.</ce:indexed-name> <ce:surname>Alvarez</ce:surname> </author> </ref-authors> <ref-sourcetitle>Patient Prefer Adherence</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="7"/> <pagerange first="275" last="284"/> </ref-volisspag> </ref-info> <ref-fulltext>Dilla T. Ciudad A. Alvarez M. (2013) Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia. Patient Prefer Adherence 7: 275–284.</ref-fulltext> </reference> <reference id="39"> <ref-info> <ref-title> <ref-titletext>Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">3142545995</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Eerdenkens M.</ce:indexed-name> <ce:surname>Eerdenkens</ce:surname> </author> <author seq="2"> <ce:initials>I.</ce:initials> <ce:indexed-name>Hove I.</ce:indexed-name> <ce:surname>Hove</ce:surname> </author> <author seq="3"> <ce:initials>B.</ce:initials> <ce:indexed-name>Remmerie B.</ce:indexed-name> <ce:surname>Remmerie</ce:surname> </author> <author seq="4"> <ce:initials>E.</ce:initials> <ce:indexed-name>Mannaert E.</ce:indexed-name> <ce:surname>Mannaert</ce:surname> </author> </ref-authors> <ref-sourcetitle>Schizophr Res</ref-sourcetitle> <ref-publicationyear first="2004"/> <ref-volisspag> <voliss volume="70"/> <pagerange first="91" last="100"/> </ref-volisspag> </ref-info> <ref-fulltext>Eerdenkens M. Hove I. Remmerie B. Mannaert E. (2004) Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 70: 91–100.</ref-fulltext> </reference> <reference id="40"> <ref-info> <ref-title> <ref-titletext>Neurocognitive function in long-term treated schizophrenia: a five-year follow-up study</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84872385889</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Ekerholm M.</ce:indexed-name> <ce:surname>Ekerholm</ce:surname> </author> <author seq="2"> <ce:initials>S.</ce:initials> <ce:indexed-name>Firus Waltersson S.</ce:indexed-name> <ce:surname>Firus Waltersson</ce:surname> </author> <author seq="3"> <ce:initials>T.</ce:initials> <ce:indexed-name>Fagerberg T.</ce:indexed-name> <ce:surname>Fagerberg</ce:surname> </author> <author seq="4"> <ce:initials>E.</ce:initials> <ce:indexed-name>Soderman E.</ce:indexed-name> <ce:surname>Söderman</ce:surname> </author> <author seq="5"> <ce:initials>L.</ce:initials> <ce:indexed-name>Terenius L.</ce:indexed-name> <ce:surname>Terenius</ce:surname> </author> <author seq="6"> <ce:initials>I.</ce:initials> <ce:indexed-name>Agartz I.</ce:indexed-name> <ce:surname>Agartz</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Psychiatry Res</ref-sourcetitle> <ref-publicationyear first="2012"/> <ref-volisspag> <voliss volume="200"/> <pagerange first="144" last="152"/> </ref-volisspag> </ref-info> <ref-fulltext>Ekerholm M. Firus Waltersson S. Fagerberg T. Söderman E. Terenius L. Agartz I. et al. (2012) Neurocognitive function in long-term treated schizophrenia: a five-year follow-up study. Psychiatry Res 200: 144–152.</ref-fulltext> </reference> <reference id="41"> <ref-info> <ref-title> <ref-titletext>Long-acting injectable antipsychotics in early psychosis: a literature review</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84881546480</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>R.</ce:initials> <ce:indexed-name>Emsley R.</ce:indexed-name> <ce:surname>Emsley</ce:surname> </author> <author seq="2"> <ce:initials>B.</ce:initials> <ce:indexed-name>Chiliza B.</ce:indexed-name> <ce:surname>Chiliza</ce:surname> </author> <author seq="3"> <ce:initials>L.</ce:initials> <ce:indexed-name>Asmal L.</ce:indexed-name> <ce:surname>Asmal</ce:surname> </author> <author seq="4"> <ce:initials>M.</ce:initials> <ce:indexed-name>Mashile M.</ce:indexed-name> <ce:surname>Mashile</ce:surname> </author> <author seq="5"> <ce:initials>P.</ce:initials> <ce:indexed-name>Fusar-Poli P.</ce:indexed-name> <ce:surname>Fusar-Poli</ce:surname> </author> </ref-authors> <ref-sourcetitle>Early Interv Psychiatry</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="7"/> <pagerange first="247" last="254"/> </ref-volisspag> </ref-info> <ref-fulltext>Emsley R. Chiliza B. Asmal L. Mashile M. Fusar-Poli P. (2013) Long-acting injectable antipsychotics in early psychosis: a literature review. Early Interv Psychiatry 7: 247–254.</ref-fulltext> </reference> <reference id="42"> <ref-info> <ref-title> <ref-titletext>Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84860561502</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>R.</ce:initials> <ce:indexed-name>Emsley R.</ce:indexed-name> <ce:surname>Emsley</ce:surname> </author> <author seq="2"> <ce:initials>P.</ce:initials> <ce:indexed-name>Oosthuizen P.</ce:indexed-name> <ce:surname>Oosthuizen</ce:surname> </author> <author seq="3"> <ce:initials>L.</ce:initials> <ce:indexed-name>Koen L.</ce:indexed-name> <ce:surname>Koen</ce:surname> </author> <author seq="4"> <ce:initials>D.</ce:initials> <ce:indexed-name>Niehaus D.</ce:indexed-name> <ce:surname>Niehaus</ce:surname> </author> <author seq="5"> <ce:initials>G.</ce:initials> <ce:indexed-name>Martinez G.</ce:indexed-name> <ce:surname>Martinez</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="2012"/> <ref-volisspag> <voliss volume="73"/> <pagerange first="e541" last="e547"/> </ref-volisspag> </ref-info> <ref-fulltext>Emsley R. Oosthuizen P. Koen L. Niehaus D. Martinez G. (2012) Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study. J Clin Psychiatry 73: e541–e547.</ref-fulltext> </reference> <reference id="43"> <ref-info> <ref-title> <ref-titletext>Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">55849131073</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>R.</ce:initials> <ce:indexed-name>Emsley R.</ce:indexed-name> <ce:surname>Emsley</ce:surname> </author> <author seq="2"> <ce:initials>P.</ce:initials> <ce:indexed-name>Oosthuizen P.</ce:indexed-name> <ce:surname>Oosthuizen</ce:surname> </author> <author seq="3"> <ce:initials>L.</ce:initials> <ce:indexed-name>Koen L.</ce:indexed-name> <ce:surname>Koen</ce:surname> </author> <author seq="4"> <ce:initials>D.</ce:initials> <ce:indexed-name>Niehaus D.</ce:indexed-name> <ce:surname>Niehaus</ce:surname> </author> <author seq="5"> <ce:initials>R.</ce:initials> <ce:indexed-name>Medori R.</ce:indexed-name> <ce:surname>Medori</ce:surname> </author> <author seq="6"> <ce:initials>J.</ce:initials> <ce:indexed-name>Rabinowitz J.</ce:indexed-name> <ce:surname>Rabinowitz</ce:surname> </author> </ref-authors> <ref-sourcetitle>Int Clin Psychopharmacol</ref-sourcetitle> <ref-publicationyear first="2008"/> <ref-volisspag> <voliss volume="23"/> <pagerange first="325" last="331"/> </ref-volisspag> </ref-info> <ref-fulltext>Emsley R. Oosthuizen P. Koen L. Niehaus D. Medori R. Rabinowitz J. (2008a) Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol 23: 325–331.</ref-fulltext> </reference> <reference id="44"> <ref-info> <ref-title> <ref-titletext>Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">58249142102</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>R.</ce:initials> <ce:indexed-name>Emsley R.</ce:indexed-name> <ce:surname>Emsley</ce:surname> </author> <author seq="2"> <ce:initials>P.</ce:initials> <ce:indexed-name>Oosthuizen P.</ce:indexed-name> <ce:surname>Oosthuizen</ce:surname> </author> <author seq="3"> <ce:initials>L.</ce:initials> <ce:indexed-name>Koen L.</ce:indexed-name> <ce:surname>Koen</ce:surname> </author> <author seq="4"> <ce:initials>D.</ce:initials> <ce:indexed-name>Niehaus D.</ce:indexed-name> <ce:surname>Niehaus</ce:surname> </author> <author seq="5"> <ce:initials>R.</ce:initials> <ce:indexed-name>Medori R.</ce:indexed-name> <ce:surname>Medori</ce:surname> </author> <author seq="6"> <ce:initials>J.</ce:initials> <ce:indexed-name>Rabinowitz J.</ce:indexed-name> <ce:surname>Rabinowitz</ce:surname> </author> </ref-authors> <ref-sourcetitle>Clin Ther</ref-sourcetitle> <ref-publicationyear first="2008"/> <ref-volisspag> <voliss volume="30"/> <pagerange first="2378" last="2386"/> </ref-volisspag> </ref-info> <ref-fulltext>Emsley R. Oosthuizen P. Koen L. Niehaus D. Medori R. Rabinowitz J. (2008b) Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther 30: 2378–2386.</ref-fulltext> </reference> <reference id="45"> <ref-info> <ref-title> <ref-titletext>Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84997946671</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>W.</ce:initials> <ce:indexed-name>Fleischhacker W.</ce:indexed-name> <ce:surname>Fleischhacker</ce:surname> </author> <author seq="2"> <ce:initials>M.</ce:initials> <ce:indexed-name>Eerdekens M.</ce:indexed-name> <ce:surname>Eerdekens</ce:surname> </author> <author seq="3"> <ce:initials>K.</ce:initials> <ce:indexed-name>Karcher K.</ce:indexed-name> <ce:surname>Karcher</ce:surname> </author> <author seq="4"> <ce:initials>G.</ce:initials> <ce:indexed-name>Remington G.</ce:indexed-name> <ce:surname>Remington</ce:surname> </author> <author seq="5"> <ce:initials>P.</ce:initials> <ce:indexed-name>Llorca P.</ce:indexed-name> <ce:surname>Llorca</ce:surname> </author> <author seq="6"> <ce:initials>W.</ce:initials> <ce:indexed-name>Chrzanowski W.</ce:indexed-name> <ce:surname>Chrzanowski</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="2003"/> <ref-volisspag> <voliss volume="64"/> <pagerange first="1250" last="1257"/> </ref-volisspag> </ref-info> <ref-fulltext>Fleischhacker W. Eerdekens M. Karcher K. Remington G. Llorca P. Chrzanowski W. et al. (2003) Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 64: 1250–1257.</ref-fulltext> </reference> <reference id="46"> <ref-info> <ref-title> <ref-titletext>Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">77952674645</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>S.</ce:initials> <ce:indexed-name>Francey S.</ce:indexed-name> <ce:surname>Francey</ce:surname> </author> <author seq="2"> <ce:initials>B.</ce:initials> <ce:indexed-name>Nelson B.</ce:indexed-name> <ce:surname>Nelson</ce:surname> </author> <author seq="3"> <ce:initials>A.</ce:initials> <ce:indexed-name>Thompson A.</ce:indexed-name> <ce:surname>Thompson</ce:surname> </author> <author seq="4"> <ce:initials>A.</ce:initials> <ce:indexed-name>Parker A.</ce:indexed-name> <ce:surname>Parker</ce:surname> </author> <author seq="5"> <ce:initials>M.</ce:initials> <ce:indexed-name>Kerr M.</ce:indexed-name> <ce:surname>Kerr</ce:surname> </author> <author seq="6"> <ce:initials>C.</ce:initials> <ce:indexed-name>Macneil C.</ce:indexed-name> <ce:surname>Macneil</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Schizophr Res</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <voliss volume="119"/> <pagerange first="1" last="10"/> </ref-volisspag> </ref-info> <ref-fulltext>Francey S. Nelson B. Thompson A. Parker A. Kerr M. Macneil C. et al. (2010) Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. Schizophr Res 119: 1–10.</ref-fulltext> </reference> <reference id="47"> <ref-info> <ref-title> <ref-titletext>Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84873406846</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>P.</ce:initials> <ce:indexed-name>Fusar-Poli P.</ce:indexed-name> <ce:surname>Fusar-Poli</ce:surname> </author> <author seq="2"> <ce:initials>M.</ce:initials> <ce:indexed-name>Kempton M.</ce:indexed-name> <ce:surname>Kempton</ce:surname> </author> <author seq="3"> <ce:initials>R.</ce:initials> <ce:indexed-name>Rosenheck R.</ce:indexed-name> <ce:surname>Rosenheck</ce:surname> </author> </ref-authors> <ref-sourcetitle>Int Clin Psychopharmacol</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="28"/> <pagerange first="57" last="66"/> </ref-volisspag> </ref-info> <ref-fulltext>Fusar-Poli P. Kempton M. Rosenheck R. (2013) Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol 28: 57–66.</ref-fulltext> </reference> <reference id="48"> <ref-info> <ref-title> <ref-titletext>First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0036133151</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>W.</ce:initials> <ce:indexed-name>Gaebel W.</ce:indexed-name> <ce:surname>Gaebel</ce:surname> </author> <author seq="2"> <ce:initials>M.</ce:initials> <ce:indexed-name>Janner M.</ce:indexed-name> <ce:surname>Jänner</ce:surname> </author> <author seq="3"> <ce:initials>N.</ce:initials> <ce:indexed-name>Frommann N.</ce:indexed-name> <ce:surname>Frommann</ce:surname> </author> <author seq="4"> <ce:initials>A.</ce:initials> <ce:indexed-name>Pietzcker A.</ce:indexed-name> <ce:surname>Pietzcker</ce:surname> </author> <author seq="5"> <ce:initials>W.</ce:initials> <ce:indexed-name>Kopcke W.</ce:indexed-name> <ce:surname>Köpcke</ce:surname> </author> <author seq="6"> <ce:initials>M.</ce:initials> <ce:indexed-name>Linden M.</ce:indexed-name> <ce:surname>Linden</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Schizophr Res</ref-sourcetitle> <ref-publicationyear first="2002"/> <ref-volisspag> <voliss volume="53"/> <pagerange first="145" last="159"/> </ref-volisspag> </ref-info> <ref-fulltext>Gaebel W. Jänner M. Frommann N. Pietzcker A. Köpcke W. Linden M. et al. (2002) First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr Res 53: 145–159.</ref-fulltext> </reference> <reference id="49"> <ref-info> <ref-title> <ref-titletext>Relapse prevention in first episode schizophrenia- maintenance ves intermittent drug treatment with prodrome –based early intervention: results of randomized controlles trial within the German research network on schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">79951981601</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>W.</ce:initials> <ce:indexed-name>Gaebel W.</ce:indexed-name> <ce:surname>Gaebel</ce:surname> </author> <author seq="2"> <ce:initials>M.</ce:initials> <ce:indexed-name>Riesbeck M.</ce:indexed-name> <ce:surname>Riesbeck</ce:surname> </author> <author seq="3"> <ce:initials>W.</ce:initials> <ce:indexed-name>Wolwer W.</ce:indexed-name> <ce:surname>Wölwer</ce:surname> </author> <author seq="4"> <ce:initials>A.</ce:initials> <ce:indexed-name>Klimke A.</ce:indexed-name> <ce:surname>Klimke</ce:surname> </author> <author seq="5"> <ce:initials>M.</ce:initials> <ce:indexed-name>Eickhoff M.</ce:indexed-name> <ce:surname>Eickhoff</ce:surname> </author> <author seq="6"> <ce:initials>M.</ce:initials> <ce:indexed-name>von Wilmsdorff M.</ce:indexed-name> <ce:surname>von Wilmsdorff</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="2011"/> <ref-volisspag> <voliss volume="72"/> <pagerange first="205" last="218"/> </ref-volisspag> </ref-info> <ref-fulltext>Gaebel W. Riesbeck M. Wölwer W. Klimke A. Eickhoff M. von Wilmsdorff M. et al. (2011) Relapse prevention in first episode schizophrenia- maintenance ves intermittent drug treatment with prodrome –based early intervention: results of randomized controlles trial within the German research network on schizophrenia. J Clin Psychiatry 72: 205–218.</ref-fulltext> </reference> <reference id="50"> <ref-info> <ref-title> <ref-titletext>Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">77958009877</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>W.</ce:initials> <ce:indexed-name>Gaebel W.</ce:indexed-name> <ce:surname>Gaebel</ce:surname> </author> <author seq="2"> <ce:initials>A.</ce:initials> <ce:indexed-name>Schreiner A.</ce:indexed-name> <ce:surname>Schreiner</ce:surname> </author> <author seq="3"> <ce:initials>P.</ce:initials> <ce:indexed-name>Bergmans P.</ce:indexed-name> <ce:surname>Bergmans</ce:surname> </author> <author seq="4"> <ce:initials>R.</ce:initials> <ce:indexed-name>de Arce R.</ce:indexed-name> <ce:surname>de Arce</ce:surname> </author> <author seq="5"> <ce:initials>F.</ce:initials> <ce:indexed-name>Rouillon F.</ce:indexed-name> <ce:surname>Rouillon</ce:surname> </author> <author seq="6"> <ce:initials>J.</ce:initials> <ce:indexed-name>Cordes J.</ce:indexed-name> <ce:surname>Cordes</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Neuropsychopharmacology</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <voliss volume="35"/> <pagerange first="2367" last="2377"/> </ref-volisspag> </ref-info> <ref-fulltext>Gaebel W. Schreiner A. Bergmans P de Arce R. Rouillon F. Cordes J. et al. (2010) Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology 35: 2367–2377.</ref-fulltext> </reference> <reference id="51"> <ref-info> <ref-title> <ref-titletext>Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">82555190988</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>P.</ce:initials> <ce:indexed-name>Gasso P.</ce:indexed-name> <ce:surname>Gassó</ce:surname> </author> <author seq="2"> <ce:initials>S.</ce:initials> <ce:indexed-name>Mas S.</ce:indexed-name> <ce:surname>Mas</ce:surname> </author> <author seq="3"> <ce:initials>O.</ce:initials> <ce:indexed-name>Molina O.</ce:indexed-name> <ce:surname>Molina</ce:surname> </author> <author seq="4"> <ce:initials>M.</ce:initials> <ce:indexed-name>Bernardo M.</ce:indexed-name> <ce:surname>Bernardo</ce:surname> </author> <author seq="5"> <ce:initials>A.</ce:initials> <ce:indexed-name>Lafuente A.</ce:indexed-name> <ce:surname>Lafuente</ce:surname> </author> <author seq="6"> <ce:initials>E.</ce:initials> <ce:indexed-name>Parellada E.</ce:indexed-name> <ce:surname>Parellada</ce:surname> </author> </ref-authors> <ref-sourcetitle>Prog Neuropsychopharmacol Biol Psychiatry</ref-sourcetitle> <ref-publicationyear first="2012"/> <ref-volisspag> <voliss volume="36"/> <pagerange first="71" last="77"/> </ref-volisspag> </ref-info> <ref-fulltext>Gassó P. Mas S. Molina O. Bernardo M. Lafuente A. Parellada E. (2012) Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells. Prog Neuropsychopharmacol Biol Psychiatry 36: 71–77.</ref-fulltext> </reference> <reference id="52"> <ref-info> <ref-title> <ref-titletext>Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84873703521</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>P.</ce:initials> <ce:indexed-name>Geerts P.</ce:indexed-name> <ce:surname>Geerts</ce:surname> </author> <author seq="2"> <ce:initials>G.</ce:initials> <ce:indexed-name>Martinez G.</ce:indexed-name> <ce:surname>Martinez</ce:surname> </author> <author seq="3"> <ce:initials>A.</ce:initials> <ce:indexed-name>Schreiner A.</ce:indexed-name> <ce:surname>Schreiner</ce:surname> </author> </ref-authors> <ref-sourcetitle>BMC Psychiatry</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="13"/> <pagerange first="58"/> </ref-volisspag> </ref-info> <ref-fulltext>Geerts P. Martinez G. Schreiner A. (2013) Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses. BMC Psychiatry 13: 58.</ref-fulltext> </reference> <reference id="53"> <ref-info> <ref-title> <ref-titletext>Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">15244341031</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>O.</ce:initials> <ce:indexed-name>Gefvert O.</ce:indexed-name> <ce:surname>Gefvert</ce:surname> </author> <author seq="2"> <ce:initials>B.</ce:initials> <ce:indexed-name>Eriksson B.</ce:indexed-name> <ce:surname>Eriksson</ce:surname> </author> <author seq="3"> <ce:initials>P.</ce:initials> <ce:indexed-name>Persson P.</ce:indexed-name> <ce:surname>Persson</ce:surname> </author> <author seq="4"> <ce:initials>L.</ce:initials> <ce:indexed-name>Helldin L.</ce:indexed-name> <ce:surname>Helldin</ce:surname> </author> <author seq="5"> <ce:initials>A.</ce:initials> <ce:indexed-name>Bjorner A.</ce:indexed-name> <ce:surname>Björner</ce:surname> </author> <author seq="6"> <ce:initials>E.</ce:initials> <ce:indexed-name>Mannaert E.</ce:indexed-name> <ce:surname>Mannaert</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Int J Neuropsychopharmacol</ref-sourcetitle> <ref-publicationyear first="2005"/> <ref-volisspag> <voliss volume="8"/> <pagerange first="27" last="36"/> </ref-volisspag> </ref-info> <ref-fulltext>Gefvert O. Eriksson B. Persson P. Helldin L. Björner A. Mannaert E. et al. (2005) Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol 8: 27–36.</ref-fulltext> </reference> <reference id="54"> <ref-info> <ref-title> <ref-titletext>Depot neuroleptics in relapse prevention: advantages and disadvantages</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0028911075</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Gerlach J.</ce:indexed-name> <ce:surname>Gerlach</ce:surname> </author> </ref-authors> <ref-sourcetitle>Int Clin Psychopharmacol</ref-sourcetitle> <ref-publicationyear first="1995"/> <ref-volisspag> <voliss volume="9"/> <pagerange first="17" last="20"/> </ref-volisspag> </ref-info> <ref-fulltext>Gerlach J. (1995) Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol 9(Suppl. 5): 17–20.</ref-fulltext> </reference> <reference id="55"> <ref-info> <ref-title> <ref-titletext>Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84857395702</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>E.</ce:initials> <ce:indexed-name>Gilday E.</ce:indexed-name> <ce:surname>Gilday</ce:surname> </author> <author seq="2"> <ce:initials>H.</ce:initials> <ce:indexed-name>Nasrallah H.</ce:indexed-name> <ce:surname>Nasrallah</ce:surname> </author> </ref-authors> <ref-sourcetitle>Rev Recent Clin Trials</ref-sourcetitle> <ref-publicationyear first="2012"/> <ref-volisspag> <voliss volume="7"/> <pagerange first="2" last="9"/> </ref-volisspag> </ref-info> <ref-fulltext>Gilday E. Nasrallah H. (2012) Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia. Rev Recent Clin Trials 7: 2–9.</ref-fulltext> </reference> <reference id="56"> <ref-info> <ref-title> <ref-titletext>Adherence to treatment with antipsychotic medication and healthcare costs among Medicaid beneficiaries with schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">1842428207</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>T.</ce:initials> <ce:indexed-name>Gilmer T.</ce:indexed-name> <ce:surname>Gilmer</ce:surname> </author> <author seq="2"> <ce:initials>C.</ce:initials> <ce:indexed-name>Dolder C.</ce:indexed-name> <ce:surname>Dolder</ce:surname> </author> <author seq="3"> <ce:initials>J.</ce:initials> <ce:indexed-name>Lacro J.</ce:indexed-name> <ce:surname>Lacro</ce:surname> </author> <author seq="4"> <ce:initials>D.</ce:initials> <ce:indexed-name>Folsom D.</ce:indexed-name> <ce:surname>Folsom</ce:surname> </author> <author seq="5"> <ce:initials>L.</ce:initials> <ce:indexed-name>Lindamer L.</ce:indexed-name> <ce:surname>Lindamer</ce:surname> </author> <author seq="6"> <ce:initials>P.</ce:initials> <ce:indexed-name>Garcia P.</ce:indexed-name> <ce:surname>Garcia</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Am J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2004"/> <ref-volisspag> <voliss volume="161"/> <pagerange first="692" last="699"/> </ref-volisspag> </ref-info> <ref-fulltext>Gilmer T. Dolder C. Lacro J. Folsom D. Lindamer L. Garcia P. et al. (2004) Adherence to treatment with antipsychotic medication and healthcare costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 161: 692–699.</ref-fulltext> </reference> <reference id="57"> <ref-info> <ref-title> <ref-titletext>Clinical outcome following neuroleptic discontinuation in patients with remitted recent –onset schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0035154103</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Gitlin M.</ce:indexed-name> <ce:surname>Gitlin</ce:surname> </author> <author seq="2"> <ce:initials>K.</ce:initials> <ce:indexed-name>Nuechterlein K.</ce:indexed-name> <ce:surname>Nuechterlein</ce:surname> </author> <author seq="3"> <ce:initials>K.</ce:initials> <ce:indexed-name>Subotnik K.</ce:indexed-name> <ce:surname>Subotnik</ce:surname> </author> <author seq="4"> <ce:initials>J.</ce:initials> <ce:indexed-name>Ventura J.</ce:indexed-name> <ce:surname>Ventura</ce:surname> </author> <author seq="5"> <ce:initials>J.</ce:initials> <ce:indexed-name>Mintz J.</ce:indexed-name> <ce:surname>Mintz</ce:surname> </author> <author seq="6"> <ce:initials>D.</ce:initials> <ce:indexed-name>Fogelson D.</ce:indexed-name> <ce:surname>Fogelson</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Am J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2001"/> <ref-volisspag> <voliss volume="158"/> <pagerange first="1835" last="1842"/> </ref-volisspag> </ref-info> <ref-fulltext>Gitlin M. Nuechterlein K. Subotnik K. Ventura J. Mintz J. Fogelson D. et al. (2001) Clinical outcome following neuroleptic discontinuation in patients with remitted recent –onset schizophrenia. Am J Psychiatry 158: 1835–1842.</ref-fulltext> </reference> <reference id="58"> <ref-info> <ref-title> <ref-titletext>Depot fluphenazine: risk/benefit ratio</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0021248058</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>W.</ce:initials> <ce:indexed-name>Glazer W.</ce:indexed-name> <ce:surname>Glazer</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="1984"/> <ref-volisspag> <voliss volume="45"/> <pagerange first="28" last="35"/> </ref-volisspag> </ref-info> <ref-fulltext>Glazer W. (1984) Depot fluphenazine: risk/benefit ratio. J Clin Psychiatry 45: 28–35.</ref-fulltext> </reference> <reference id="59"> <ref-info> <ref-title> <ref-titletext>Who receives long-acting antipsychotic medications?</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">34247398793</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>W.</ce:initials> <ce:indexed-name>Glazer W.</ce:indexed-name> <ce:surname>Glazer</ce:surname> </author> </ref-authors> <ref-sourcetitle>Psychiatr Services</ref-sourcetitle> <ref-publicationyear first="2007"/> <ref-volisspag> <voliss volume="58"/> <pagerange first="437"/> </ref-volisspag> </ref-info> <ref-fulltext>Glazer W. (2007) Who receives long-acting antipsychotic medications? Psychiatr Services 58: 437.</ref-fulltext> </reference> <reference id="60"> <ref-info> <ref-title> <ref-titletext>Depot neuroleptic therapy: an underutilized treatment option</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0027053166</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>W.</ce:initials> <ce:indexed-name>Glazer W.</ce:indexed-name> <ce:surname>Glazer</ce:surname> </author> <author seq="2"> <ce:initials>J.</ce:initials> <ce:indexed-name>Kane J.</ce:indexed-name> <ce:surname>Kane</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="1992"/> <ref-volisspag> <voliss volume="53"/> <pagerange first="426" last="433"/> </ref-volisspag> </ref-info> <ref-fulltext>Glazer W. Kane J. (1992) Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 53: 426–433.</ref-fulltext> </reference> <reference id="61"> <ref-info> <ref-title> <ref-titletext>Flupenthixol decanoate in treatment of out-patients</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0016144808</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>C.</ce:initials> <ce:indexed-name>Gottfries C.</ce:indexed-name> <ce:surname>Gottfries</ce:surname> </author> <author seq="2"> <ce:initials>L.</ce:initials> <ce:indexed-name>Green L.</ce:indexed-name> <ce:surname>Green</ce:surname> </author> </ref-authors> <ref-sourcetitle>Acta Psychiatr Scand</ref-sourcetitle> <ref-publicationyear first="1974"/> <ref-volisspag> <voliss volume="255"/> <pagerange first="15" last="24"/> </ref-volisspag> </ref-info> <ref-fulltext>Gottfries C. Green L (1974). Flupenthixol decanoate in treatment of out-patients. Acta Psychiatr Scand 255: 15–24.</ref-fulltext> </reference> <reference id="62"> <ref-info> <ref-title> <ref-titletext>Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS)</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84856267843</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>L.</ce:initials> <ce:indexed-name>Grimaldi-Bensouda L.</ce:indexed-name> <ce:surname>Grimaldi-Bensouda</ce:surname> </author> <author seq="2"> <ce:initials>F.</ce:initials> <ce:indexed-name>Rouillon F.</ce:indexed-name> <ce:surname>Rouillon</ce:surname> </author> <author seq="3"> <ce:initials>B.</ce:initials> <ce:indexed-name>Astruc B.</ce:indexed-name> <ce:surname>Astruc</ce:surname> </author> <author seq="4"> <ce:initials>M.</ce:initials> <ce:indexed-name>Rossignol M.</ce:indexed-name> <ce:surname>Rossignol</ce:surname> </author> <author seq="5"> <ce:initials>J.</ce:initials> <ce:indexed-name>Benichou J.</ce:indexed-name> <ce:surname>Benichou</ce:surname> </author> <author seq="6"> <ce:initials>B.</ce:initials> <ce:indexed-name>Falissard B.</ce:indexed-name> <ce:surname>Falissard</ce:surname> </author> <collaboration seq="1"> <ce:indexed-name>CGS Study Group</ce:indexed-name> <ce:text>CGS Study Group</ce:text> </collaboration> <et-al/> </ref-authors> <ref-sourcetitle>Schizophr Res</ref-sourcetitle> <ref-publicationyear first="2012"/> <ref-volisspag> <voliss volume="134"/> <pagerange first="187" last="194"/> </ref-volisspag> </ref-info> <ref-fulltext>Grimaldi-Bensouda L. Rouillon F. Astruc B. Rossignol M. Benichou J. Falissard B.; CGS Study Group et al. (2012) Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res 134: 187–194.</ref-fulltext> </reference> <reference id="63"> <ref-info> <ref-title> <ref-titletext>First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of Randomized controlled trials and observational studies</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">71249112357</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>P.</ce:initials> <ce:indexed-name>Haddad P.</ce:indexed-name> <ce:surname>Haddad</ce:surname> </author> <author seq="2"> <ce:initials>M.</ce:initials> <ce:indexed-name>Taylor M.</ce:indexed-name> <ce:surname>Taylor</ce:surname> </author> <author seq="3"> <ce:initials>O.</ce:initials> <ce:indexed-name>Niaz O.</ce:indexed-name> <ce:surname>Niaz</ce:surname> </author> </ref-authors> <ref-sourcetitle>Br J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2009"/> <ref-volisspag> <voliss volume="95"/> <pagerange first="S20" last="S28"/> </ref-volisspag> </ref-info> <ref-fulltext>Haddad P. Taylor M. Niaz O. (2009) First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of Randomized controlled trials and observational studies. Br J Psychiatry 95: S20–S28.</ref-fulltext> </reference> <reference id="64"> <ref-info> <ref-title> <ref-titletext>Remission and relapse in outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">33751102906</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Haro J.</ce:indexed-name> <ce:surname>Haro</ce:surname> </author> <author seq="2"> <ce:initials>D.</ce:initials> <ce:indexed-name>Novick D.</ce:indexed-name> <ce:surname>Novick</ce:surname> </author> <author seq="3"> <ce:initials>D.</ce:initials> <ce:indexed-name>Suarez D.</ce:indexed-name> <ce:surname>Suarez</ce:surname> </author> <author seq="4"> <ce:initials>J.</ce:initials> <ce:indexed-name>Alonso J.</ce:indexed-name> <ce:surname>Alonso</ce:surname> </author> <author seq="5"> <ce:initials>J.</ce:initials> <ce:indexed-name>Lepine J.</ce:indexed-name> <ce:surname>Lépine</ce:surname> </author> <author seq="6"> <ce:initials>M.</ce:initials> <ce:indexed-name>Ratcliffe M.</ce:indexed-name> <ce:surname>Ratcliffe</ce:surname> </author> <collaboration seq="1"> <ce:indexed-name>SOHO Study Group</ce:indexed-name> <ce:text>SOHO Study Group</ce:text> </collaboration> </ref-authors> <ref-sourcetitle>J Clin Psychopharmacol</ref-sourcetitle> <ref-publicationyear first="2006"/> <ref-volisspag> <voliss volume="26"/> <pagerange first="571" last="578"/> </ref-volisspag> </ref-info> <ref-fulltext>Haro J. Novick D. Suarez D. Alonso J. Lépine J. Ratcliffe M.; SOHO Study Group (2006) Remission and relapse in outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 26: 571–578.</ref-fulltext> </reference> <reference id="65"> <ref-info> <ref-title> <ref-titletext>Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">33846558834</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Haro J.</ce:indexed-name> <ce:surname>Haro</ce:surname> </author> <author seq="2"> <ce:initials>D.</ce:initials> <ce:indexed-name>Suarez D.</ce:indexed-name> <ce:surname>Suarez</ce:surname> </author> <author seq="3"> <ce:initials>D.</ce:initials> <ce:indexed-name>Novick D.</ce:indexed-name> <ce:surname>Novick</ce:surname> </author> <author seq="4"> <ce:initials>J.</ce:initials> <ce:indexed-name>Brown J.</ce:indexed-name> <ce:surname>Brown</ce:surname> </author> <author seq="5"> <ce:initials>J.</ce:initials> <ce:indexed-name>Usall J.</ce:indexed-name> <ce:surname>Usall</ce:surname> </author> <author seq="6"> <ce:initials>D.</ce:initials> <ce:indexed-name>Naber D.</ce:indexed-name> <ce:surname>Naber</ce:surname> </author> <collaboration seq="1"> <ce:indexed-name>SOHO Study Group</ce:indexed-name> <ce:text>SOHO Study Group</ce:text> </collaboration> </ref-authors> <ref-sourcetitle>Eur Neuropsychopharmacol</ref-sourcetitle> <ref-publicationyear first="2007"/> <ref-volisspag> <voliss volume="17"/> <pagerange first="235" last="244"/> </ref-volisspag> </ref-info> <ref-fulltext>Haro J. Suarez D. Novick D. Brown J. Usall J. Naber D.; SOHO Study Group (2007) Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 17: 235–244.</ref-fulltext> </reference> <reference id="66"> <ref-info> <ref-title> <ref-titletext>Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">33644829405</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>A.</ce:initials> <ce:indexed-name>Haycox A.</ce:indexed-name> <ce:surname>Haycox</ce:surname> </author> </ref-authors> <ref-sourcetitle>Pharmacoeconomics</ref-sourcetitle> <ref-publicationyear first="2005"/> <ref-volisspag> <voliss volume="23"/> <pagerange first="3" last="16"/> </ref-volisspag> </ref-info> <ref-fulltext>Haycox A. (2005) Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. Pharmacoeconomics 23(Suppl. 1): 3–16.</ref-fulltext> </reference> <reference id="67"> <ref-info> <ref-title> <ref-titletext>Attitudes of psychiatrists toward antipsychotic depot medication</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">33845998909</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>S.</ce:initials> <ce:indexed-name>Heres S.</ce:indexed-name> <ce:surname>Heres</ce:surname> </author> <author seq="2"> <ce:initials>J.</ce:initials> <ce:indexed-name>Hamann J.</ce:indexed-name> <ce:surname>Hamann</ce:surname> </author> <author seq="3"> <ce:initials>W.</ce:initials> <ce:indexed-name>Kissling W.</ce:indexed-name> <ce:surname>Kissling</ce:surname> </author> <author seq="4"> <ce:initials>S.</ce:initials> <ce:indexed-name>Leucht S.</ce:indexed-name> <ce:surname>Leucht</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="2006"/> <ref-volisspag> <voliss volume="67"/> <pagerange first="1948" last="1953"/> </ref-volisspag> </ref-info> <ref-fulltext>Heres S. Hamann J. Kissling W. Leucht S. (2006) Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 67: 1948–1953.</ref-fulltext> </reference> <reference id="68"> <ref-info> <ref-title> <ref-titletext>Identifying the profile of optimal candidates for antipsychotic depot therapy A cluster analysis</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">56449130841</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>S.</ce:initials> <ce:indexed-name>Heres S.</ce:indexed-name> <ce:surname>Heres</ce:surname> </author> <author seq="2"> <ce:initials>J.</ce:initials> <ce:indexed-name>Hamann J.</ce:indexed-name> <ce:surname>Hamann</ce:surname> </author> <author seq="3"> <ce:initials>R.</ce:initials> <ce:indexed-name>Mendel R.</ce:indexed-name> <ce:surname>Mendel</ce:surname> </author> <author seq="4"> <ce:initials>F.</ce:initials> <ce:indexed-name>Wickelmaier F.</ce:indexed-name> <ce:surname>Wickelmaier</ce:surname> </author> <author seq="5"> <ce:initials>F.</ce:initials> <ce:indexed-name>Pajonk F.</ce:indexed-name> <ce:surname>Pajonk</ce:surname> </author> <author seq="6"> <ce:initials>S.</ce:initials> <ce:indexed-name>Leucht S.</ce:indexed-name> <ce:surname>Leucht</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Prog Neuropsychopharmacol Biol Psychiatry</ref-sourcetitle> <ref-publicationyear first="2008"/> <ref-volisspag> <voliss volume="32"/> <pagerange first="1987" last="1993"/> </ref-volisspag> </ref-info> <ref-fulltext>Heres S. Hamann J. Mendel R. Wickelmaier F. Pajonk F. Leucht S. et al. (2008) Identifying the profile of optimal candidates for antipsychotic depot therapy A cluster analysis. Prog Neuropsychopharmacol Biol Psychiatry 32: 1987–1993.</ref-fulltext> </reference> <reference id="69"> <ref-info> <ref-title> <ref-titletext>The attitude of patients towards antipsychotic depot treatment</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">34547785173</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>S.</ce:initials> <ce:indexed-name>Heres S.</ce:indexed-name> <ce:surname>Heres</ce:surname> </author> <author seq="2"> <ce:initials>F.</ce:initials> <ce:indexed-name>Schmitz F.</ce:indexed-name> <ce:surname>Schmitz</ce:surname> </author> <author seq="3"> <ce:initials>S.</ce:initials> <ce:indexed-name>Leucht S.</ce:indexed-name> <ce:surname>Leucht</ce:surname> </author> <author seq="4"> <ce:initials>F.</ce:initials> <ce:indexed-name>Pajonk F.</ce:indexed-name> <ce:surname>Pajonk</ce:surname> </author> </ref-authors> <ref-sourcetitle>Int Clin Psychopharmacol</ref-sourcetitle> <ref-publicationyear first="2007"/> <ref-volisspag> <voliss volume="22"/> <pagerange first="275" last="282"/> </ref-volisspag> </ref-info> <ref-fulltext>Heres S. Schmitz F. Leucht S. Pajonk F. (2007) The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol 22: 275–282.</ref-fulltext> </reference> <reference id="70"> <ref-info> <ref-title> <ref-titletext>Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">79951503453</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>B.</ce:initials> <ce:indexed-name>Ho B.</ce:indexed-name> <ce:surname>Ho</ce:surname> </author> <author seq="2"> <ce:initials>N.</ce:initials> <ce:indexed-name>Andreasen N.</ce:indexed-name> <ce:surname>Andreasen</ce:surname> </author> <author seq="3"> <ce:initials>S.</ce:initials> <ce:indexed-name>Ziebell S.</ce:indexed-name> <ce:surname>Ziebell</ce:surname> </author> <author seq="4"> <ce:initials>R.</ce:initials> <ce:indexed-name>Pierson R.</ce:indexed-name> <ce:surname>Pierson</ce:surname> </author> <author seq="5"> <ce:initials>V.</ce:initials> <ce:indexed-name>Magnotta V.</ce:indexed-name> <ce:surname>Magnotta</ce:surname> </author> </ref-authors> <ref-sourcetitle>Arch Gen Psychiatry</ref-sourcetitle> <ref-publicationyear first="2011"/> <ref-volisspag> <voliss volume="68"/> <pagerange first="128" last="137"/> </ref-volisspag> </ref-info> <ref-fulltext>Ho B. Andreasen N. Ziebell S. Pierson R. Magnotta V. (2011) Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 68: 128–137.</ref-fulltext> </reference> <reference id="71"> <ref-info> <ref-title> <ref-titletext>Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0018686085</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>G.</ce:initials> <ce:indexed-name>Hogarty G.</ce:indexed-name> <ce:surname>Hogarty</ce:surname> </author> <author seq="2"> <ce:initials>N.</ce:initials> <ce:indexed-name>Schooler N.</ce:indexed-name> <ce:surname>Schooler</ce:surname> </author> <author seq="3"> <ce:initials>R.</ce:initials> <ce:indexed-name>Ulrich R.</ce:indexed-name> <ce:surname>Ulrich</ce:surname> </author> <author seq="4"> <ce:initials>F.</ce:initials> <ce:indexed-name>Mussare F.</ce:indexed-name> <ce:surname>Mussare</ce:surname> </author> <author seq="5"> <ce:initials>P.</ce:initials> <ce:indexed-name>Ferro P.</ce:indexed-name> <ce:surname>Ferro</ce:surname> </author> <author seq="6"> <ce:initials>E.</ce:initials> <ce:indexed-name>Herron E.</ce:indexed-name> <ce:surname>Herron</ce:surname> </author> </ref-authors> <ref-sourcetitle>Arch Gen Psychiatry</ref-sourcetitle> <ref-publicationyear first="1979"/> <ref-volisspag> <voliss volume="36"/> <pagerange first="1283" last="1294"/> </ref-volisspag> </ref-info> <ref-fulltext>Hogarty G. Schooler N. Ulrich R. Mussare F. Ferro P. Herron E (1979) Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 36: 1283–1294.</ref-fulltext> </reference> <reference id="72"> <ref-info> <ref-title> <ref-titletext>Temporal effects of drug and placebo in delaying relapse in schizophrenia outpatients</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0017361552</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>G.</ce:initials> <ce:indexed-name>Hogarty G.</ce:indexed-name> <ce:surname>Hogarty</ce:surname> </author> <author seq="2"> <ce:initials>R.</ce:initials> <ce:indexed-name>Ulrich R.</ce:indexed-name> <ce:surname>Ulrich</ce:surname> </author> </ref-authors> <ref-sourcetitle>Arch Gen Psychiatry</ref-sourcetitle> <ref-publicationyear first="1977"/> <ref-volisspag> <voliss volume="34"/> <pagerange first="297" last="301"/> </ref-volisspag> </ref-info> <ref-fulltext>Hogarty G. Ulrich R. (1977) Temporal effects of drug and placebo in delaying relapse in schizophrenia outpatients. Arch Gen Psychiatry 34: 297–301.</ref-fulltext> </reference> <reference id="73"> <ref-info> <ref-title> <ref-titletext>The limitations of antipsychotic medication on schizophrenia relapse and adjustments and the contribution of psychosocial treatment</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0032071193</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>G.</ce:initials> <ce:indexed-name>Hogarty G.</ce:indexed-name> <ce:surname>Hogarty</ce:surname> </author> <author seq="2"> <ce:initials>R.</ce:initials> <ce:indexed-name>Ulrich R.</ce:indexed-name> <ce:surname>Ulrich</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Psychiatr Res</ref-sourcetitle> <ref-publicationyear first="1998"/> <ref-volisspag> <voliss volume="32"/> <pagerange first="243" last="250"/> </ref-volisspag> </ref-info> <ref-fulltext>Hogarty G. Ulrich R. (1998) The limitations of antipsychotic medication on schizophrenia relapse and adjustments and the contribution of psychosocial treatment. J Psychiatr Res 32: 243–250.</ref-fulltext> </reference> <reference id="74"> <ref-info> <ref-title> <ref-titletext>An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">2342475084</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>V.</ce:initials> <ce:indexed-name>Humberstone V.</ce:indexed-name> <ce:surname>Humberstone</ce:surname> </author> <author seq="2"> <ce:initials>A.</ce:initials> <ce:indexed-name>Wheeler A.</ce:indexed-name> <ce:surname>Wheeler</ce:surname> </author> <author seq="3"> <ce:initials>T.</ce:initials> <ce:indexed-name>Lambert T.</ce:indexed-name> <ce:surname>Lambert</ce:surname> </author> </ref-authors> <ref-sourcetitle>Aust N Z J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2004"/> <ref-volisspag> <voliss volume="38"/> <pagerange first="240" last="245"/> </ref-volisspag> </ref-info> <ref-fulltext>Humberstone V. Wheeler A. Lambert T. (2004) An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand. Aust N Z J Psychiatry 38: 240–245.</ref-fulltext> </reference> <reference id="75"> <ref-info> <ref-title> <ref-titletext>Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">72049091199</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Jaeger M.</ce:indexed-name> <ce:surname>Jaeger</ce:surname> </author> <author seq="2"> <ce:initials>W.</ce:initials> <ce:indexed-name>Rossler W.</ce:indexed-name> <ce:surname>Rossler</ce:surname> </author> </ref-authors> <ref-sourcetitle>Psychiatry Res</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <voliss volume="175"/> <pagerange first="58" last="62"/> </ref-volisspag> </ref-info> <ref-fulltext>Jaeger M. Rossler W. (2010) Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res 175: 58–62.</ref-fulltext> </reference> <reference id="76"> <ref-info> <ref-title> <ref-titletext>Clinical pharmacokinetics of the depot antipsychotics</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0021843298</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Jann M.</ce:indexed-name> <ce:surname>Jann</ce:surname> </author> <author seq="2"> <ce:initials>L.</ce:initials> <ce:indexed-name>Ereshefsky L.</ce:indexed-name> <ce:surname>Ereshefsky</ce:surname> </author> <author seq="3"> <ce:initials>S.</ce:initials> <ce:indexed-name>Saklad S.</ce:indexed-name> <ce:surname>Saklad</ce:surname> </author> </ref-authors> <ref-sourcetitle>Clin Pharmacokinet</ref-sourcetitle> <ref-publicationyear first="1985"/> <ref-volisspag> <voliss volume="10"/> <pagerange first="315" last="333"/> </ref-volisspag> </ref-info> <ref-fulltext>Jann M. Ereshefsky L. Saklad S. (1985) Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet 10: 315–333.</ref-fulltext> </reference> <reference id="77"> <ref-info> <ref-title> <ref-titletext>Historical perspective on antipsychotic long-acting injections</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84997885741</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>D.</ce:initials> <ce:indexed-name>Johnson D.</ce:indexed-name> <ce:surname>Johnson</ce:surname> </author> </ref-authors> <ref-sourcetitle>Br J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2009"/> <ref-volisspag> <voliss volume="195"/> <pagerange first="S7" last="S12"/> </ref-volisspag> </ref-info> <ref-fulltext>Johnson D. (2009) Historical perspective on antipsychotic long-acting injections. Br J Psychiatry 195: S7–S12.</ref-fulltext> </reference> <reference id="78"> <ref-info> <ref-title> <ref-titletext>The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0020595658</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>D.</ce:initials> <ce:indexed-name>Johnson D.</ce:indexed-name> <ce:surname>Johnson</ce:surname> </author> <author seq="2"> <ce:initials>G.</ce:initials> <ce:indexed-name>Pasterski G.</ce:indexed-name> <ce:surname>Pasterski</ce:surname> </author> <author seq="3"> <ce:initials>J.</ce:initials> <ce:indexed-name>Ludlow J.</ce:indexed-name> <ce:surname>Ludlow</ce:surname> </author> <author seq="4"> <ce:initials>K.</ce:initials> <ce:indexed-name>Street K.</ce:indexed-name> <ce:surname>Street</ce:surname> </author> <author seq="5"> <ce:initials>R.</ce:initials> <ce:indexed-name>Taylor R.</ce:indexed-name> <ce:surname>Taylor</ce:surname> </author> </ref-authors> <ref-sourcetitle>Acta Psychiatr Scand</ref-sourcetitle> <ref-publicationyear first="1983"/> <ref-volisspag> <voliss volume="67"/> <pagerange first="339" last="352"/> </ref-volisspag> </ref-info> <ref-fulltext>Johnson D. Pasterski G. Ludlow J. Street K. Taylor R. (1983) The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand 67: 339–352.</ref-fulltext> </reference> <reference id="79"> <ref-info> <ref-title> <ref-titletext>Pharmacokinetic studies in volunteers of intravenous and oral cis (Z)-flupentixol and intramuscular cis (Z)-flupentixol decanoate in Viscoleo</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0018930602</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>A.</ce:initials> <ce:indexed-name>J⊘rgensen A.</ce:indexed-name> <ce:surname>J⊘rgensen</ce:surname> </author> </ref-authors> <ref-sourcetitle>Eur J Clin Pharmacol</ref-sourcetitle> <ref-publicationyear first="1980"/> <ref-volisspag> <voliss volume="18"/> <pagerange first="355" last="360"/> </ref-volisspag> </ref-info> <ref-fulltext>J⊘rgensen A. (1980) Pharmacokinetic studies in volunteers of intravenous and oral cis (Z)-flupentixol and intramuscular cis (Z)-flupentixol decanoate in Viscoleo. Eur J Clin Pharmacol 18: 355–360.</ref-fulltext> </reference> <reference id="80"> <ref-info> <ref-title> <ref-titletext>Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0031983904</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Kane J.</ce:indexed-name> <ce:surname>Kane</ce:surname> </author> <author seq="2"> <ce:initials>E.</ce:initials> <ce:indexed-name>Aguglia E.</ce:indexed-name> <ce:surname>Aguglia</ce:surname> </author> <author seq="3"> <ce:initials>A.</ce:initials> <ce:indexed-name>Altamura A.</ce:indexed-name> <ce:surname>Altamura</ce:surname> </author> <author seq="4"> <ce:initials>J.</ce:initials> <ce:indexed-name>Ayuso Gutierrez J.</ce:indexed-name> <ce:surname>Ayuso Gutierrez</ce:surname> </author> <author seq="5"> <ce:initials>N.</ce:initials> <ce:indexed-name>Brunello N.</ce:indexed-name> <ce:surname>Brunello</ce:surname> </author> <author seq="6"> <ce:initials>W.</ce:initials> <ce:indexed-name>Fleischhacker W.</ce:indexed-name> <ce:surname>Fleischhacker</ce:surname> </author> </ref-authors> <ref-sourcetitle>Eur Neuropsychopharmacol</ref-sourcetitle> <ref-publicationyear first="1998"/> <ref-volisspag> <voliss volume="8"/> <pagerange first="55" last="66"/> </ref-volisspag> </ref-info> <ref-fulltext>Kane J. Aguglia E. Altamura A. Ayuso Gutierrez J. Brunello N. Fleischhacker W. (1998) Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 8: 55–66</ref-fulltext> </reference> <reference id="81"> <ref-info> <ref-title> <ref-titletext>Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">75749098515</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Kane J.</ce:indexed-name> <ce:surname>Kane</ce:surname> </author> <author seq="2"> <ce:initials>H.</ce:initials> <ce:indexed-name>Detke H.</ce:indexed-name> <ce:surname>Detke</ce:surname> </author> <author seq="3"> <ce:initials>D.</ce:initials> <ce:indexed-name>Naber D.</ce:indexed-name> <ce:surname>Naber</ce:surname> </author> <author seq="4"> <ce:initials>G.</ce:initials> <ce:indexed-name>Sethuraman G.</ce:indexed-name> <ce:surname>Sethuraman</ce:surname> </author> <author seq="5"> <ce:initials>D.</ce:initials> <ce:indexed-name>Lin D.</ce:indexed-name> <ce:surname>Lin</ce:surname> </author> <author seq="6"> <ce:initials>R.</ce:initials> <ce:indexed-name>Bergstrom R.</ce:indexed-name> <ce:surname>Bergstrom</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Am J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <voliss volume="167"/> <pagerange first="181" last="189"/> </ref-volisspag> </ref-info> <ref-fulltext>Kane J. Detke H. Naber D. Sethuraman G. Lin D. Bergstrom R. et al. (2010) Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 167: 181–189.</ref-fulltext> </reference> <reference id="82"> <ref-info> <ref-title> <ref-titletext>Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0038149626</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Kane J.</ce:indexed-name> <ce:surname>Kane</ce:surname> </author> <author seq="2"> <ce:initials>M.</ce:initials> <ce:indexed-name>Eerdekens M.</ce:indexed-name> <ce:surname>Eerdekens</ce:surname> </author> <author seq="3"> <ce:initials>J.</ce:initials> <ce:indexed-name>Lindenmayer J.</ce:indexed-name> <ce:surname>Lindenmayer</ce:surname> </author> <author seq="4"> <ce:initials>S.</ce:initials> <ce:indexed-name>Keith S.</ce:indexed-name> <ce:surname>Keith</ce:surname> </author> <author seq="5"> <ce:initials>M.</ce:initials> <ce:indexed-name>Lesem M.</ce:indexed-name> <ce:surname>Lesem</ce:surname> </author> <author seq="6"> <ce:initials>K.</ce:initials> <ce:indexed-name>Karcher K.</ce:indexed-name> <ce:surname>Karcher</ce:surname> </author> </ref-authors> <ref-sourcetitle>Am J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2003"/> <ref-volisspag> <voliss volume="160"/> <pagerange first="1125" last="1132"/> </ref-volisspag> </ref-info> <ref-fulltext>Kane J. Eerdekens M. Lindenmayer J. Keith S. Lesem M. Karcher K. (2003) Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160: 1125–1132.</ref-fulltext> </reference> <reference id="83"> <ref-info> <ref-title> <ref-titletext>Clinical guideline recommendations for antipsychotic long-acting injections</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">71249096481</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Kane J.</ce:indexed-name> <ce:surname>Kane</ce:surname> </author> <author seq="2"> <ce:initials>C.</ce:initials> <ce:indexed-name>Garcia-Ribera C.</ce:indexed-name> <ce:surname>Garcia-Ribera</ce:surname> </author> </ref-authors> <ref-sourcetitle>Br J Psychiatry Suppl</ref-sourcetitle> <ref-publicationyear first="2009"/> <ref-volisspag> <voliss volume="52"/> <pagerange first="63" last="67"/> </ref-volisspag> </ref-info> <ref-fulltext>Kane J. Garcia-Ribera C. (2009) Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry Suppl 52: 63–67.</ref-fulltext> </reference> <reference id="84"> <ref-info> <ref-title> <ref-titletext>Clozapine for treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0023812652</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Kane J.</ce:indexed-name> <ce:surname>Kane</ce:surname> </author> <author seq="2"> <ce:initials>G.</ce:initials> <ce:indexed-name>Honigfeld G.</ce:indexed-name> <ce:surname>Honigfeld</ce:surname> </author> <author seq="3"> <ce:initials>J.</ce:initials> <ce:indexed-name>Singer J.</ce:indexed-name> <ce:surname>Singer</ce:surname> </author> <author seq="4"> <ce:initials>H.</ce:initials> <ce:indexed-name>Meltzer H.</ce:indexed-name> <ce:surname>Meltzer</ce:surname> </author> </ref-authors> <ref-sourcetitle>Arch Gen Psychiatry</ref-sourcetitle> <ref-publicationyear first="1988"/> <ref-volisspag> <voliss volume="45"/> <pagerange first="789" last="796"/> </ref-volisspag> </ref-info> <ref-fulltext>Kane J. Honigfeld G. Singer J. Meltzer H. (1988) Clozapine for treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789–796.</ref-fulltext> </reference> <reference id="85"> <ref-info> <ref-title> <ref-titletext>Assessing the comparative effectiveness of long-acting injectable versus oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84880193278</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Kane J.</ce:indexed-name> <ce:surname>Kane</ce:surname> </author> <author seq="2"> <ce:initials>T.</ce:initials> <ce:indexed-name>Kishimoto T.</ce:indexed-name> <ce:surname>Kishimoto</ce:surname> </author> <author seq="3"> <ce:initials>C.</ce:initials> <ce:indexed-name>Correll C.</ce:indexed-name> <ce:surname>Correll</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Clin Epidemiol</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="66"/> <pagerange first="S37" last="S41"/> </ref-volisspag> </ref-info> <ref-fulltext>Kane J. Kishimoto T. Correll C. (2013a) Assessing the comparative effectiveness of long-acting injectable versus oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol 66(8 Suppl.): S37–S41.</ref-fulltext> </reference> <reference id="86"> <ref-info> <ref-title> <ref-titletext>Fluphenazine vs placebo in patients with remitted, acute first episode schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0020068603</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Kane J.</ce:indexed-name> <ce:surname>Kane</ce:surname> </author> <author seq="2"> <ce:initials>A.</ce:initials> <ce:indexed-name>Rifkin A.</ce:indexed-name> <ce:surname>Rifkin</ce:surname> </author> <author seq="3"> <ce:initials>F.</ce:initials> <ce:indexed-name>Quitkin F.</ce:indexed-name> <ce:surname>Quitkin</ce:surname> </author> <author seq="4"> <ce:initials>D.</ce:initials> <ce:indexed-name>Nayak D.</ce:indexed-name> <ce:surname>Nayak</ce:surname> </author> <author seq="5"> <ce:initials>J.</ce:initials> <ce:indexed-name>Ramos-Lorenzi J.</ce:indexed-name> <ce:surname>Ramos-Lorenzi</ce:surname> </author> </ref-authors> <ref-sourcetitle>Arch Gen Psychiatry</ref-sourcetitle> <ref-publicationyear first="1982"/> <ref-volisspag> <voliss volume="39"/> <pagerange first="70" last="73"/> </ref-volisspag> </ref-info> <ref-fulltext>Kane J. Rifkin A. Quitkin F. Nayak D. Ramos-Lorenzi J. (1982) Fluphenazine vs placebo in patients with remitted, acute first episode schizophrenia. Arch Gen Psychiatry 39: 70–73.</ref-fulltext> </reference> <reference id="87"> <ref-info> <ref-title> <ref-titletext>Hospitalization rates in patients switched from oral antipsychotics to aripiprazole once-monthly for the management of schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84879744844</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Kane J.</ce:indexed-name> <ce:surname>Kane</ce:surname> </author> <author seq="2"> <ce:initials>R.</ce:initials> <ce:indexed-name>Sanchez R.</ce:indexed-name> <ce:surname>Sanchez</ce:surname> </author> <author seq="3"> <ce:initials>J.</ce:initials> <ce:indexed-name>Zhao J.</ce:indexed-name> <ce:surname>Zhao</ce:surname> </author> <author seq="4"> <ce:initials>A.</ce:initials> <ce:indexed-name>Duca A.</ce:indexed-name> <ce:surname>Duca</ce:surname> </author> <author seq="5"> <ce:initials>B.</ce:initials> <ce:indexed-name>Johnson B.</ce:indexed-name> <ce:surname>Johnson</ce:surname> </author> <author seq="6"> <ce:initials>R.</ce:initials> <ce:indexed-name>McQuade R.</ce:indexed-name> <ce:surname>McQuade</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>J Med Econ</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="16"/> <pagerange first="917" last="925"/> </ref-volisspag> </ref-info> <ref-fulltext>Kane J. Sanchez R. Zhao J. Duca A. Johnson B. McQuade R. et al. (2013b) Hospitalization rates in patients switched from oral antipsychotics to aripiprazole once-monthly for the management of schizophrenia. J Med Econ 16: 917–925.</ref-fulltext> </reference> <reference id="88"> <ref-info> <ref-title> <ref-titletext>Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84888149306</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>G.</ce:initials> <ce:indexed-name>Kaplan G.</ce:indexed-name> <ce:surname>Kaplan</ce:surname> </author> <author seq="2"> <ce:initials>J.</ce:initials> <ce:indexed-name>Casoy J.</ce:indexed-name> <ce:surname>Casoy</ce:surname> </author> <author seq="3"> <ce:initials>J.</ce:initials> <ce:indexed-name>Zummo J.</ce:indexed-name> <ce:surname>Zummo</ce:surname> </author> </ref-authors> <ref-sourcetitle>Patient Prefer Adherence</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="13"/> <pagerange first="1171" last="1180"/> </ref-volisspag> </ref-info> <ref-fulltext>Kaplan G. Casoy J. Zummo J. (2013) Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence 13: 1171–1180.</ref-fulltext> </reference> <reference id="89"> <ref-info> <ref-title> <ref-titletext>Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">2942565924</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>R.</ce:initials> <ce:indexed-name>Keefe R.</ce:indexed-name> <ce:surname>Keefe</ce:surname> </author> <author seq="2"> <ce:initials>L.</ce:initials> <ce:indexed-name>Seidman L.</ce:indexed-name> <ce:surname>Seidman</ce:surname> </author> <author seq="3"> <ce:initials>B.</ce:initials> <ce:indexed-name>Christensen B.</ce:indexed-name> <ce:surname>Christensen</ce:surname> </author> <author seq="4"> <ce:initials>R.</ce:initials> <ce:indexed-name>Hamer R.</ce:indexed-name> <ce:surname>Hamer</ce:surname> </author> <author seq="5"> <ce:initials>T.</ce:initials> <ce:indexed-name>Sharma T.</ce:indexed-name> <ce:surname>Sharma</ce:surname> </author> <author seq="6"> <ce:initials>M.</ce:initials> <ce:indexed-name>Sitskoorn M.</ce:indexed-name> <ce:surname>Sitskoorn</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Am J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2004"/> <ref-volisspag> <voliss volume="161"/> <pagerange first="985" last="995"/> </ref-volisspag> </ref-info> <ref-fulltext>Keefe R. Seidman L. Christensen B. Hamer R. Sharma T. Sitskoorn M. et al. (2004) Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 161: 985–995.</ref-fulltext> </reference> <reference id="90"> <ref-info> <ref-title> <ref-titletext>Association of violence with emergence of persecutory delusions in untreated schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84898743454</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>R.</ce:initials> <ce:indexed-name>Keers R.</ce:indexed-name> <ce:surname>Keers</ce:surname> </author> <author seq="2"> <ce:initials>S.</ce:initials> <ce:indexed-name>Ullrich S.</ce:indexed-name> <ce:surname>Ullrich</ce:surname> </author> <author seq="3"> <ce:initials>B.</ce:initials> <ce:indexed-name>Destavola B.</ce:indexed-name> <ce:surname>Destavola</ce:surname> </author> <author seq="4"> <ce:initials>J.</ce:initials> <ce:indexed-name>Coid J.</ce:indexed-name> <ce:surname>Coid</ce:surname> </author> </ref-authors> <ref-sourcetitle>Am J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2014"/> <ref-volisspag> <voliss volume="171"/> <pagerange first="332" last="339"/> </ref-volisspag> </ref-info> <ref-fulltext>Keers R. Ullrich S Destavola B. Coid J. (2014) Association of violence with emergence of persecutory delusions in untreated schizophrenia. Am J Psychiatry 171: 332–339.</ref-fulltext> </reference> <reference id="91"> <ref-info> <ref-title> <ref-titletext>Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">58149270737</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>S.</ce:initials> <ce:indexed-name>Keith S.</ce:indexed-name> <ce:surname>Keith</ce:surname> </author> </ref-authors> <ref-sourcetitle>Expert Rev Neurother</ref-sourcetitle> <ref-publicationyear first="2009"/> <ref-volisspag> <voliss volume="9"/> <pagerange first="9" last="31"/> </ref-volisspag> </ref-info> <ref-fulltext>Keith S. (2009) Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness. Expert Rev Neurother 9: 9–31.</ref-fulltext> </reference> <reference id="92"> <ref-info> <ref-title> <ref-titletext>First-episode schizophrenia: a focus on pharmacological treatment and safety considerations</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">20544458079</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>D.</ce:initials> <ce:indexed-name>Kelly D.</ce:indexed-name> <ce:surname>Kelly</ce:surname> </author> <author seq="2"> <ce:initials>R.</ce:initials> <ce:indexed-name>Conley R.</ce:indexed-name> <ce:surname>Conley</ce:surname> </author> <author seq="3"> <ce:initials>W.</ce:initials> <ce:indexed-name>Carpenter W.</ce:indexed-name> <ce:surname>Carpenter</ce:surname> </author> </ref-authors> <ref-sourcetitle>Drugs</ref-sourcetitle> <ref-publicationyear first="2005"/> <ref-volisspag> <voliss volume="65"/> <pagerange first="1113" last="1138"/> </ref-volisspag> </ref-info> <ref-fulltext>Kelly D. Conley R. Carpenter W. (2005) First-episode schizophrenia: a focus on pharmacological treatment and safety considerations. Drugs 65: 1113–1138.</ref-fulltext> </reference> <reference id="93"> <ref-info> <ref-title> <ref-titletext>Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">49849092027</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>B.</ce:initials> <ce:indexed-name>Kim B.</ce:indexed-name> <ce:surname>Kim</ce:surname> </author> <author seq="2"> <ce:initials>S.</ce:initials> <ce:indexed-name>Lee S.</ce:indexed-name> <ce:surname>Lee</ce:surname> </author> <author seq="3"> <ce:initials>T.</ce:initials> <ce:indexed-name>Choi T.</ce:indexed-name> <ce:surname>Choi</ce:surname> </author> <author seq="4"> <ce:initials>S.</ce:initials> <ce:indexed-name>Suh S.</ce:indexed-name> <ce:surname>Suh</ce:surname> </author> <author seq="5"> <ce:initials>Y.</ce:initials> <ce:indexed-name>Kim Y.</ce:indexed-name> <ce:surname>Kim</ce:surname> </author> <author seq="6"> <ce:initials>E.</ce:initials> <ce:indexed-name>Lee E.</ce:indexed-name> <ce:surname>Lee</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Prog Neuropsychopharmacol Biol Psychiatry</ref-sourcetitle> <ref-publicationyear first="2008"/> <ref-volisspag> <voliss volume="32"/> <pagerange first="1231" last="1235"/> </ref-volisspag> </ref-info> <ref-fulltext>Kim B. Lee S. Choi T. Suh S. Kim Y. Lee E. et al. (2008) Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry 32: 1231–1235.</ref-fulltext> </reference> <reference id="94"> <ref-info> <ref-title> <ref-titletext>Comparison of attitudes toward long-acting injectable antipsychotics among psychiatrists and patients</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84873408260</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>S.</ce:initials> <ce:indexed-name>Kim S.</ce:indexed-name> <ce:surname>Kim</ce:surname> </author> <author seq="2"> <ce:initials>Y.</ce:initials> <ce:indexed-name>Lee Y.</ce:indexed-name> <ce:surname>Lee</ce:surname> </author> <author seq="3"> <ce:initials>J.</ce:initials> <ce:indexed-name>Jang J.</ce:indexed-name> <ce:surname>Jang</ce:surname> </author> <author seq="4"> <ce:initials>T.</ce:initials> <ce:indexed-name>Yoo T.</ce:indexed-name> <ce:surname>Yoo</ce:surname> </author> <author seq="5"> <ce:initials>J.</ce:initials> <ce:indexed-name>Kim J.</ce:indexed-name> <ce:surname>Kim</ce:surname> </author> <author seq="6"> <ce:initials>I.</ce:initials> <ce:indexed-name>Shin I.</ce:indexed-name> <ce:surname>Shin</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Int Clin Psychopharmacol</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="28"/> <pagerange first="80" last="86"/> </ref-volisspag> </ref-info> <ref-fulltext>Kim S. Lee Y. Jang J. Yoo T. Kim J. Shin I. et al. (2013) Comparison of attitudes toward long-acting injectable antipsychotics among psychiatrists and patients. Int Clin Psychopharmacol 28: 80–86.</ref-fulltext> </reference> <reference id="95"> <ref-info> <ref-title> <ref-titletext>Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84882742386</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>S.</ce:initials> <ce:indexed-name>Kim S.</ce:indexed-name> <ce:surname>Kim</ce:surname> </author> <author seq="2"> <ce:initials>H.</ce:initials> <ce:indexed-name>Solari H.</ce:indexed-name> <ce:surname>Solari</ce:surname> </author> <author seq="3"> <ce:initials>P.</ce:initials> <ce:indexed-name>Weiden P.</ce:indexed-name> <ce:surname>Weiden</ce:surname> </author> <author seq="4"> <ce:initials>J.</ce:initials> <ce:indexed-name>Bishop J.</ce:indexed-name> <ce:surname>Bishop</ce:surname> </author> </ref-authors> <ref-sourcetitle>Patient Prefer Adherence</ref-sourcetitle> <ref-publicationyear first="2012"/> <ref-volisspag> <voliss volume="6"/> <pagerange first="533" last="545"/> </ref-volisspag> </ref-info> <ref-fulltext>Kim S. Solari H. Weiden P. Bishop J. (2012) Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults. Patient Prefer Adherence 6: 533–545.</ref-fulltext> </reference> <reference id="96"> <ref-info> <ref-title> <ref-titletext>Patients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84997891835</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Kirschner M.</ce:indexed-name> <ce:surname>Kirschner</ce:surname> </author> <author seq="2"> <ce:initials>A.</ce:initials> <ce:indexed-name>Theodoridou A.</ce:indexed-name> <ce:surname>Theodoridou</ce:surname> </author> <author seq="3"> <ce:initials>I.</ce:initials> <ce:indexed-name>Fusar-Pol I.</ce:indexed-name> <ce:surname>Fusar-Pol</ce:surname> </author> <author seq="4"> <ce:initials>S.</ce:initials> <ce:indexed-name>Kaiser S.</ce:indexed-name> <ce:surname>Kaiser</ce:surname> </author> <author seq="5"> <ce:initials>M.</ce:initials> <ce:indexed-name>Jager M.</ce:indexed-name> <ce:surname>Jäger</ce:surname> </author> </ref-authors> <ref-sourcetitle>Ther Adv Psychopharmacol</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="3"/> <pagerange first="89" last="99"/> </ref-volisspag> </ref-info> <ref-fulltext>Kirschner M. Theodoridou A. Fusar-Pol I. Kaiser S. Jäger M. (2013) Patients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis. Ther Adv Psychopharmacol 3: 89–99.</ref-fulltext> </reference> <reference id="97"> <ref-info> <ref-title> <ref-titletext>Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84879595485</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>N.</ce:initials> <ce:indexed-name>Kirson N.</ce:indexed-name> <ce:surname>Kirson</ce:surname> </author> <author seq="2"> <ce:initials>P.</ce:initials> <ce:indexed-name>Weiden P.</ce:indexed-name> <ce:surname>Weiden</ce:surname> </author> <author seq="3"> <ce:initials>S.</ce:initials> <ce:indexed-name>Yermakov S.</ce:indexed-name> <ce:surname>Yermakov</ce:surname> </author> <author seq="4"> <ce:initials>W.</ce:initials> <ce:indexed-name>Huang W.</ce:indexed-name> <ce:surname>Huang</ce:surname> </author> <author seq="5"> <ce:initials>T.</ce:initials> <ce:indexed-name>Samuelson T.</ce:indexed-name> <ce:surname>Samuelson</ce:surname> </author> <author seq="6"> <ce:initials>S.</ce:initials> <ce:indexed-name>Offord S.</ce:indexed-name> <ce:surname>Offord</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="74"/> <pagerange first="568" last="575"/> </ref-volisspag> </ref-info> <ref-fulltext>Kirson N. Weiden P. Yermakov S. Huang W. Samuelson T. Offord S. et al. (2013) Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 74: 568–575.</ref-fulltext> </reference> <reference id="98"> <ref-info> <ref-title> <ref-titletext>Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84892639627</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>T.</ce:initials> <ce:indexed-name>Kishimoto T.</ce:indexed-name> <ce:surname>Kishimoto</ce:surname> </author> <author seq="2"> <ce:initials>A.</ce:initials> <ce:indexed-name>Robenzadeh A.</ce:indexed-name> <ce:surname>Robenzadeh</ce:surname> </author> <author seq="3"> <ce:initials>C.</ce:initials> <ce:indexed-name>Leucht C.</ce:indexed-name> <ce:surname>Leucht</ce:surname> </author> <author seq="4"> <ce:initials>S.</ce:initials> <ce:indexed-name>Leucht S.</ce:indexed-name> <ce:surname>Leucht</ce:surname> </author> <author seq="5"> <ce:initials>K.</ce:initials> <ce:indexed-name>Watanabe K.</ce:indexed-name> <ce:surname>Watanabe</ce:surname> </author> <author seq="6"> <ce:initials>M.</ce:initials> <ce:indexed-name>Mimura M.</ce:indexed-name> <ce:surname>Mimura</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Schizophr Bull</ref-sourcetitle> <ref-publicationyear first="2014"/> <ref-volisspag> <voliss volume="40"/> <pagerange first="192" last="213"/> </ref-volisspag> </ref-info> <ref-fulltext>Kishimoto T. Robenzadeh A. Leucht C. Leucht S. Watanabe K. Mimura M. et al. (2014) Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 40: 192–213.</ref-fulltext> </reference> <reference id="99"> <ref-info> <ref-title> <ref-titletext>Guidelines for neuroleptic relapse prevention in schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84998170755</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>W.</ce:initials> <ce:indexed-name>Kissling W.</ce:indexed-name> <ce:surname>Kissling</ce:surname> </author> </ref-authors> <ref-sourcetitle>Guidelines for Neuroleptic Relapse Prevention in Schizophrenia</ref-sourcetitle> <ref-publicationyear first="1991"/> <ref-volisspag> <pagerange first="1" last="6"/> </ref-volisspag> <ref-text>In: Kissling W. (ed.), Berlin: Springer Verlag</ref-text> </ref-info> <ref-fulltext>Kissling W. (1991) Guidelines for neuroleptic relapse prevention in schizophrenia. In: Kissling W. (ed.), Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. Berlin: Springer Verlag, pp. 1–6.</ref-fulltext> </reference> <reference id="100"> <ref-info> <ref-title> <ref-titletext>Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months’ treatment for relapse prevention</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0021809467</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>W.</ce:initials> <ce:indexed-name>Kissling W.</ce:indexed-name> <ce:surname>Kissling</ce:surname> </author> <author seq="2"> <ce:initials>H.</ce:initials> <ce:indexed-name>Moller H.</ce:indexed-name> <ce:surname>Moller</ce:surname> </author> <author seq="3"> <ce:initials>K.</ce:initials> <ce:indexed-name>Walter K.</ce:indexed-name> <ce:surname>Walter</ce:surname> </author> <author seq="4"> <ce:initials>B.</ce:initials> <ce:indexed-name>Wittmann B.</ce:indexed-name> <ce:surname>Wittmann</ce:surname> </author> <author seq="5"> <ce:initials>R.</ce:initials> <ce:indexed-name>Krueger R.</ce:indexed-name> <ce:surname>Krueger</ce:surname> </author> <author seq="6"> <ce:initials>D.</ce:initials> <ce:indexed-name>Trenk D.</ce:indexed-name> <ce:surname>Trenk</ce:surname> </author> </ref-authors> <ref-sourcetitle>Pharmacopsychiatry</ref-sourcetitle> <ref-publicationyear first="1985"/> <ref-volisspag> <voliss volume="18"/> <pagerange first="240" last="245"/> </ref-volisspag> </ref-info> <ref-fulltext>Kissling W. Moller H. Walter K. Wittmann B. Krueger R. Trenk D. (1985) Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months’ treatment for relapse prevention. Pharmacopsychiatry 18: 240–245.</ref-fulltext> </reference> <reference id="101"> <ref-info> <ref-title> <ref-titletext>The global costs of schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">1842858243</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Knapp M.</ce:indexed-name> <ce:surname>Knapp</ce:surname> </author> <author seq="2"> <ce:initials>R.</ce:initials> <ce:indexed-name>Mangalore R.</ce:indexed-name> <ce:surname>Mangalore</ce:surname> </author> <author seq="3"> <ce:initials>J.</ce:initials> <ce:indexed-name>Simon J.</ce:indexed-name> <ce:surname>Simon</ce:surname> </author> </ref-authors> <ref-sourcetitle>Schizophr Bull</ref-sourcetitle> <ref-publicationyear first="2004"/> <ref-volisspag> <voliss volume="30"/> <pagerange first="279" last="293"/> </ref-volisspag> </ref-info> <ref-fulltext>Knapp M. Mangalore R. Simon J. (2004) The global costs of schizophrenia. Schizophr Bull 30: 279–293.</ref-fulltext> </reference> <reference id="102"> <ref-info> <ref-title> <ref-titletext>Clinical review of a long-acting, injectable formulation of risperidone</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">14844364327</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>E.</ce:initials> <ce:indexed-name>Knox E.</ce:indexed-name> <ce:surname>Knox</ce:surname> </author> <author seq="2"> <ce:initials>G.</ce:initials> <ce:indexed-name>Stimmel G.</ce:indexed-name> <ce:surname>Stimmel</ce:surname> </author> </ref-authors> <ref-sourcetitle>Clin Ther</ref-sourcetitle> <ref-publicationyear first="2004"/> <ref-volisspag> <voliss volume="26"/> <pagerange first="1994" last="2002"/> </ref-volisspag> </ref-info> <ref-fulltext>Knox E. Stimmel G. (2004) Clinical review of a long-acting, injectable formulation of risperidone. Clin Ther 26: 1994–2002.</ref-fulltext> </reference> <reference id="103"> <ref-info> <ref-title> <ref-titletext>Chemotherapy with neuroleptics: clinical and pharmacokinetic aspects with a particular view to depot preparations</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0022335835</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>P.</ce:initials> <ce:indexed-name>Knudsen P.</ce:indexed-name> <ce:surname>Knudsen</ce:surname> </author> </ref-authors> <ref-sourcetitle>Acta Psychiatr Scand</ref-sourcetitle> <ref-publicationyear first="1985"/> <ref-volisspag> <voliss volume="72"/> <pagerange first="51" last="75"/> </ref-volisspag> </ref-info> <ref-fulltext>Knudsen P. (1985) Chemotherapy with neuroleptics: clinical and pharmacokinetic aspects with a particular view to depot preparations. Acta Psychiatr Scand 72(Suppl. 322): 51–75.</ref-fulltext> </reference> <reference id="104"> <ref-info> <ref-title> <ref-titletext>The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84857215033</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Koola M.</ce:indexed-name> <ce:surname>Koola</ce:surname> </author> <author seq="2"> <ce:initials>H.</ce:initials> <ce:indexed-name>Wehring H.</ce:indexed-name> <ce:surname>Wehring</ce:surname> </author> <author seq="3"> <ce:initials>D.</ce:initials> <ce:indexed-name>Kelly D.</ce:indexed-name> <ce:surname>Kelly</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Dual Diagn</ref-sourcetitle> <ref-publicationyear first="2012"/> <ref-volisspag> <voliss volume="8"/> <pagerange first="50" last="61"/> </ref-volisspag> </ref-info> <ref-fulltext>Koola M. Wehring H. Kelly D. (2012) The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use. J Dual Diagn 8: 50–61.</ref-fulltext> </reference> <reference id="105"> <ref-info> <ref-title> <ref-titletext>Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84884195927</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.H.</ce:initials> <ce:indexed-name>Lafeuille M.H.</ce:indexed-name> <ce:surname>Lafeuille</ce:surname> </author> <author seq="2"> <ce:initials>F.</ce:initials> <ce:indexed-name>Laliberte-Auger F.</ce:indexed-name> <ce:surname>Laliberté-Auger</ce:surname> </author> <author seq="3"> <ce:initials>P.</ce:initials> <ce:indexed-name>Lefebvre P.</ce:indexed-name> <ce:surname>Lefebvre</ce:surname> </author> <author seq="4"> <ce:initials>C.</ce:initials> <ce:indexed-name>Frois C.</ce:indexed-name> <ce:surname>Frois</ce:surname> </author> <author seq="5"> <ce:initials>J.</ce:initials> <ce:indexed-name>Fastenau J.</ce:indexed-name> <ce:surname>Fastenau</ce:surname> </author> <author seq="6"> <ce:initials>M.S.</ce:initials> <ce:indexed-name>Duh M.S.</ce:indexed-name> <ce:surname>Duh</ce:surname> </author> </ref-authors> <ref-sourcetitle>BMC Psychiatry</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="13"/> <pagerange first="221"/> </ref-volisspag> </ref-info> <ref-fulltext>Lafeuille M.H. Laliberté-Auger F. Lefebvre P. Frois C. Fastenau J. Duh M.S. (2013) Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry 13: 221.</ref-fulltext> </reference> <reference id="106"> <ref-info> <ref-title> <ref-titletext>Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">68149126465</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>Y.</ce:initials> <ce:indexed-name>Lai Y.</ce:indexed-name> <ce:surname>Lai</ce:surname> </author> <author seq="2"> <ce:initials>M.</ce:initials> <ce:indexed-name>Huang M.</ce:indexed-name> <ce:surname>Huang</ce:surname> </author> <author seq="3"> <ce:initials>C.</ce:initials> <ce:indexed-name>Chen C.</ce:indexed-name> <ce:surname>Chen</ce:surname> </author> <author seq="4"> <ce:initials>C.</ce:initials> <ce:indexed-name>Tsai C.</ce:indexed-name> <ce:surname>Tsai</ce:surname> </author> <author seq="5"> <ce:initials>C.</ce:initials> <ce:indexed-name>Pan C.</ce:indexed-name> <ce:surname>Pan</ce:surname> </author> <author seq="6"> <ce:initials>C.</ce:initials> <ce:indexed-name>Chiu C.</ce:indexed-name> <ce:surname>Chiu</ce:surname> </author> </ref-authors> <ref-sourcetitle>Psychiatry Clin Neurosci</ref-sourcetitle> <ref-publicationyear first="2009"/> <ref-volisspag> <voliss volume="63"/> <pagerange first="440" last="448"/> </ref-volisspag> </ref-info> <ref-fulltext>Lai Y. Huang M. Chen C. Tsai C. Pan C. Chiu C. (2009) Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders. Psychiatry Clin Neurosci 63: 440–448.</ref-fulltext> </reference> <reference id="107"> <ref-info> <ref-title> <ref-titletext>Prediction of the optimal perphenazine decanoate dose based on blood samples drawn within the first three weeks</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0024439419</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>N.</ce:initials> <ce:indexed-name>Larsen N.</ce:indexed-name> <ce:surname>Larsen</ce:surname> </author> <author seq="2"> <ce:initials>L.</ce:initials> <ce:indexed-name>Hansen L.</ce:indexed-name> <ce:surname>Hansen</ce:surname> </author> </ref-authors> <ref-sourcetitle>Ther Drug Monit</ref-sourcetitle> <ref-publicationyear first="1989"/> <ref-volisspag> <voliss volume="11"/> <pagerange first="642" last="646"/> </ref-volisspag> </ref-info> <ref-fulltext>Larsen N. Hansen L. (1989) Prediction of the optimal perphenazine decanoate dose based on blood samples drawn within the first three weeks. Ther Drug Monit 11: 642–646.</ref-fulltext> </reference> <reference id="108"> <ref-info> <ref-title> <ref-titletext>Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">2942694109</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>R.</ce:initials> <ce:indexed-name>Lasser R.</ce:indexed-name> <ce:surname>Lasser</ce:surname> </author> <author seq="2"> <ce:initials>C.</ce:initials> <ce:indexed-name>Bossie C.</ce:indexed-name> <ce:surname>Bossie</ce:surname> </author> <author seq="3"> <ce:initials>G.</ce:initials> <ce:indexed-name>Gharabawi G.</ce:indexed-name> <ce:surname>Gharabawi</ce:surname> </author> <author seq="4"> <ce:initials>M.</ce:initials> <ce:indexed-name>Turner M.</ce:indexed-name> <ce:surname>Turner</ce:surname> </author> </ref-authors> <ref-sourcetitle>Eur Psychiatry</ref-sourcetitle> <ref-publicationyear first="2004"/> <ref-volisspag> <voliss volume="19"/> <pagerange first="219" last="225"/> </ref-volisspag> </ref-info> <ref-fulltext>Lasser R. Bossie C. Gharabawi G. Turner M. (2004) Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 19: 219–225.</ref-fulltext> </reference> <reference id="109"> <ref-info> <ref-title> <ref-titletext>Practice guideline for the treatment of patients with schizophrenia, second edition</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">1642283731</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>A.</ce:initials> <ce:indexed-name>Lehman A.</ce:indexed-name> <ce:surname>Lehman</ce:surname> </author> <author seq="2"> <ce:initials>J.</ce:initials> <ce:indexed-name>Lieberman J.</ce:indexed-name> <ce:surname>Lieberman</ce:surname> </author> <author seq="3"> <ce:initials>L.</ce:initials> <ce:indexed-name>Dixon L.</ce:indexed-name> <ce:surname>Dixon</ce:surname> </author> <author seq="4"> <ce:initials>T.</ce:initials> <ce:indexed-name>McGlashan T.</ce:indexed-name> <ce:surname>McGlashan</ce:surname> </author> <author seq="5"> <ce:initials>A.</ce:initials> <ce:indexed-name>Miller A.</ce:indexed-name> <ce:surname>Miller</ce:surname> </author> <author seq="6"> <ce:initials>D.</ce:initials> <ce:indexed-name>Perkins D.</ce:indexed-name> <ce:surname>Perkins</ce:surname> </author> <collaboration seq="1"> <ce:indexed-name>American Psychiatric Association; Steering Committee on Practice Guidelines</ce:indexed-name> <ce:text>American Psychiatric Association; Steering Committee on Practice Guidelines</ce:text> </collaboration> <et-al/> </ref-authors> <ref-sourcetitle>Am J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2004"/> <ref-volisspag> <voliss volume="161"/> <pagerange first="1" last="56"/> </ref-volisspag> </ref-info> <ref-fulltext>Lehman A. Lieberman J. Dixon L. McGlashan T. Miller A. Perkins D.; American Psychiatric Association; Steering Committee on Practice Guidelines et al. (2004) Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161(2 Suppl.): 1–56.</ref-fulltext> </reference> <reference id="110"> <ref-info> <ref-title> <ref-titletext>Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">33744795750</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>S.</ce:initials> <ce:indexed-name>Leucht S.</ce:indexed-name> <ce:surname>Leucht</ce:surname> </author> <author seq="2"> <ce:initials>S.</ce:initials> <ce:indexed-name>Heres S.</ce:indexed-name> <ce:surname>Heres</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="2006"/> <ref-volisspag> <voliss volume="67"/> <pagerange first="3" last="8"/> </ref-volisspag> </ref-info> <ref-fulltext>Leucht S. Heres S. (2006) Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 67: 3–8.</ref-fulltext> </reference> <reference id="111"> <ref-info> <ref-title> <ref-titletext>Oral versus depot antipsychotic drugs for schizophrenia—A critical systematic review and meta-analysis of randomised long-term trials</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">79952312699</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>C.</ce:initials> <ce:indexed-name>Leucht C.</ce:indexed-name> <ce:surname>Leucht</ce:surname> </author> <author seq="2"> <ce:initials>S.</ce:initials> <ce:indexed-name>Heres S.</ce:indexed-name> <ce:surname>Heres</ce:surname> </author> <author seq="3"> <ce:initials>J.</ce:initials> <ce:indexed-name>Kane J.</ce:indexed-name> <ce:surname>Kane</ce:surname> </author> <author seq="4"> <ce:initials>W.</ce:initials> <ce:indexed-name>Kissling W.</ce:indexed-name> <ce:surname>Kissling</ce:surname> </author> <author seq="5"> <ce:initials>J.</ce:initials> <ce:indexed-name>Davis J.</ce:indexed-name> <ce:surname>Davis</ce:surname> </author> <author seq="6"> <ce:initials>S.</ce:initials> <ce:indexed-name>Leucht S.</ce:indexed-name> <ce:surname>Leucht</ce:surname> </author> </ref-authors> <ref-sourcetitle>Schizophr Res</ref-sourcetitle> <ref-publicationyear first="2011"/> <ref-volisspag> <voliss volume="127"/> <pagerange first="83" last="92"/> </ref-volisspag> </ref-info> <ref-fulltext>Leucht C. Heres S. Kane J. Kissling W. Davis J. Leucht S. (2011) Oral versus depot antipsychotic drugs for schizophrenia—A critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 127: 83–92.</ref-fulltext> </reference> <reference id="112"> <ref-info> <ref-title> <ref-titletext>Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84879502816</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Lin J.</ce:indexed-name> <ce:surname>Lin</ce:surname> </author> <author seq="2"> <ce:initials>B.</ce:initials> <ce:indexed-name>Wong B.</ce:indexed-name> <ce:surname>Wong</ce:surname> </author> <author seq="3"> <ce:initials>S.</ce:initials> <ce:indexed-name>Offord S.</ce:indexed-name> <ce:surname>Offord</ce:surname> </author> <author seq="4"> <ce:initials>D.</ce:initials> <ce:indexed-name>Mirski D.</ce:indexed-name> <ce:surname>Mirski</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Behav Health Serv Res</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="40"/> <pagerange first="355" last="366"/> </ref-volisspag> </ref-info> <ref-fulltext>Lin J. Wong B. Offord S. Mirski D. (2013) Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia. J Behav Health Serv Res 40: 355–366.</ref-fulltext> </reference> <reference id="113"> <ref-info> <ref-title> <ref-titletext>Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">68049135880</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Lindenmayer J.</ce:indexed-name> <ce:surname>Lindenmayer</ce:surname> </author> <author seq="2"> <ce:initials>H.</ce:initials> <ce:indexed-name>Liu-Seifert H.</ce:indexed-name> <ce:surname>Liu-Seifert</ce:surname> </author> <author seq="3"> <ce:initials>P.</ce:initials> <ce:indexed-name>Kulkarni P.</ce:indexed-name> <ce:surname>Kulkarni</ce:surname> </author> <author seq="4"> <ce:initials>B.</ce:initials> <ce:indexed-name>Kinon B.</ce:indexed-name> <ce:surname>Kinon</ce:surname> </author> <author seq="5"> <ce:initials>V.</ce:initials> <ce:indexed-name>Stauffer V.</ce:indexed-name> <ce:surname>Stauffer</ce:surname> </author> <author seq="6"> <ce:initials>S.</ce:initials> <ce:indexed-name>Edwards S.</ce:indexed-name> <ce:surname>Edwards</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="2009"/> <ref-volisspag> <voliss volume="70"/> <pagerange first="990" last="996"/> </ref-volisspag> </ref-info> <ref-fulltext>Lindenmayer J. Liu-Seifert H. Kulkarni P. Kinon B. Stauffer V. Edwards S. et al. (2009) Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry 70: 990–996.</ref-fulltext> </reference> <reference id="114"> <ref-info> <ref-title> <ref-titletext>Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84890522664</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>P.</ce:initials> <ce:indexed-name>Llorca P.</ce:indexed-name> <ce:surname>Llorca</ce:surname> </author> <author seq="2"> <ce:initials>M.</ce:initials> <ce:indexed-name>Abbar M.</ce:indexed-name> <ce:surname>Abbar</ce:surname> </author> <author seq="3"> <ce:initials>P.</ce:initials> <ce:indexed-name>Courtet P.</ce:indexed-name> <ce:surname>Courtet</ce:surname> </author> <author seq="4"> <ce:initials>S.</ce:initials> <ce:indexed-name>Guillaume S.</ce:indexed-name> <ce:surname>Guillaume</ce:surname> </author> <author seq="5"> <ce:initials>S.</ce:initials> <ce:indexed-name>Lancrenon S.</ce:indexed-name> <ce:surname>Lancrenon</ce:surname> </author> <author seq="6"> <ce:initials>L.</ce:initials> <ce:indexed-name>Samalin L.</ce:indexed-name> <ce:surname>Samalin</ce:surname> </author> </ref-authors> <ref-sourcetitle>BMC Psychiatry</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="13"/> </ref-volisspag> <ref-text>article 340</ref-text> </ref-info> <ref-fulltext>Llorca P. Abbar M. Courtet P Guillaume S. Lancrenon S. Samalin L. (2013) Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry 13: article 340.</ref-fulltext> </reference> <reference id="115"> <ref-info> <ref-title> <ref-titletext>A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">78650058642</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>W.</ce:initials> <ce:indexed-name>MacFadden W.</ce:indexed-name> <ce:surname>MacFadden</ce:surname> </author> <author seq="2"> <ce:initials>Y.</ce:initials> <ce:indexed-name>Ma Y.</ce:indexed-name> <ce:surname>Ma</ce:surname> </author> <author seq="3"> <ce:indexed-name>Thomas</ce:indexed-name> <ce:surname>Thomas</ce:surname> </author> <author seq="4"> <ce:initials>J.</ce:initials> <ce:indexed-name>Haskins J.</ce:indexed-name> <ce:surname>Haskins</ce:surname> </author> <author seq="5"> <ce:initials>C.</ce:initials> <ce:indexed-name>Bossie C.</ce:indexed-name> <ce:surname>Bossie</ce:surname> </author> <author seq="6"> <ce:initials>L.</ce:initials> <ce:indexed-name>Alphs L.</ce:indexed-name> <ce:surname>Alphs</ce:surname> </author> </ref-authors> <ref-sourcetitle>Psychiatry</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <voliss volume="7"/> <pagerange first="23" last="31"/> </ref-volisspag> </ref-info> <ref-fulltext>MacFadden W. Ma Y. Thomas Haskins J. Bossie C. Alphs L. (2010) A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry 7: 23–31.</ref-fulltext> </reference> <reference id="116"> <ref-info> <ref-title> <ref-titletext>The case for practical clinical trials in psychiatry</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">18744396959</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>March J.</ce:indexed-name> <ce:surname>March</ce:surname> </author> <author seq="2"> <ce:initials>S.</ce:initials> <ce:indexed-name>Silva S.</ce:indexed-name> <ce:surname>Silva</ce:surname> </author> <author seq="3"> <ce:initials>S.</ce:initials> <ce:indexed-name>Compton S.</ce:indexed-name> <ce:surname>Compton</ce:surname> </author> <author seq="4"> <ce:initials>M.</ce:initials> <ce:indexed-name>Shapiro M.</ce:indexed-name> <ce:surname>Shapiro</ce:surname> </author> <author seq="5"> <ce:initials>R.</ce:initials> <ce:indexed-name>Califf R.</ce:indexed-name> <ce:surname>Califf</ce:surname> </author> <author seq="6"> <ce:initials>R.</ce:initials> <ce:indexed-name>Krishnan R.</ce:indexed-name> <ce:surname>Krishnan</ce:surname> </author> </ref-authors> <ref-sourcetitle>Am J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2005"/> <ref-volisspag> <voliss volume="162"/> <pagerange first="836" last="846"/> </ref-volisspag> </ref-info> <ref-fulltext>March J. Silva S. Compton S. Shapiro M. Califf R. Krishnan R. (2005) The case for practical clinical trials in psychiatry. Am J Psychiatry 162: 836–846.</ref-fulltext> </reference> <reference id="117"> <ref-info> <ref-title> <ref-titletext>Naturalistic, retrospective comparison between second-generation antipsychotics and depot neuroleptics in patients affected by schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">28844492199</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>L.</ce:initials> <ce:indexed-name>Marchiaro L.</ce:indexed-name> <ce:surname>Marchiaro</ce:surname> </author> <author seq="2"> <ce:initials>P.</ce:initials> <ce:indexed-name>Rocca P.</ce:indexed-name> <ce:surname>Rocca</ce:surname> </author> <author seq="3"> <ce:initials>F.</ce:initials> <ce:indexed-name>LeNoci F.</ce:indexed-name> <ce:surname>LeNoci</ce:surname> </author> <author seq="4"> <ce:initials>P.</ce:initials> <ce:indexed-name>Longo P.</ce:indexed-name> <ce:surname>Longo</ce:surname> </author> <author seq="5"> <ce:initials>C.</ce:initials> <ce:indexed-name>Montemagni C.</ce:indexed-name> <ce:surname>Montemagni</ce:surname> </author> <author seq="6"> <ce:initials>C.</ce:initials> <ce:indexed-name>Rigazzi C.</ce:indexed-name> <ce:surname>Rigazzi</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="2005"/> <ref-volisspag> <voliss volume="66"/> <pagerange first="1423" last="1431"/> </ref-volisspag> </ref-info> <ref-fulltext>Marchiaro L. Rocca P. LeNoci F. Longo P. Montemagni C. Rigazzi C. et al. (2005) Naturalistic, retrospective comparison between second-generation antipsychotics and depot neuroleptics in patients affected by schizophrenia. J Clin Psychiatry 66: 1423–1431</ref-fulltext> </reference> <reference id="118"> <ref-info> <ref-title> <ref-titletext>Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0024412741</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>S.</ce:initials> <ce:indexed-name>Marder S.</ce:indexed-name> <ce:surname>Marder</ce:surname> </author> <author seq="2"> <ce:initials>J.</ce:initials> <ce:indexed-name>Hubbard J.</ce:indexed-name> <ce:surname>Hubbard</ce:surname> </author> <author seq="3"> <ce:initials>T.</ce:initials> <ce:indexed-name>Van Putten T.</ce:indexed-name> <ce:surname>Van Putten</ce:surname> </author> <author seq="4"> <ce:initials>K.</ce:initials> <ce:indexed-name>Midha K.</ce:indexed-name> <ce:surname>Midha</ce:surname> </author> </ref-authors> <ref-sourcetitle>Psychopharmacology</ref-sourcetitle> <ref-publicationyear first="1989"/> <ref-volisspag> <voliss volume="98"/> <pagerange first="433" last="439"/> </ref-volisspag> </ref-info> <ref-fulltext>Marder S. Hubbard J. Van Putten T. Midha K. (1989) Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications. Psychopharmacology 98: 433–439.</ref-fulltext> </reference> <reference id="119"> <ref-info> <ref-title> <ref-titletext>Costs and benefits of two doses of fluphenazine</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0021220598</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>S.</ce:initials> <ce:indexed-name>Marder S.</ce:indexed-name> <ce:surname>Marder</ce:surname> </author> <author seq="2"> <ce:initials>T.</ce:initials> <ce:indexed-name>Van Putten T.</ce:indexed-name> <ce:surname>Van Putten</ce:surname> </author> <author seq="3"> <ce:initials>J.</ce:initials> <ce:indexed-name>Mintz J.</ce:indexed-name> <ce:surname>Mintz</ce:surname> </author> <author seq="4"> <ce:initials>J.</ce:initials> <ce:indexed-name>McKenzie J.</ce:indexed-name> <ce:surname>McKenzie</ce:surname> </author> <author seq="5"> <ce:initials>M.</ce:initials> <ce:indexed-name>Lebell M.</ce:indexed-name> <ce:surname>Lebell</ce:surname> </author> <author seq="6"> <ce:initials>G.</ce:initials> <ce:indexed-name>Faltico G.</ce:indexed-name> <ce:surname>Faltico</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Arch Gen Psychiatry</ref-sourcetitle> <ref-publicationyear first="1984"/> <ref-volisspag> <voliss volume="41"/> <pagerange first="1025" last="1029"/> </ref-volisspag> </ref-info> <ref-fulltext>Marder S. Van Putten T. Mintz J. McKenzie J. Lebell M. Faltico G. et al. (1984) Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 41: 1025–1029.</ref-fulltext> </reference> <reference id="120"> <ref-info> <ref-title> <ref-titletext>Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">36849048918</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>T.</ce:initials> <ce:indexed-name>Marinis T.</ce:indexed-name> <ce:surname>Marinis</ce:surname> </author> <author seq="2"> <ce:initials>P.</ce:initials> <ce:indexed-name>Saleem P.</ce:indexed-name> <ce:surname>Saleem</ce:surname> </author> <author seq="3"> <ce:initials>P.</ce:initials> <ce:indexed-name>Glue P.</ce:indexed-name> <ce:surname>Glue</ce:surname> </author> <author seq="4"> <ce:initials>W.</ce:initials> <ce:indexed-name>Arnoldussen W.</ce:indexed-name> <ce:surname>Arnoldussen</ce:surname> </author> <author seq="5"> <ce:initials>R.</ce:initials> <ce:indexed-name>Teijeiro R.</ce:indexed-name> <ce:surname>Teijeiro</ce:surname> </author> <author seq="6"> <ce:initials>A.</ce:initials> <ce:indexed-name>Lex A.</ce:indexed-name> <ce:surname>Lex</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Pharmacopsychiatry</ref-sourcetitle> <ref-publicationyear first="2007"/> <ref-volisspag> <voliss volume="40"/> <pagerange first="257" last="263"/> </ref-volisspag> </ref-info> <ref-fulltext>Marinis T. Saleem P. Glue P. Arnoldussen W. Teijeiro R. Lex A. et al. (2007) Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry 40: 257–263.</ref-fulltext> </reference> <reference id="121"> <ref-info> <ref-title> <ref-titletext>A mirror image outpatient study at a depot phenothiazine clinic</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0017063172</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>P.</ce:initials> <ce:indexed-name>Marriot P.</ce:indexed-name> <ce:surname>Marriot</ce:surname> </author> <author seq="2"> <ce:initials>A.</ce:initials> <ce:indexed-name>Hiep A.</ce:indexed-name> <ce:surname>Hiep</ce:surname> </author> </ref-authors> <ref-sourcetitle>Aust N Z J Psychiatry</ref-sourcetitle> <ref-publicationyear first="1976"/> <ref-volisspag> <voliss volume="10"/> <pagerange first="163"/> </ref-volisspag> </ref-info> <ref-fulltext>Marriot P. Hiep A. (1976) A mirror image outpatient study at a depot phenothiazine clinic. Aust N Z J Psychiatry 10: 163.</ref-fulltext> </reference> <reference id="122"> <ref-info> <ref-title> <ref-titletext>The Scottish first episode schizophrenia study. VII. Two year follow-up</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0024833669</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>R.</ce:initials> <ce:indexed-name>McCreadie R.</ce:indexed-name> <ce:surname>McCreadie</ce:surname> </author> <author seq="2"> <ce:initials>D.</ce:initials> <ce:indexed-name>Wiles D.</ce:indexed-name> <ce:surname>Wiles</ce:surname> </author> <author seq="3"> <ce:initials>S.</ce:initials> <ce:indexed-name>Grant S.</ce:indexed-name> <ce:surname>Grant</ce:surname> </author> <author seq="4"> <ce:initials>G.</ce:initials> <ce:indexed-name>Crokett G.</ce:indexed-name> <ce:surname>Crokett</ce:surname> </author> <author seq="5"> <ce:initials>Z.</ce:initials> <ce:indexed-name>Mahmood Z.</ce:indexed-name> <ce:surname>Mahmood</ce:surname> </author> <author seq="6"> <ce:initials>M.</ce:initials> <ce:indexed-name>Livingston M.</ce:indexed-name> <ce:surname>Livingston</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Acta Psychiatr Scand</ref-sourcetitle> <ref-publicationyear first="1989"/> <ref-volisspag> <voliss volume="80"/> <pagerange first="597" last="602"/> </ref-volisspag> </ref-info> <ref-fulltext>McCreadie R. Wiles D. Grant S. Crokett G. Mahmood Z. Livingston M. et al. (1989) The Scottish first episode schizophrenia study. VII. Two year follow-up. Acta Psychiatr Scand 80: 597–602.</ref-fulltext> </reference> <reference id="123"> <ref-info> <ref-title> <ref-titletext>Risks versus benefits of different types of long-acting injectable antipsychotics</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">33744793769</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>McEvoy J.</ce:indexed-name> <ce:surname>McEvoy</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="2006"/> <ref-volisspag> <voliss volume="67"/> <pagerange first="15" last="18"/> </ref-volisspag> </ref-info> <ref-fulltext>McEvoy J. (2006) Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry 67(Suppl. 5): 15–18.</ref-fulltext> </reference> <reference id="124"> <ref-info> <ref-title> <ref-titletext>Early intervention in psychotic disorders: detection and treatment of the first episode and the critical early stages</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">38449090906</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>P.</ce:initials> <ce:indexed-name>McGorry P.</ce:indexed-name> <ce:surname>McGorry</ce:surname> </author> <author seq="2"> <ce:initials>E.</ce:initials> <ce:indexed-name>Killackey E.</ce:indexed-name> <ce:surname>Killackey</ce:surname> </author> <author seq="3"> <ce:initials>A.</ce:initials> <ce:indexed-name>Yung A.</ce:indexed-name> <ce:surname>Yung</ce:surname> </author> </ref-authors> <ref-sourcetitle>Med J Aust</ref-sourcetitle> <ref-publicationyear first="2007"/> <ref-volisspag> <voliss volume="187"/> <pagerange first="S8" last="S10"/> </ref-volisspag> </ref-info> <ref-fulltext>McGorry P. Killackey E. Yung A. (2007) Early intervention in psychotic disorders: detection and treatment of the first episode and the critical early stages. Med J Aust 187: S8–S10.</ref-fulltext> </reference> <reference id="125"> <ref-info> <ref-title> <ref-titletext>The metabolic syndrome and schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">57449083235</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Meyer J.</ce:indexed-name> <ce:surname>Meyer</ce:surname> </author> <author seq="2"> <ce:initials>S.</ce:initials> <ce:indexed-name>Stahl S.</ce:indexed-name> <ce:surname>Stahl</ce:surname> </author> </ref-authors> <ref-sourcetitle>Acta Psychiatr Scand</ref-sourcetitle> <ref-publicationyear first="2009"/> <ref-volisspag> <voliss volume="119"/> <pagerange first="4" last="14"/> </ref-volisspag> </ref-info> <ref-fulltext>Meyer J. Stahl S. (2009) The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 119: 4–14.</ref-fulltext> </reference> <reference id="126"> <ref-info> <ref-title> <ref-titletext>Quality of life of schizophrenic patients treated with haloperidol depot and injection preparation of long-lasting risperidone</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84858426638</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>G.</ce:initials> <ce:indexed-name>Mihajlovic G.</ce:indexed-name> <ce:surname>Mihajlović</ce:surname> </author> <author seq="2"> <ce:initials>N.</ce:initials> <ce:indexed-name>Jovanovic-Mihajlovic N.</ce:indexed-name> <ce:surname>Jovanović-Mihajlović</ce:surname> </author> <author seq="3"> <ce:initials>B.</ce:initials> <ce:indexed-name>Radmanovic B.</ce:indexed-name> <ce:surname>Radmanović</ce:surname> </author> <author seq="4"> <ce:initials>K.</ce:initials> <ce:indexed-name>Radonjic K.</ce:indexed-name> <ce:surname>Radonjić</ce:surname> </author> <author seq="5"> <ce:initials>S.</ce:initials> <ce:indexed-name>Djukic-Dejanovic S.</ce:indexed-name> <ce:surname>Djukić-Dejanović</ce:surname> </author> <author seq="6"> <ce:initials>S.</ce:initials> <ce:indexed-name>Jankovic S.</ce:indexed-name> <ce:surname>Janković</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Srp Arh Celok Lek</ref-sourcetitle> <ref-publicationyear first="2011"/> <ref-volisspag> <voliss volume="139"/> <pagerange first="36" last="40"/> </ref-volisspag> </ref-info> <ref-fulltext>Mihajlović G. Jovanović-Mihajlović N. Radmanović B. Radonjić K. Djukić-Dejanović S. Janković S. et al. (2011) Quality of life of schizophrenic patients treated with haloperidol depot and injection preparation of long-lasting risperidone. Srp Arh Celok Lek 139: 36–40.</ref-fulltext> </reference> <reference id="127"> <ref-info> <ref-title> <ref-titletext>Does antipsychotic withdrawl provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal–related relapse</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">33745108559</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Moncrieff J.</ce:indexed-name> <ce:surname>Moncrieff</ce:surname> </author> </ref-authors> <ref-sourcetitle>Acta Psychiatr Scand</ref-sourcetitle> <ref-publicationyear first="2006"/> <ref-volisspag> <voliss volume="114"/> <pagerange first="3" last="13"/> </ref-volisspag> </ref-info> <ref-fulltext>Moncrieff J. (2006) Does antipsychotic withdrawl provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal–related relapse. Acta Psychiatr Scand 114: 3–13.</ref-fulltext> </reference> <reference id="128"> <ref-info> <ref-title> <ref-titletext>Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0032534880</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>D.</ce:initials> <ce:indexed-name>Moore D.</ce:indexed-name> <ce:surname>Moore</ce:surname> </author> <author seq="2"> <ce:initials>D.</ce:initials> <ce:indexed-name>Kelly D.</ce:indexed-name> <ce:surname>Kelly</ce:surname> </author> <author seq="3"> <ce:initials>J.</ce:initials> <ce:indexed-name>Sherr J.</ce:indexed-name> <ce:surname>Sherr</ce:surname> </author> <author seq="4"> <ce:initials>R.</ce:initials> <ce:indexed-name>Love R.</ce:indexed-name> <ce:surname>Love</ce:surname> </author> <author seq="5"> <ce:initials>R.</ce:initials> <ce:indexed-name>Conley R.</ce:indexed-name> <ce:surname>Conley</ce:surname> </author> </ref-authors> <ref-sourcetitle>Am J Health Syst Pharm</ref-sourcetitle> <ref-publicationyear first="1998"/> <ref-volisspag> <voliss volume="55"/> <pagerange first="17" last="19"/> </ref-volisspag> </ref-info> <ref-fulltext>Moore D. Kelly D. Sherr J. Love R. Conley R. (1998) Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. Am J Health Syst Pharm 55(Suppl. 4): 17–19.</ref-fulltext> </reference> <reference id="129"> <ref-info> <ref-title> <ref-titletext>The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">37049003034</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>T.</ce:initials> <ce:indexed-name>Moore T.</ce:indexed-name> <ce:surname>Moore</ce:surname> </author> <author seq="2"> <ce:initials>R.</ce:initials> <ce:indexed-name>Buchanan R.</ce:indexed-name> <ce:surname>Buchanan</ce:surname> </author> <author seq="3"> <ce:initials>P.</ce:initials> <ce:indexed-name>Buckley P.</ce:indexed-name> <ce:surname>Buckley</ce:surname> </author> <author seq="4"> <ce:initials>J.</ce:initials> <ce:indexed-name>Chiles J.</ce:indexed-name> <ce:surname>Chiles</ce:surname> </author> <author seq="5"> <ce:initials>R.</ce:initials> <ce:indexed-name>Conley R.</ce:indexed-name> <ce:surname>Conley</ce:surname> </author> <author seq="6"> <ce:initials>M.</ce:initials> <ce:indexed-name>Crismon M.</ce:indexed-name> <ce:surname>Crismon</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="2007"/> <ref-volisspag> <voliss volume="68"/> <pagerange first="1751" last="1762"/> </ref-volisspag> </ref-info> <ref-fulltext>Moore T. Buchanan R. Buckley P. Chiles J. Conley R. Crismon M. et al. (2007) The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 68: 1751–1762.</ref-fulltext> </reference> <reference id="130"> <ref-info> <ref-title> <ref-titletext>Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">44249114045</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>G.</ce:initials> <ce:indexed-name>Morken G.</ce:indexed-name> <ce:surname>Morken</ce:surname> </author> <author seq="2"> <ce:initials>J.</ce:initials> <ce:indexed-name>Widen J.</ce:indexed-name> <ce:surname>Widen</ce:surname> </author> <author seq="3"> <ce:initials>R.</ce:initials> <ce:indexed-name>Grawe R.</ce:indexed-name> <ce:surname>Grawe</ce:surname> </author> </ref-authors> <ref-sourcetitle>BMC Psychiatry</ref-sourcetitle> <ref-publicationyear first="2008"/> <ref-volisspag> <voliss volume="8"/> </ref-volisspag> <ref-text>article 32</ref-text> </ref-info> <ref-fulltext>Morken G. Widen J. Grawe R. (2008) Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 8: article 32.</ref-fulltext> </reference> <reference id="131"> <ref-info> <ref-title> <ref-titletext>Effectiveness of community treatment orders for treatment of schizophrenia with oral or depot antipsychotic medication: clinical outcomes</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">33744480282</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>D.</ce:initials> <ce:indexed-name>Muirhead D.</ce:indexed-name> <ce:surname>Muirhead</ce:surname> </author> <author seq="2"> <ce:initials>C.</ce:initials> <ce:indexed-name>Harvey C.</ce:indexed-name> <ce:surname>Harvey</ce:surname> </author> <author seq="3"> <ce:initials>G.</ce:initials> <ce:indexed-name>Ingram G.</ce:indexed-name> <ce:surname>Ingram</ce:surname> </author> </ref-authors> <ref-sourcetitle>Aust N Z J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2006"/> <ref-volisspag> <voliss volume="40"/> <pagerange first="596" last="605"/> </ref-volisspag> </ref-info> <ref-fulltext>Muirhead D. Harvey C. Ingram G. (2006) Effectiveness of community treatment orders for treatment of schizophrenia with oral or depot antipsychotic medication: clinical outcomes. Aust N Z J Psychiatry 40: 596–605.</ref-fulltext> </reference> <reference id="132"> <ref-info> <ref-title> <ref-titletext>Formulation optimization of long-acting depot injection of aripiprazole by using D-optimal mixture design</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">68349100113</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>T.</ce:initials> <ce:indexed-name>Nahata T.</ce:indexed-name> <ce:surname>Nahata</ce:surname> </author> <author seq="2"> <ce:initials>T.</ce:initials> <ce:indexed-name>Saini T.</ce:indexed-name> <ce:surname>Saini</ce:surname> </author> </ref-authors> <ref-sourcetitle>PDA J Pharm Sci Technol</ref-sourcetitle> <ref-publicationyear first="2009"/> <ref-volisspag> <voliss volume="63"/> <pagerange first="113" last="122"/> </ref-volisspag> </ref-info> <ref-fulltext>Nahata T. Saini T. (2009) Formulation optimization of long-acting depot injection of aripiprazole by using D-optimal mixture design. PDA J Pharm Sci Technol 63: 113–122.</ref-fulltext> </reference> <reference id="133"> <ref-info> <refd-itemidlist> <itemid idtype="SGR">84997920758</itemid> </refd-itemidlist> <ref-authors> <collaboration seq="1"> <ce:indexed-name>NICE</ce:indexed-name> <ce:text>NICE</ce:text> </collaboration> </ref-authors> <ref-sourcetitle>Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (update)</ref-sourcetitle> <ref-publicationyear first="2009"/> <ref-text>NICE Clinical Guidelines No. 82. London: National Institute for Health and Care Excellence</ref-text> </ref-info> <ref-fulltext>NICE (2009) Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (update). NICE Clinical Guidelines No. 82. London: National Institute for Health and Care Excellence.</ref-fulltext> </reference> <reference id="134"> <ref-info> <ref-title> <ref-titletext>Injectable long-acting antipsychotics (LAI)</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84997884280</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>O.</ce:initials> <ce:indexed-name>Niaz O.</ce:indexed-name> <ce:surname>Niaz</ce:surname> </author> <author seq="2"> <ce:initials>P.</ce:initials> <ce:indexed-name>Haddad P.</ce:indexed-name> <ce:surname>Haddad</ce:surname> </author> </ref-authors> <ref-sourcetitle>The Year in Schizophrenia, 2010</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <pagerange first="33" last="54"/> </ref-volisspag> <ref-text>In: Mortimer A., McKenna P. (eds), Oxford: Atlas Medical Publishing</ref-text> </ref-info> <ref-fulltext>Niaz O. Haddad P. (2010) Injectable long-acting antipsychotics (LAI). In: Mortimer A. McKenna P. (eds), The Year in Schizophrenia, 2010. Oxford: Atlas Medical Publishing, pp. 33–54.</ref-fulltext> </reference> <reference id="135"> <ref-info> <ref-title> <ref-titletext>Progressive pathology is functionally linked to the domains of language and emotion: meta-analysis of brain structure changes in schizophrenia patients</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84355161713</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>T.</ce:initials> <ce:indexed-name>Nickl-Jockschat T.</ce:indexed-name> <ce:surname>Nickl-Jockschat</ce:surname> </author> <author seq="2"> <ce:initials>F.</ce:initials> <ce:indexed-name>Schneider F.</ce:indexed-name> <ce:surname>Schneider</ce:surname> </author> <author seq="3"> <ce:initials>A.</ce:initials> <ce:indexed-name>Pagel A.</ce:indexed-name> <ce:surname>Pagel</ce:surname> </author> <author seq="4"> <ce:initials>A.</ce:initials> <ce:indexed-name>Laird A.</ce:indexed-name> <ce:surname>Laird</ce:surname> </author> <author seq="5"> <ce:initials>P.</ce:initials> <ce:indexed-name>Fox P.</ce:indexed-name> <ce:surname>Fox</ce:surname> </author> <author seq="6"> <ce:initials>S.</ce:initials> <ce:indexed-name>Eickhoff S.</ce:indexed-name> <ce:surname>Eickhoff</ce:surname> </author> </ref-authors> <ref-sourcetitle>Eur Arch Psychiatry Clin Neurosci</ref-sourcetitle> <ref-publicationyear first="2011"/> <ref-volisspag> <voliss volume="261"/> <pagerange first="S166" last="S171"/> </ref-volisspag> </ref-info> <ref-fulltext>Nickl-Jockschat T. Schneider F. Pagel A. Laird A. Fox P. Eickhoff S. (2011) Progressive pathology is functionally linked to the domains of language and emotion: meta-analysis of brain structure changes in schizophrenia patients. Eur Arch Psychiatry Clin Neurosci 261: S166–S171.</ref-fulltext> </reference> <reference id="136"> <ref-info> <ref-title> <ref-titletext>Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS)</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84875413162</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>V.</ce:initials> <ce:indexed-name>Novakovic V.</ce:indexed-name> <ce:surname>Novakovic</ce:surname> </author> <author seq="2"> <ce:initials>T.</ce:initials> <ce:indexed-name>Adel T.</ce:indexed-name> <ce:surname>Adel</ce:surname> </author> <author seq="3"> <ce:initials>E.</ce:initials> <ce:indexed-name>Peselow E.</ce:indexed-name> <ce:surname>Peselow</ce:surname> </author> <author seq="4"> <ce:initials>J.</ce:initials> <ce:indexed-name>Lindenmayer J.</ce:indexed-name> <ce:surname>Lindenmayer</ce:surname> </author> </ref-authors> <ref-sourcetitle>Clin Neuropharmacol</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="36"/> <pagerange first="59" last="62"/> </ref-volisspag> </ref-info> <ref-fulltext>Novakovic V. Adel T. Peselow E. Lindenmayer J. (2013) Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS). Clin Neuropharmacol 36: 59–62.</ref-fulltext> </reference> <reference id="137"> <ref-info> <ref-title> <ref-titletext>Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84877978630</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>S.</ce:initials> <ce:indexed-name>Offord S.</ce:indexed-name> <ce:surname>Offord</ce:surname> </author> <author seq="2"> <ce:initials>B.</ce:initials> <ce:indexed-name>Wong B.</ce:indexed-name> <ce:surname>Wong</ce:surname> </author> <author seq="3"> <ce:initials>D.</ce:initials> <ce:indexed-name>Mirski D.</ce:indexed-name> <ce:surname>Mirski</ce:surname> </author> <author seq="4"> <ce:initials>R.</ce:initials> <ce:indexed-name>Baker R.</ce:indexed-name> <ce:surname>Baker</ce:surname> </author> <author seq="5"> <ce:initials>J.</ce:initials> <ce:indexed-name>Lin J.</ce:indexed-name> <ce:surname>Lin</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Med Econ</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="16"/> <pagerange first="231" last="239"/> </ref-volisspag> </ref-info> <ref-fulltext>Offord S Wong B. Mirski D. Baker R. Lin J. (2013) Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. J Med Econ 16: 231–239.</ref-fulltext> </reference> <reference id="138"> <ref-info> <ref-title> <ref-titletext>Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0035702461</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>P.</ce:initials> <ce:indexed-name>Oh P.</ce:indexed-name> <ce:surname>Oh</ce:surname> </author> <author seq="2"> <ce:initials>K.</ce:initials> <ce:indexed-name>Lanctot K.</ce:indexed-name> <ce:surname>Lanctôt</ce:surname> </author> <author seq="3"> <ce:initials>N.</ce:initials> <ce:indexed-name>Mittman N.</ce:indexed-name> <ce:surname>Mittman</ce:surname> </author> <author seq="4"> <ce:initials>M.</ce:initials> <ce:indexed-name>Iskedjian M.</ce:indexed-name> <ce:surname>Iskedjian</ce:surname> </author> <author seq="5"> <ce:initials>T.</ce:initials> <ce:indexed-name>Einarson T.</ce:indexed-name> <ce:surname>Einarson</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Med Econ</ref-sourcetitle> <ref-publicationyear first="2001"/> <ref-volisspag> <voliss volume="4"/> <pagerange first="137" last="156"/> </ref-volisspag> </ref-info> <ref-fulltext>Oh P. Lanctôt K. Mittman N. Iskedjian M. Einarson T. (2001) Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ 4: 137–156.</ref-fulltext> </reference> <reference id="139"> <ref-info> <ref-title> <ref-titletext>Prediction of homelessness within three months of discharge among inpatients with schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0032958246</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Olfson M.</ce:indexed-name> <ce:surname>Olfson</ce:surname> </author> <author seq="2"> <ce:initials>D.</ce:initials> <ce:indexed-name>Mechanic D.</ce:indexed-name> <ce:surname>Mechanic</ce:surname> </author> <author seq="3"> <ce:initials>S.</ce:initials> <ce:indexed-name>Hansell S.</ce:indexed-name> <ce:surname>Hansell</ce:surname> </author> <author seq="4"> <ce:initials>C.</ce:initials> <ce:indexed-name>Boyer C.</ce:indexed-name> <ce:surname>Boyer</ce:surname> </author> <author seq="5"> <ce:initials>J.</ce:initials> <ce:indexed-name>Walkup J.</ce:indexed-name> <ce:surname>Walkup</ce:surname> </author> </ref-authors> <ref-sourcetitle>Psychiatr Serv</ref-sourcetitle> <ref-publicationyear first="1999"/> <ref-volisspag> <voliss volume="50"/> <pagerange first="667" last="673"/> </ref-volisspag> </ref-info> <ref-fulltext>Olfson M. Mechanic D. Hansell S. Boyer C. Walkup J. (1999) Prediction of homelessness within three months of discharge among inpatients with schizophrenia. Psychiatr Serv 50: 667–673.</ref-fulltext> </reference> <reference id="140"> <ref-info> <ref-title> <ref-titletext>Comparison of long-acting antipsychotic injection and oral antipsychotics in schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84866979349</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Olivares J.</ce:indexed-name> <ce:surname>Olivares</ce:surname> </author> <author seq="2"> <ce:initials>B.</ce:initials> <ce:indexed-name>Pinal B.</ce:indexed-name> <ce:surname>Pinal</ce:surname> </author> <author seq="3"> <ce:initials>C.</ce:initials> <ce:indexed-name>Cinos C.</ce:indexed-name> <ce:surname>Cinos</ce:surname> </author> </ref-authors> <ref-sourcetitle>Neuropsychiatry</ref-sourcetitle> <ref-publicationyear first="2011"/> <ref-volisspag> <voliss volume="1"/> <pagerange first="275" last="289"/> </ref-volisspag> </ref-info> <ref-fulltext>Olivares J. Pinal B. Cinos C. (2011) Comparison of long-acting antipsychotic injection and oral antipsychotics in schizophrenia. Neuropsychiatry 1: 275–289.</ref-fulltext> </reference> <reference id="141"> <ref-info> <ref-title> <ref-titletext>Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">65649114856</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Olivares J.</ce:indexed-name> <ce:surname>Olivares</ce:surname> </author> <author seq="2"> <ce:initials>A.</ce:initials> <ce:indexed-name>Rodriguez-Morales A.</ce:indexed-name> <ce:surname>Rodriguez-Morales</ce:surname> </author> <author seq="3"> <ce:initials>J.</ce:initials> <ce:indexed-name>Diels J.</ce:indexed-name> <ce:surname>Diels</ce:surname> </author> <author seq="4"> <ce:initials>M.</ce:initials> <ce:indexed-name>Povey M.</ce:indexed-name> <ce:surname>Povey</ce:surname> </author> <author seq="5"> <ce:initials>A.</ce:initials> <ce:indexed-name>Jacobs A.</ce:indexed-name> <ce:surname>Jacobs</ce:surname> </author> <author seq="6"> <ce:initials>Z.</ce:initials> <ce:indexed-name>Zhao Z.</ce:indexed-name> <ce:surname>Zhao</ce:surname> </author> <collaboration seq="1"> <ce:indexed-name>e-STAR Spanish Study Group</ce:indexed-name> <ce:text>e-STAR Spanish Study Group</ce:text> </collaboration> <et-al/> </ref-authors> <ref-sourcetitle>Eur Psychiatry</ref-sourcetitle> <ref-publicationyear first="2009"/> <ref-volisspag> <voliss volume="24"/> <pagerange first="287" last="296"/> </ref-volisspag> </ref-info> <ref-fulltext>Olivares J. Rodriguez-Morales A. Diels J. Povey M. Jacobs A. Zhao Z.; e-STAR Spanish Study Group et al. (2009) Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 24: 287–296.</ref-fulltext> </reference> <reference id="142"> <ref-info> <ref-title> <ref-titletext>The long-acting depot antipsychotic drugs</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0642372928</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Pandarakalam J.</ce:indexed-name> <ce:surname>Pandarakalam</ce:surname> </author> </ref-authors> <ref-sourcetitle>Hosp Med</ref-sourcetitle> <ref-publicationyear first="2003"/> <ref-volisspag> <voliss volume="64"/> <pagerange first="603" last="608"/> </ref-volisspag> </ref-info> <ref-fulltext>Pandarakalam J. (2003) The long-acting depot antipsychotic drugs. Hosp Med 64: 603–608.</ref-fulltext> </reference> <reference id="143"> <ref-info> <ref-title> <ref-titletext>Long-acting injectable antipsychotics in first-episode schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84879945635</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>E.</ce:initials> <ce:indexed-name>Parellada E.</ce:indexed-name> <ce:surname>Parellada</ce:surname> </author> <author seq="2"> <ce:initials>D.</ce:initials> <ce:indexed-name>Velligan D.</ce:indexed-name> <ce:surname>Velligan</ce:surname> </author> <author seq="3"> <ce:initials>R.</ce:initials> <ce:indexed-name>Emsley R.</ce:indexed-name> <ce:surname>Emsley</ce:surname> </author> <author seq="4"> <ce:initials>W.</ce:initials> <ce:indexed-name>Kissling W.</ce:indexed-name> <ce:surname>Kissling</ce:surname> </author> </ref-authors> <ref-sourcetitle>Schizophr Res Treatment</ref-sourcetitle> <ref-publicationyear first="2012"/> <ref-volisspag> <voliss volume="2012"/> <pagerange first="318535"/> </ref-volisspag> </ref-info> <ref-fulltext>Parellada E. Velligan D. Emsley R. Kissling W. (2012) Long-acting injectable antipsychotics in first-episode schizophrenia. Schizophr Res Treatment 2012: 318535.</ref-fulltext> </reference> <reference id="144"> <ref-info> <ref-title> <ref-titletext>Why aren't depot antipsychotics prescribed more often and what can be done about it?</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">18844378365</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Patel M.</ce:indexed-name> <ce:surname>Patel</ce:surname> </author> <author seq="2"> <ce:initials>A.</ce:initials> <ce:indexed-name>David A.</ce:indexed-name> <ce:surname>David</ce:surname> </author> </ref-authors> <ref-sourcetitle>Adv Psychiatr Treatment</ref-sourcetitle> <ref-publicationyear first="2005"/> <ref-volisspag> <voliss volume="11"/> <pagerange first="203" last="213"/> </ref-volisspag> </ref-info> <ref-fulltext>Patel M. David A. (2005) Why aren't depot antipsychotics prescribed more often and what can be done about it? Adv Psychiatr Treatment 11: 203–213.</ref-fulltext> </reference> <reference id="145"> <ref-info> <ref-title> <ref-titletext>Depot and oral antipsychotics: patient preferences and attitudes are not the same thing</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">69049107779</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Patel M.</ce:indexed-name> <ce:surname>Patel</ce:surname> </author> <author seq="2"> <ce:initials>N.</ce:initials> <ce:indexed-name>De Zoysa N.</ce:indexed-name> <ce:surname>De Zoysa</ce:surname> </author> <author seq="3"> <ce:initials>M.</ce:initials> <ce:indexed-name>Bernadt M.</ce:indexed-name> <ce:surname>Bernadt</ce:surname> </author> <author seq="4"> <ce:initials>A.</ce:initials> <ce:indexed-name>David A.</ce:indexed-name> <ce:surname>David</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Psychopharmacol</ref-sourcetitle> <ref-publicationyear first="2009"/> <ref-volisspag> <voliss volume="23"/> <pagerange first="789" last="796"/> </ref-volisspag> </ref-info> <ref-fulltext>Patel M. De Zoysa N. Bernadt M. David A. (2009) Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol 23: 789–796.</ref-fulltext> </reference> <reference id="146"> <ref-info> <ref-title> <ref-titletext>Psychiatrists’ use, knowledge and attitudes to first and second generation antipsychotic long-acting injections: comparison over five years</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">77958002310</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Patel M.</ce:indexed-name> <ce:surname>Patel</ce:surname> </author> <author seq="2"> <ce:initials>P.</ce:initials> <ce:indexed-name>Haddad P.</ce:indexed-name> <ce:surname>Haddad</ce:surname> </author> <author seq="3"> <ce:initials>I.</ce:initials> <ce:indexed-name>Chaudhry I.</ce:indexed-name> <ce:surname>Chaudhry</ce:surname> </author> <author seq="4"> <ce:initials>S.</ce:initials> <ce:indexed-name>McLoughlin S.</ce:indexed-name> <ce:surname>McLoughlin</ce:surname> </author> <author seq="5"> <ce:initials>N.</ce:initials> <ce:indexed-name>Husain N.</ce:indexed-name> <ce:surname>Husain</ce:surname> </author> <author seq="6"> <ce:initials>A.</ce:initials> <ce:indexed-name>David A.</ce:indexed-name> <ce:surname>David</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Psychopharmacol</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <voliss volume="24"/> <pagerange first="1473" last="1482"/> </ref-volisspag> </ref-info> <ref-fulltext>Patel M. Haddad P. Chaudhry I. McLoughlin S. Husain N. David A. (2010) Psychiatrists’ use, knowledge and attitudes to first and second generation antipsychotic long-acting injections: comparison over five years. J Psychopharmacol 24: 1473–1482.</ref-fulltext> </reference> <reference id="147"> <ref-info> <ref-title> <ref-titletext>Eliciting psychiatrists’ beliefs about side effects of typical and atypical antipsychotic drugs</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0042267433</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Patel M.</ce:indexed-name> <ce:surname>Patel</ce:surname> </author> <author seq="2"> <ce:initials>V.</ce:initials> <ce:indexed-name>Nikolaou V.</ce:indexed-name> <ce:surname>Nikolaou</ce:surname> </author> <author seq="3"> <ce:initials>A.</ce:initials> <ce:indexed-name>David A.</ce:indexed-name> <ce:surname>David</ce:surname> </author> </ref-authors> <ref-sourcetitle>Int J Psychiatry Clin Pract</ref-sourcetitle> <ref-publicationyear first="2003"/> <ref-volisspag> <voliss volume="7"/> <pagerange first="117" last="120"/> </ref-volisspag> </ref-info> <ref-fulltext>Patel M. Nikolaou V. David A. (2003) Eliciting psychiatrists’ beliefs about side effects of typical and atypical antipsychotic drugs. Int J Psychiatry Clin Pract 7: 117–120.</ref-fulltext> </reference> <reference id="148"> <ref-info> <ref-title> <ref-titletext>Predictors of noncompliance in patients with schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0036942527</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>D.</ce:initials> <ce:indexed-name>Perkins D.</ce:indexed-name> <ce:surname>Perkins</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="2002"/> <ref-volisspag> <voliss volume="63"/> <pagerange first="1121" last="1128"/> </ref-volisspag> </ref-info> <ref-fulltext>Perkins D. (2002) Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 63: 1121–1128.</ref-fulltext> </reference> <reference id="149"> <ref-info> <ref-title> <ref-titletext>Long acting risperidone in the treatment of schizophrenia: data from a 24-month Belgian electronic schizophrenia adherence registry (eSTAR): an observational study</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84874971324</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Peusken J.</ce:indexed-name> <ce:surname>Peusken</ce:surname> </author> <author seq="2"> <ce:initials>C.</ce:initials> <ce:indexed-name>Mertens C.</ce:indexed-name> <ce:surname>Mertens</ce:surname> </author> <author seq="3"> <ce:initials>J.</ce:initials> <ce:indexed-name>Kusters J.</ce:indexed-name> <ce:surname>Kusters</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Acta Psychiatr Belg</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <voliss volume="110"/> <pagerange first="34" last="46"/> </ref-volisspag> </ref-info> <ref-fulltext>Peusken J. Mertens C. Kusters J. et al. (2010a) Long acting risperidone in the treatment of schizophrenia: data from a 24-month Belgian electronic schizophrenia adherence registry (eSTAR): an observational study. Acta Psychiatr Belg 110: 34–46.</ref-fulltext> </reference> <reference id="150"> <ref-info> <ref-title> <ref-titletext>Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">76949089882</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Peuskens J.</ce:indexed-name> <ce:surname>Peuskens</ce:surname> </author> <author seq="2"> <ce:initials>J.</ce:initials> <ce:indexed-name>Olivares J.</ce:indexed-name> <ce:surname>Olivares</ce:surname> </author> <author seq="3"> <ce:initials>J.</ce:initials> <ce:indexed-name>Pecenak J.</ce:indexed-name> <ce:surname>Pecenak</ce:surname> </author> <author seq="4"> <ce:initials>I.</ce:initials> <ce:indexed-name>Tuma I.</ce:indexed-name> <ce:surname>Tuma</ce:surname> </author> <author seq="5"> <ce:initials>H.</ce:initials> <ce:indexed-name>Bij de Weg H.</ce:indexed-name> <ce:surname>Bij de Weg</ce:surname> </author> <author seq="6"> <ce:initials>L.</ce:initials> <ce:indexed-name>Eriksson L.</ce:indexed-name> <ce:surname>Eriksson</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Curr Med Res Opin</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <voliss volume="26"/> <pagerange first="501" last="509"/> </ref-volisspag> </ref-info> <ref-fulltext>Peuskens J. Olivares J. Pecenak J. Tuma I. Bij de Weg H. Eriksson L. et al. (2010b) Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin 26: 501–509.</ref-fulltext> </reference> <reference id="151"> <ref-info> <ref-title> <ref-titletext>Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84885438433</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>S.</ce:initials> <ce:indexed-name>Potkin S.</ce:indexed-name> <ce:surname>Potkin</ce:surname> </author> <author seq="2"> <ce:initials>R.</ce:initials> <ce:indexed-name>Bera R.</ce:indexed-name> <ce:surname>Bera</ce:surname> </author> <author seq="3"> <ce:initials>D.</ce:initials> <ce:indexed-name>Zubek D.</ce:indexed-name> <ce:surname>Zubek</ce:surname> </author> <author seq="4"> <ce:initials>G.</ce:initials> <ce:indexed-name>Lau G.</ce:indexed-name> <ce:surname>Lau</ce:surname> </author> </ref-authors> <ref-sourcetitle>BMC Psychiatry</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="13"/> </ref-volisspag> <ref-text>article 261</ref-text> </ref-info> <ref-fulltext>Potkin S. Bera R. Zubek D. Lau G. (2013) Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry 13: article 261.</ref-fulltext> </reference> <reference id="152"> <ref-info> <ref-title> <ref-titletext>Fluctuation of serum zuclopenthixol concentrations in patients treated with zuclopenthixol decanoate in viscoleo</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0028223909</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Poulsen J.</ce:indexed-name> <ce:surname>Poulsen</ce:surname> </author> <author seq="2"> <ce:initials>O.</ce:initials> <ce:indexed-name>Olesen O.</ce:indexed-name> <ce:surname>Olesen</ce:surname> </author> <author seq="3"> <ce:initials>N.</ce:initials> <ce:indexed-name>Larsen N.</ce:indexed-name> <ce:surname>Larsen</ce:surname> </author> </ref-authors> <ref-sourcetitle>Ther Drug Monit</ref-sourcetitle> <ref-publicationyear first="1994"/> <ref-volisspag> <voliss volume="16"/> <pagerange first="155" last="159"/> </ref-volisspag> </ref-info> <ref-fulltext>Poulsen J. Olesen O. Larsen N. (1994) Fluctuation of serum zuclopenthixol concentrations in patients treated with zuclopenthixol decanoate in viscoleo. Ther Drug Monit 16: 155–159.</ref-fulltext> </reference> <reference id="153"> <ref-info> <ref-title> <ref-titletext>In vitro and in vivo demonstration of risperidone implants in mice</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">36849047806</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>C.</ce:initials> <ce:indexed-name>Rabin C.</ce:indexed-name> <ce:surname>Rabin</ce:surname> </author> <author seq="2"> <ce:initials>Y.</ce:initials> <ce:indexed-name>Liang Y.</ce:indexed-name> <ce:surname>Liang</ce:surname> </author> <author seq="3"> <ce:initials>R.</ce:initials> <ce:indexed-name>Ehrlichman R.</ce:indexed-name> <ce:surname>Ehrlichman</ce:surname> </author> <author seq="4"> <ce:initials>A.</ce:initials> <ce:indexed-name>Budhian A.</ce:indexed-name> <ce:surname>Budhian</ce:surname> </author> <author seq="5"> <ce:initials>K.</ce:initials> <ce:indexed-name>Metzger K.</ce:indexed-name> <ce:surname>Metzger</ce:surname> </author> <author seq="6"> <ce:initials>C.</ce:initials> <ce:indexed-name>Majewski-Tiedeken C.</ce:indexed-name> <ce:surname>Majewski-Tiedeken</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Schizophr Res</ref-sourcetitle> <ref-publicationyear first="2008"/> <ref-volisspag> <voliss volume="98"/> <pagerange first="66" last="78"/> </ref-volisspag> </ref-info> <ref-fulltext>Rabin C. Liang Y Ehrlichman R. Budhian A. Metzger K. Majewski-Tiedeken C. et al. (2008) In vitro and in vivo demonstration of risperidone implants in mice. Schizophr Res 98: 66–78.</ref-fulltext> </reference> <reference id="154"> <ref-info> <ref-title> <ref-titletext>Analisi di costo-efficacia dello switch da un antipsicotico orale a risperidone a rilascio prolungato nel trattamento dei pazienti affetti da schizofrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84998064730</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>R.</ce:initials> <ce:indexed-name>Ravasio R.</ce:indexed-name> <ce:surname>Ravasio</ce:surname> </author> <author seq="2"> <ce:initials>L.</ce:initials> <ce:indexed-name>Sanfilippo L.</ce:indexed-name> <ce:surname>Sanfilippo</ce:surname> </author> <author seq="3"> <ce:initials>G.</ce:initials> <ce:indexed-name>De Paoli G.</ce:indexed-name> <ce:surname>De Paoli</ce:surname> </author> <author seq="4"> <ce:initials>C.</ce:initials> <ce:indexed-name>Cerra C.</ce:indexed-name> <ce:surname>Cerra</ce:surname> </author> <author seq="5"> <ce:initials>P.</ce:initials> <ce:indexed-name>Fratino P.</ce:indexed-name> <ce:surname>Fratino</ce:surname> </author> <author seq="6"> <ce:initials>M.</ce:initials> <ce:indexed-name>Della Giovanna M.</ce:indexed-name> <ce:surname>Della Giovanna</ce:surname> </author> </ref-authors> <ref-sourcetitle>Giorn Ital Health Technol Ass</ref-sourcetitle> <ref-publicationyear first="2009"/> <ref-volisspag> <voliss volume="2"/> <pagerange first="1" last="8"/> </ref-volisspag> </ref-info> <ref-fulltext>Ravasio R. Sanfilippo L. De Paoli G. Cerra C. Fratino P. Della Giovanna M. (2009) Analisi di costo-efficacia dello switch da un antipsicotico orale a risperidone a rilascio prolungato nel trattamento dei pazienti affetti da schizofrenia. Giorn Ital Health Technol Ass 2: 1–8.</ref-fulltext> </reference> <reference id="155"> <ref-info> <ref-title> <ref-titletext>Societal costs of nonadherence in schizophrenia: homicide/suicide</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84998046983</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>T.</ce:initials> <ce:indexed-name>Reichhart T.</ce:indexed-name> <ce:surname>Reichhart</ce:surname> </author> <author seq="2"> <ce:initials>W.</ce:initials> <ce:indexed-name>Kissling W.</ce:indexed-name> <ce:surname>Kissling</ce:surname> </author> </ref-authors> <ref-sourcetitle>M&amp;B</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="1"/> <pagerange first="19" last="22"/> </ref-volisspag> </ref-info> <ref-fulltext>Reichhart T. Kissling W. (2013) Societal costs of nonadherence in schizophrenia: homicide/suicide. M&amp;B 1: 19–22.</ref-fulltext> </reference> <reference id="156"> <ref-info> <ref-title> <ref-titletext>Depot neuroleptic therapy: clinical considerations</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0029043922</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>G.</ce:initials> <ce:indexed-name>Remington G.</ce:indexed-name> <ce:surname>Remington</ce:surname> </author> <author seq="2"> <ce:initials>M.</ce:initials> <ce:indexed-name>Adams M.</ce:indexed-name> <ce:surname>Adams</ce:surname> </author> </ref-authors> <ref-sourcetitle>Can J Psychiatry</ref-sourcetitle> <ref-publicationyear first="1995"/> <ref-volisspag> <voliss volume="40"/> <pagerange first="S5" last="S11"/> </ref-volisspag> </ref-info> <ref-fulltext>Remington G. Adams M. (1995) Depot neuroleptic therapy: clinical considerations. Can J Psychiatry 40: S5–S11.</ref-fulltext> </reference> <reference id="157"> <ref-info> <ref-title> <ref-titletext>Pharmacokinetics of haloperidol decanoate</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0020262814</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>A.</ce:initials> <ce:indexed-name>Reyntijens A.</ce:indexed-name> <ce:surname>Reyntijens</ce:surname> </author> <author seq="2"> <ce:initials>J.</ce:initials> <ce:indexed-name>Heykants J.</ce:indexed-name> <ce:surname>Heykants</ce:surname> </author> <author seq="3"> <ce:initials>R.</ce:initials> <ce:indexed-name>Woestenborghs R.</ce:indexed-name> <ce:surname>Woestenborghs</ce:surname> </author> <author seq="4"> <ce:initials>Y.</ce:initials> <ce:indexed-name>Gelders Y.</ce:indexed-name> <ce:surname>Gelders</ce:surname> </author> <author seq="5"> <ce:initials>T.</ce:initials> <ce:indexed-name>Aerts T.</ce:indexed-name> <ce:surname>Aerts</ce:surname> </author> </ref-authors> <ref-sourcetitle>Int Pharmacopsychiatry</ref-sourcetitle> <ref-publicationyear first="1982"/> <ref-volisspag> <voliss volume="17"/> <pagerange first="238" last="246"/> </ref-volisspag> </ref-info> <ref-fulltext>Reyntijens A. Heykants J. Woestenborghs R. Gelders Y. Aerts T. (1982) Pharmacokinetics of haloperidol decanoate. Int Pharmacopsychiatry 17: 238–246.</ref-fulltext> </reference> <reference id="158"> <ref-info> <ref-title> <ref-titletext>Fluphenazine decanoate, fluphenazine hydrochloride given orally and placebo in remitted schizophrenia: relapse rate over one year</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0017327231</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>A.</ce:initials> <ce:indexed-name>Rifkin A.</ce:indexed-name> <ce:surname>Rifkin</ce:surname> </author> <author seq="2"> <ce:initials>F.</ce:initials> <ce:indexed-name>Quitkin F.</ce:indexed-name> <ce:surname>Quitkin</ce:surname> </author> <author seq="3"> <ce:initials>C.</ce:initials> <ce:indexed-name>Rabiner C.</ce:indexed-name> <ce:surname>Rabiner</ce:surname> </author> </ref-authors> <ref-sourcetitle>Arch Gen Psychiatry</ref-sourcetitle> <ref-publicationyear first="1977"/> <ref-volisspag> <voliss volume="34"/> <pagerange first="43" last="47"/> </ref-volisspag> </ref-info> <ref-fulltext>Rifkin A. Quitkin F. Rabiner C. (1977) Fluphenazine decanoate, fluphenazine hydrochloride given orally and placebo in remitted schizophrenia: relapse rate over one year. Arch Gen Psychiatry 34: 43–47.</ref-fulltext> </reference> <reference id="159"> <ref-info> <ref-title> <ref-titletext>Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">33846305400</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>D.</ce:initials> <ce:indexed-name>Robinson D.</ce:indexed-name> <ce:surname>Robinson</ce:surname> </author> <author seq="2"> <ce:initials>M.</ce:initials> <ce:indexed-name>Woerner M.</ce:indexed-name> <ce:surname>Woerner</ce:surname> </author> <author seq="3"> <ce:initials>B.</ce:initials> <ce:indexed-name>Napolitano B.</ce:indexed-name> <ce:surname>Napolitano</ce:surname> </author> <author seq="4"> <ce:initials>R.</ce:initials> <ce:indexed-name>Patel R.</ce:indexed-name> <ce:surname>Patel</ce:surname> </author> <author seq="5"> <ce:initials>S.</ce:initials> <ce:indexed-name>Sevy S.</ce:indexed-name> <ce:surname>Sevy</ce:surname> </author> <author seq="6"> <ce:initials>H.</ce:initials> <ce:indexed-name>Gunfez-Bruce H.</ce:indexed-name> <ce:surname>Gunfez-Bruce</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Am J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2006"/> <ref-volisspag> <voliss volume="163"/> <pagerange first="2096" last="2102"/> </ref-volisspag> </ref-info> <ref-fulltext>Robinson D. Woerner M. Napolitano B. Patel R. Sevy S. Gunfez-Bruce H. et al. (2006) Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry 163: 2096–2102.</ref-fulltext> </reference> <reference id="160"> <ref-info> <ref-title> <ref-titletext>Risperidone long-acting injection in the treatment of first episode schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84997945263</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>P.</ce:initials> <ce:indexed-name>Rocca P.</ce:indexed-name> <ce:surname>Rocca</ce:surname> </author> <author seq="2"> <ce:initials>L.</ce:initials> <ce:indexed-name>Sandei L.</ce:indexed-name> <ce:surname>Sandei</ce:surname> </author> <author seq="3"> <ce:initials>I.</ce:initials> <ce:indexed-name>Bava I.</ce:indexed-name> <ce:surname>Bava</ce:surname> </author> <author seq="4"> <ce:initials>T.</ce:initials> <ce:indexed-name>Frieri T.</ce:indexed-name> <ce:surname>Frieri</ce:surname> </author> </ref-authors> <ref-sourcetitle>Curr Psychopharmacol</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="2"/> <pagerange first="29" last="36"/> </ref-volisspag> </ref-info> <ref-fulltext>Rocca P. Sandei L. Bava I. Frieri T. (2013) Risperidone long-acting injection in the treatment of first episode schizophrenia. Curr Psychopharmacol 2: 29–36.</ref-fulltext> </reference> <reference id="161"> <ref-info> <ref-title> <ref-titletext>Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84997879604</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>D.</ce:initials> <ce:indexed-name>Rosaria D.</ce:indexed-name> <ce:surname>Rosaria</ce:surname> </author> <author seq="2"> <ce:initials>B.</ce:initials> <ce:indexed-name>Alice B.</ce:indexed-name> <ce:surname>Alice</ce:surname> </author> </ref-authors> <ref-sourcetitle>Neuropsychiatr Dis Treat</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <voliss volume="6"/> <pagerange first="573" last="581"/> </ref-volisspag> </ref-info> <ref-fulltext>Rosaria D. Alice B. (2010) Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia. Neuropsychiatr Dis Treat 6: 573–581.</ref-fulltext> </reference> <reference id="162"> <ref-info> <ref-title> <ref-titletext>Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0242364067</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>A.</ce:initials> <ce:indexed-name>Rothbard A.</ce:indexed-name> <ce:surname>Rothbard</ce:surname> </author> <author seq="2"> <ce:initials>E.</ce:initials> <ce:indexed-name>Kuno E.</ce:indexed-name> <ce:surname>Kuno</ce:surname> </author> <author seq="3"> <ce:initials>K.</ce:initials> <ce:indexed-name>Foley K.</ce:indexed-name> <ce:surname>Foley</ce:surname> </author> </ref-authors> <ref-sourcetitle>Schizophr Bull</ref-sourcetitle> <ref-publicationyear first="2003"/> <ref-volisspag> <voliss volume="29"/> <pagerange first="531" last="540"/> </ref-volisspag> </ref-info> <ref-fulltext>Rothbard A. Kuno E. Foley K. (2003) Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophr Bull 29: 531–540.</ref-fulltext> </reference> <reference id="163"> <ref-info> <ref-title> <ref-titletext>Clinicians’ attitudes toward the use of long-acting injectable antipsychotics</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84879850841</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>L.</ce:initials> <ce:indexed-name>Samalin L.</ce:indexed-name> <ce:surname>Samalin</ce:surname> </author> <author seq="2"> <ce:initials>T.</ce:initials> <ce:indexed-name>Charpeaud T.</ce:indexed-name> <ce:surname>Charpeaud</ce:surname> </author> <author seq="3"> <ce:initials>O.</ce:initials> <ce:indexed-name>Blanc O.</ce:indexed-name> <ce:surname>Blanc</ce:surname> </author> <author seq="4"> <ce:initials>S.</ce:initials> <ce:indexed-name>Heres S.</ce:indexed-name> <ce:surname>Heres</ce:surname> </author> <author seq="5"> <ce:initials>P.</ce:initials> <ce:indexed-name>Llorca P.</ce:indexed-name> <ce:surname>Llorca</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Nerv Ment Dis</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="201"/> <pagerange first="553" last="559"/> </ref-volisspag> </ref-info> <ref-fulltext>Samalin L. Charpeaud T. Blanc O. Heres S. Llorca P. (2013) Clinicians’ attitudes toward the use of long-acting injectable antipsychotics. J Nerv Ment Dis 201: 553–559.</ref-fulltext> </reference> <reference id="164"> <ref-info> <ref-title> <ref-titletext>Relapse and rehospitalization: comparing oral and depot antipsychotics</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0346753734</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>N.</ce:initials> <ce:indexed-name>Schooler N.</ce:indexed-name> <ce:surname>Schooler</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="2003"/> <ref-volisspag> <voliss volume="64"/> <pagerange first="14" last="17"/> </ref-volisspag> </ref-info> <ref-fulltext>Schooler N. (2003) Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 64: 14–17.</ref-fulltext> </reference> <reference id="165"> <ref-info> <ref-title> <ref-titletext>Prevention of relapse in schizophrenia: an evaluation of fluphenazine decanoate</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0018835404</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>N.</ce:initials> <ce:indexed-name>Schooler N.</ce:indexed-name> <ce:surname>Schooler</ce:surname> </author> <author seq="2"> <ce:initials>J.</ce:initials> <ce:indexed-name>Levine J.</ce:indexed-name> <ce:surname>Levine</ce:surname> </author> <author seq="3"> <ce:initials>J.</ce:initials> <ce:indexed-name>Severe J.</ce:indexed-name> <ce:surname>Severe</ce:surname> </author> <author seq="4"> <ce:initials>B.</ce:initials> <ce:indexed-name>Brauzer B.</ce:indexed-name> <ce:surname>Brauzer</ce:surname> </author> <author seq="5"> <ce:initials>A.</ce:initials> <ce:indexed-name>DiMascio A.</ce:indexed-name> <ce:surname>DiMascio</ce:surname> </author> <author seq="6"> <ce:initials>G.</ce:initials> <ce:indexed-name>Klerman G.</ce:indexed-name> <ce:surname>Klerman</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Arch Gen Psychiatry</ref-sourcetitle> <ref-publicationyear first="1980"/> <ref-volisspag> <voliss volume="37"/> <pagerange first="16" last="24"/> </ref-volisspag> </ref-info> <ref-fulltext>Schooler N. Levine J. Severe J. Brauzer B. DiMascio A. Klerman G. et al. (1980) Prevention of relapse in schizophrenia: an evaluation of fluphenazine decanoate. Arch Gen Psychiatry 37: 16–24.</ref-fulltext> </reference> <reference id="166"> <ref-info> <ref-title> <ref-titletext>Does evidence from clinical trials in psychopharmacology apply in clinical practice?</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0035121837</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>S.</ce:initials> <ce:indexed-name>Stahl S.</ce:indexed-name> <ce:surname>Stahl</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="2001"/> <ref-volisspag> <voliss volume="62"/> <pagerange first="6" last="7"/> </ref-volisspag> </ref-info> <ref-fulltext>Stahl S. (2001) Does evidence from clinical trials in psychopharmacology apply in clinical practice? J Clin Psychiatry 62: 6–7.</ref-fulltext> </reference> <reference id="167"> <ref-info> <ref-title> <ref-titletext>An expert opinion from the Association des médecins psychiatres du Québec</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">79960439010</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>E.</ce:initials> <ce:indexed-name>Stip E.</ce:indexed-name> <ce:surname>Stip</ce:surname> </author> <author seq="2"> <ce:initials>A.</ce:initials> <ce:indexed-name>Abdel-Baki A.</ce:indexed-name> <ce:surname>Abdel-Baki</ce:surname> </author> <author seq="3"> <ce:initials>D.</ce:initials> <ce:indexed-name>Bloom D.</ce:indexed-name> <ce:surname>Bloom</ce:surname> </author> <author seq="4"> <ce:initials>S.</ce:initials> <ce:indexed-name>Grignon S.</ce:indexed-name> <ce:surname>Grignon</ce:surname> </author> <author seq="5"> <ce:initials>M.</ce:initials> <ce:indexed-name>Roy M.</ce:indexed-name> <ce:surname>Roy</ce:surname> </author> </ref-authors> <ref-sourcetitle>Can J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2011"/> <ref-volisspag> <voliss volume="56"/> <pagerange first="367" last="376"/> </ref-volisspag> </ref-info> <ref-fulltext>Stip E. Abdel-Baki A. Bloom D. Grignon S. Roy M. (2011) An expert opinion from the Association des médecins psychiatres du Québec. Can J Psychiatry 56: 367–376.</ref-fulltext> </reference> <reference id="168"> <ref-info> <ref-title> <ref-titletext>Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">34249331312</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Strassnig M.</ce:indexed-name> <ce:surname>Strassnig</ce:surname> </author> <author seq="2"> <ce:initials>J.</ce:initials> <ce:indexed-name>Miewald J.</ce:indexed-name> <ce:surname>Miewald</ce:surname> </author> <author seq="3"> <ce:initials>M.</ce:initials> <ce:indexed-name>Keshavan M.</ce:indexed-name> <ce:surname>Keshavan</ce:surname> </author> <author seq="4"> <ce:initials>R.</ce:initials> <ce:indexed-name>Ganguli R.</ce:indexed-name> <ce:surname>Ganguli</ce:surname> </author> </ref-authors> <ref-sourcetitle>Schizophr Res</ref-sourcetitle> <ref-publicationyear first="2007"/> <ref-volisspag> <voliss volume="93"/> <pagerange first="90" last="98"/> </ref-volisspag> </ref-info> <ref-fulltext>Strassnig M. Miewald J. Keshavan M. Ganguli R. (2007) Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res 93: 90–98.</ref-fulltext> </reference> <reference id="169"> <ref-info> <ref-title> <ref-titletext>The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84866734138</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>H.</ce:initials> <ce:indexed-name>Suzuki H.</ce:indexed-name> <ce:surname>Suzuki</ce:surname> </author> <author seq="2"> <ce:initials>K.</ce:initials> <ce:indexed-name>Gen K.</ce:indexed-name> <ce:surname>Gen</ce:surname> </author> </ref-authors> <ref-sourcetitle>Hum Psychopharmacol</ref-sourcetitle> <ref-publicationyear first="2012"/> <ref-volisspag> <voliss volume="27"/> <pagerange first="470" last="475"/> </ref-volisspag> </ref-info> <ref-fulltext>Suzuki H. Gen K. (2012) The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. Hum Psychopharmacol 27: 470–475.</ref-fulltext> </reference> <reference id="170"> <ref-info> <ref-title> <ref-titletext>On the path to recovery: patients’ experiences of treatment with long-acting injections of antipsychotic medication</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0242367950</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>B.</ce:initials> <ce:indexed-name>Svedberg B.</ce:indexed-name> <ce:surname>Svedberg</ce:surname> </author> <author seq="2"> <ce:initials>G.</ce:initials> <ce:indexed-name>Backenroth-Ohsako G.</ce:indexed-name> <ce:surname>Backenroth-Ohsako</ce:surname> </author> <author seq="3"> <ce:initials>K.</ce:initials> <ce:indexed-name>Lutzen K.</ce:indexed-name> <ce:surname>Lützén</ce:surname> </author> </ref-authors> <ref-sourcetitle>Int J Ment Health Nurs</ref-sourcetitle> <ref-publicationyear first="2003"/> <ref-volisspag> <voliss volume="12"/> <pagerange first="110" last="118"/> </ref-volisspag> </ref-info> <ref-fulltext>Svedberg B. Backenroth-Ohsako G. Lützén K. (2003) On the path to recovery: patients’ experiences of treatment with long-acting injections of antipsychotic medication. Int J Ment Health Nurs 12: 110–18.</ref-fulltext> </reference> <reference id="171"> <ref-info> <ref-title> <ref-titletext>Effects of involuntary outpatient commitment and depot antipsychotics on treatment adherence in persons with severe mental illness</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0034809505</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Swartz M.</ce:indexed-name> <ce:surname>Swartz</ce:surname> </author> <author seq="2"> <ce:initials>J.</ce:initials> <ce:indexed-name>Swanson J.</ce:indexed-name> <ce:surname>Swanson</ce:surname> </author> <author seq="3"> <ce:initials>H.</ce:initials> <ce:indexed-name>Wagner H.</ce:indexed-name> <ce:surname>Wagner</ce:surname> </author> <author seq="4"> <ce:initials>B.</ce:initials> <ce:indexed-name>Burns B.</ce:indexed-name> <ce:surname>Burns</ce:surname> </author> <author seq="5"> <ce:initials>V.</ce:initials> <ce:indexed-name>Hiday V.</ce:indexed-name> <ce:surname>Hiday</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Nerv Ment Dis</ref-sourcetitle> <ref-publicationyear first="2001"/> <ref-volisspag> <voliss volume="189"/> <pagerange first="583" last="592"/> </ref-volisspag> </ref-info> <ref-fulltext>Swartz M. Swanson J. Wagner H. Burns B. Hiday V. (2001) Effects of involuntary outpatient commitment and depot antipsychotics on treatment adherence in persons with severe mental illness. J Nerv Ment Dis 189: 583–592.</ref-fulltext> </reference> <reference id="172"> <ref-info> <ref-title> <ref-titletext>Establishing a dose-response relationship for haloperidol decanoate</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">14944358633</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>D.</ce:initials> <ce:indexed-name>Taylor D.</ce:indexed-name> <ce:surname>Taylor</ce:surname> </author> </ref-authors> <ref-sourcetitle>Psychiatrist</ref-sourcetitle> <ref-publicationyear first="2005"/> <ref-volisspag> <voliss volume="29"/> <pagerange first="104" last="107"/> </ref-volisspag> </ref-info> <ref-fulltext>Taylor D. (2005) Establishing a dose-response relationship for haloperidol decanoate. Psychiatrist 29: 104–107.</ref-fulltext> </reference> <reference id="173"> <ref-info> <ref-title> <ref-titletext>Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84997959341</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>D.</ce:initials> <ce:indexed-name>Taylor D.</ce:indexed-name> <ce:surname>Taylor</ce:surname> </author> </ref-authors> <ref-sourcetitle>Br J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2009"/> <ref-volisspag> <voliss volume="195"/> <pagerange first="S13" last="S19"/> </ref-volisspag> </ref-info> <ref-fulltext>Taylor D. (2009) Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry 195: S13–S19.</ref-fulltext> </reference> <reference id="174"> <ref-info> <ref-title> <ref-titletext>Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84883270994</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Taylor M.</ce:indexed-name> <ce:surname>Taylor</ce:surname> </author> <author seq="2"> <ce:initials>K.</ce:initials> <ce:indexed-name>Ng K.</ce:indexed-name> <ce:surname>Ng</ce:surname> </author> </ref-authors> <ref-sourcetitle>Aust N Z J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2013"/> <ref-volisspag> <voliss volume="47"/> <pagerange first="624" last="630"/> </ref-volisspag> </ref-info> <ref-fulltext>Taylor M. Ng K. (2013) Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review. Aust N Z J Psychiatry 47: 624–630.</ref-fulltext> </reference> <reference id="175"> <ref-info> <ref-title> <ref-titletext>Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">77957670072</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>A.</ce:initials> <ce:indexed-name>Thyssen A.</ce:indexed-name> <ce:surname>Thyssen</ce:surname> </author> <author seq="2"> <ce:initials>S.</ce:initials> <ce:indexed-name>Rusch S.</ce:indexed-name> <ce:surname>Rusch</ce:surname> </author> <author seq="3"> <ce:initials>V.</ce:initials> <ce:indexed-name>Herben V.</ce:indexed-name> <ce:surname>Herben</ce:surname> </author> <author seq="4"> <ce:initials>J.</ce:initials> <ce:indexed-name>Quiroz J.</ce:indexed-name> <ce:surname>Quiroz</ce:surname> </author> <author seq="5"> <ce:initials>E.</ce:initials> <ce:indexed-name>Mannaert E.</ce:indexed-name> <ce:surname>Mannaert</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Clin Pharmacol</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <voliss volume="50"/> <pagerange first="1011" last="1021"/> </ref-volisspag> </ref-info> <ref-fulltext>Thyssen A. Rusch S. Herben V. Quiroz J. Mannaert E. (2010) Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients. J Clin Pharmacol 50: 1011–1021.</ref-fulltext> </reference> <reference id="176"> <ref-info> <ref-title> <ref-titletext>A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">79958233416</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Tiihonen J.</ce:indexed-name> <ce:surname>Tiihonen</ce:surname> </author> <author seq="2"> <ce:initials>J.</ce:initials> <ce:indexed-name>Haukka J.</ce:indexed-name> <ce:surname>Haukka</ce:surname> </author> <author seq="3"> <ce:initials>M.</ce:initials> <ce:indexed-name>Taylor M.</ce:indexed-name> <ce:surname>Taylor</ce:surname> </author> <author seq="4"> <ce:initials>P.</ce:initials> <ce:indexed-name>Haddad P.</ce:indexed-name> <ce:surname>Haddad</ce:surname> </author> <author seq="5"> <ce:initials>M.</ce:initials> <ce:indexed-name>Patel M.</ce:indexed-name> <ce:surname>Patel</ce:surname> </author> <author seq="6"> <ce:initials>P.</ce:initials> <ce:indexed-name>Korhonen P.</ce:indexed-name> <ce:surname>Korhonen</ce:surname> </author> </ref-authors> <ref-sourcetitle>Am J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2011"/> <ref-volisspag> <voliss volume="168"/> <pagerange first="603" last="609"/> </ref-volisspag> </ref-info> <ref-fulltext>Tiihonen J. Haukka J. Taylor M. Haddad P. Patel M. Korhonen P. (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168: 603–609.</ref-fulltext> </reference> <reference id="177"> <ref-info> <ref-title> <ref-titletext>Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">33747185865</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Tiihonen J.</ce:indexed-name> <ce:surname>Tiihonen</ce:surname> </author> <author seq="2"> <ce:initials>K.</ce:initials> <ce:indexed-name>Wahlbeck K.</ce:indexed-name> <ce:surname>Wahlbeck</ce:surname> </author> <author seq="3"> <ce:initials>J.</ce:initials> <ce:indexed-name>Lonnqvist J.</ce:indexed-name> <ce:surname>Lönnqvist</ce:surname> </author> <author seq="4"> <ce:initials>T.</ce:initials> <ce:indexed-name>Klaukka T.</ce:indexed-name> <ce:surname>Klaukka</ce:surname> </author> <author seq="5"> <ce:initials>J.</ce:initials> <ce:indexed-name>Ioannidis J.</ce:indexed-name> <ce:surname>Ioannidis</ce:surname> </author> <author seq="6"> <ce:initials>J.</ce:initials> <ce:indexed-name>Volavka J.</ce:indexed-name> <ce:surname>Volavka</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>BMJ</ref-sourcetitle> <ref-publicationyear first="2006"/> <ref-volisspag> <voliss volume="333"/> <pagerange first="224"/> </ref-volisspag> </ref-info> <ref-fulltext>Tiihonen J. Wahlbeck K. Lönnqvist J. Klaukka T. Ioannidis J. Volavka J. et al. (2006) Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333: 224.</ref-fulltext> </reference> <reference id="178"> <ref-info> <ref-title> <ref-titletext>[Categorical refusal of treatment by psychiatric patients: balance, survey and prospects]</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0033176046</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Trudeau M.</ce:indexed-name> <ce:surname>Trudeau</ce:surname> </author> <author seq="2"> <ce:initials>M.</ce:initials> <ce:indexed-name>Bruneau M.</ce:indexed-name> <ce:surname>Bruneau</ce:surname> </author> <author seq="3"> <ce:initials>E.</ce:initials> <ce:indexed-name>Stip E.</ce:indexed-name> <ce:surname>Stip</ce:surname> </author> <author seq="4"> <ce:initials>F.</ce:initials> <ce:indexed-name>Grunberg F.</ce:indexed-name> <ce:surname>Grünberg</ce:surname> </author> <author seq="5"> <ce:initials>M.</ce:initials> <ce:indexed-name>Boivin M.</ce:indexed-name> <ce:surname>Boivin</ce:surname> </author> </ref-authors> <ref-sourcetitle>Can J Psychiatry</ref-sourcetitle> <ref-publicationyear first="1999"/> <ref-volisspag> <voliss volume="44"/> <pagerange first="583" last="588"/> </ref-volisspag> </ref-info> <ref-fulltext>Trudeau M. Bruneau M. Stip E. Grünberg F. Boivin M. (1999) [Categorical refusal of treatment by psychiatric patients: balance, survey and prospects]. Can J Psychiatry 44: 583–588.</ref-fulltext> </reference> <reference id="179"> <ref-info> <ref-title> <ref-titletext>Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">3142523378</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Turner M.</ce:indexed-name> <ce:surname>Turner</ce:surname> </author> <author seq="2"> <ce:initials>E.</ce:initials> <ce:indexed-name>Eerdekens E.</ce:indexed-name> <ce:surname>Eerdekens</ce:surname> </author> <author seq="3"> <ce:initials>M.</ce:initials> <ce:indexed-name>Jacko M.</ce:indexed-name> <ce:surname>Jacko</ce:surname> </author> <author seq="4"> <ce:initials>M.</ce:initials> <ce:indexed-name>Eerdekens M.</ce:indexed-name> <ce:surname>Eerdekens</ce:surname> </author> </ref-authors> <ref-sourcetitle>Int Clin Psychopharmacol</ref-sourcetitle> <ref-publicationyear first="2004"/> <ref-volisspag> <voliss volume="19"/> <pagerange first="241" last="249"/> </ref-volisspag> </ref-info> <ref-fulltext>Turner M. Eerdekens E. Jacko M. Eerdekens M. (2004) Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol 19: 241–249.</ref-fulltext> </reference> <reference id="180"> <ref-info> <ref-title> <ref-titletext>Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0036673659</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>M.</ce:initials> <ce:indexed-name>Valenstein M.</ce:indexed-name> <ce:surname>Valenstein</ce:surname> </author> <author seq="2"> <ce:initials>L.</ce:initials> <ce:indexed-name>Copeland L.</ce:indexed-name> <ce:surname>Copeland</ce:surname> </author> <author seq="3"> <ce:initials>F.</ce:initials> <ce:indexed-name>Blow F.</ce:indexed-name> <ce:surname>Blow</ce:surname> </author> <author seq="4"> <ce:initials>J.</ce:initials> <ce:indexed-name>McCarthy J.</ce:indexed-name> <ce:surname>McCarthy</ce:surname> </author> <author seq="5"> <ce:initials>J.</ce:initials> <ce:indexed-name>Zeber J.</ce:indexed-name> <ce:surname>Zeber</ce:surname> </author> <author seq="6"> <ce:initials>L.</ce:initials> <ce:indexed-name>Gillon L.</ce:indexed-name> <ce:surname>Gillon</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Med Care</ref-sourcetitle> <ref-publicationyear first="2002"/> <ref-volisspag> <voliss volume="40"/> <pagerange first="630" last="639"/> </ref-volisspag> </ref-info> <ref-fulltext>Valenstein M. Copeland L. Blow F. McCarthy J. Zeber J. Gillon L. et al. (2002) Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 40: 630–639.</ref-fulltext> </reference> <reference id="181"> <ref-info> <ref-title> <ref-titletext>Community treatment orders: relationship to clinical care, medication compliance, behavioural disturbance and readmission</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0033819128</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>K.</ce:initials> <ce:indexed-name>Vaughan K.</ce:indexed-name> <ce:surname>Vaughan</ce:surname> </author> <author seq="2"> <ce:initials>N.</ce:initials> <ce:indexed-name>McConaghy N.</ce:indexed-name> <ce:surname>McConaghy</ce:surname> </author> <author seq="3"> <ce:initials>C.</ce:initials> <ce:indexed-name>Wolf C.</ce:indexed-name> <ce:surname>Wolf</ce:surname> </author> <author seq="4"> <ce:initials>C.</ce:initials> <ce:indexed-name>Myhr C.</ce:indexed-name> <ce:surname>Myhr</ce:surname> </author> <author seq="5"> <ce:initials>T.</ce:initials> <ce:indexed-name>Black T.</ce:indexed-name> <ce:surname>Black</ce:surname> </author> </ref-authors> <ref-sourcetitle>Aust N Z J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2000"/> <ref-volisspag> <voliss volume="34"/> <pagerange first="801" last="808"/> </ref-volisspag> </ref-info> <ref-fulltext>Vaughan K. McConaghy N. Wolf C. Myhr C. Black T. (2000) Community treatment orders: relationship to clinical care, medication compliance, behavioural disturbance and readmission. Aust N Z J Psychiatry 34: 801–808.</ref-fulltext> </reference> <reference id="182"> <ref-info> <ref-title> <ref-titletext>Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness (2009) The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84998039936</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>D.I.</ce:initials> <ce:indexed-name>Velligan D.I.</ce:indexed-name> <ce:surname>Velligan</ce:surname> </author> <author seq="2"> <ce:initials>P.J.</ce:initials> <ce:indexed-name>Weiden P.J.</ce:indexed-name> <ce:surname>Weiden</ce:surname> </author> <author seq="3"> <ce:initials>M.</ce:initials> <ce:indexed-name>Sajatovic M.</ce:indexed-name> <ce:surname>Sajatovic</ce:surname> </author> <author seq="4"> <ce:initials>J.</ce:initials> <ce:indexed-name>Scott J.</ce:indexed-name> <ce:surname>Scott</ce:surname> </author> <author seq="5"> <ce:initials>D.</ce:initials> <ce:indexed-name>Carpenter D.</ce:indexed-name> <ce:surname>Carpenter</ce:surname> </author> <author seq="6"> <ce:initials>R.</ce:initials> <ce:indexed-name>Ross R.</ce:indexed-name> <ce:surname>Ross</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-volisspag> <voliss volume="70"/> <pagerange first="1" last="46"/> </ref-volisspag> </ref-info> <ref-fulltext>Velligan D.I. Weiden P.J. Sajatovic M. Scott J. Carpenter D. Ross R., Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness et al. (2009) The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 70: 1–46</ref-fulltext> </reference> <reference id="183"> <ref-info> <ref-title> <ref-titletext>Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">77957556520</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>D.</ce:initials> <ce:indexed-name>Velligan D.</ce:indexed-name> <ce:surname>Velligan</ce:surname> </author> <author seq="2"> <ce:initials>P.</ce:initials> <ce:indexed-name>Weiden P.</ce:indexed-name> <ce:surname>Weiden</ce:surname> </author> <author seq="3"> <ce:initials>M.</ce:initials> <ce:indexed-name>Sajatovic M.</ce:indexed-name> <ce:surname>Sajatovic</ce:surname> </author> <author seq="4"> <ce:initials>J.</ce:initials> <ce:indexed-name>Scott J.</ce:indexed-name> <ce:surname>Scott</ce:surname> </author> <author seq="5"> <ce:initials>D.</ce:initials> <ce:indexed-name>Carpenter D.</ce:indexed-name> <ce:surname>Carpenter</ce:surname> </author> <author seq="6"> <ce:initials>R.</ce:initials> <ce:indexed-name>Ross R.</ce:indexed-name> <ce:surname>Ross</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>J Psychiatr Pract</ref-sourcetitle> <ref-publicationyear first="2010"/> <ref-volisspag> <voliss volume="16"/> <pagerange first="306" last="324"/> </ref-volisspag> </ref-info> <ref-fulltext>Velligan D. Weiden P. Sajatovic M. Scott J. Carpenter D. Ross R. et al. (2010) Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract 16: 306–324.</ref-fulltext> </reference> <reference id="184"> <ref-info> <ref-title> <ref-titletext>Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0030023357</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>C.</ce:initials> <ce:indexed-name>Verghese C.</ce:indexed-name> <ce:surname>Verghese</ce:surname> </author> <author seq="2"> <ce:initials>J.</ce:initials> <ce:indexed-name>DeLeon J.</ce:indexed-name> <ce:surname>DeLeon</ce:surname> </author> <author seq="3"> <ce:initials>C.</ce:initials> <ce:indexed-name>Nair C.</ce:indexed-name> <ce:surname>Nair</ce:surname> </author> <author seq="4"> <ce:initials>G.</ce:initials> <ce:indexed-name>Simpson G.</ce:indexed-name> <ce:surname>Simpson</ce:surname> </author> </ref-authors> <ref-sourcetitle>Biol Psychiatry</ref-sourcetitle> <ref-publicationyear first="1996"/> <ref-volisspag> <voliss volume="39"/> <pagerange first="135" last="138"/> </ref-volisspag> </ref-info> <ref-fulltext>Verghese C. DeLeon J. Nair C. Simpson G. (1996) Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics. Biol Psychiatry 39: 135–138.</ref-fulltext> </reference> <reference id="185"> <ref-info> <ref-title> <ref-titletext>Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84906087635</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>A.</ce:initials> <ce:indexed-name>Viala A.</ce:indexed-name> <ce:surname>Viala</ce:surname> </author> <author seq="2"> <ce:initials>F.</ce:initials> <ce:indexed-name>Cornic F.</ce:indexed-name> <ce:surname>Cornic</ce:surname> </author> <author seq="3"> <ce:initials>M.</ce:initials> <ce:indexed-name>Vacheron M.</ce:indexed-name> <ce:surname>Vacheron</ce:surname> </author> </ref-authors> <ref-sourcetitle>Schizophr Res Treatment</ref-sourcetitle> <ref-publicationyear first="2012"/> <ref-volisspag> <voliss volume="2012"/> <pagerange first="368687"/> </ref-volisspag> </ref-info> <ref-fulltext>Viala A. Cornic F. Vacheron M. (2012) Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia. Schizophr Res Treatment 2012: 368687.</ref-fulltext> </reference> <reference id="186"> <ref-info> <ref-title> <ref-titletext>Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0021243365</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>A.</ce:initials> <ce:indexed-name>Viala A.</ce:indexed-name> <ce:surname>Viala</ce:surname> </author> <author seq="2"> <ce:initials>N.</ce:initials> <ce:indexed-name>Hou N.</ce:indexed-name> <ce:surname>Hou</ce:surname> </author> <author seq="3"> <ce:initials>B.</ce:initials> <ce:indexed-name>Ba B.</ce:indexed-name> <ce:surname>Ba</ce:surname> </author> <author seq="4"> <ce:initials>A.</ce:initials> <ce:indexed-name>Durand A.</ce:indexed-name> <ce:surname>Durand</ce:surname> </author> <author seq="5"> <ce:initials>H.</ce:initials> <ce:indexed-name>Dufour H.</ce:indexed-name> <ce:surname>Dufour</ce:surname> </author> <author seq="6"> <ce:initials>N.</ce:initials> <ce:indexed-name>D'Agostino N.</ce:indexed-name> <ce:surname>D’Agostino</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Psychopharmacology</ref-sourcetitle> <ref-publicationyear first="1984"/> <ref-volisspag> <voliss volume="83"/> <pagerange first="147" last="150"/> </ref-volisspag> </ref-info> <ref-fulltext>Viala A. Hou N. Ba B. Durand A. Dufour H. D’Agostino N. et al. (1984) Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters. Psychopharmacology 83: 147–150.</ref-fulltext> </reference> <reference id="187"> <ref-info> <ref-title> <ref-titletext>Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0031013410</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>A.</ce:initials> <ce:indexed-name>Viguera A.</ce:indexed-name> <ce:surname>Viguera</ce:surname> </author> <author seq="2"> <ce:initials>R.</ce:initials> <ce:indexed-name>Baldessarini R.</ce:indexed-name> <ce:surname>Baldessarini</ce:surname> </author> <author seq="3"> <ce:initials>J.</ce:initials> <ce:indexed-name>Hegarty J.</ce:indexed-name> <ce:surname>Hegarty</ce:surname> </author> <author seq="4"> <ce:initials>D.</ce:initials> <ce:indexed-name>van Kammen D.</ce:indexed-name> <ce:surname>van Kammen</ce:surname> </author> <author seq="5"> <ce:initials>M.</ce:initials> <ce:indexed-name>Tohen M.</ce:indexed-name> <ce:surname>Tohen</ce:surname> </author> </ref-authors> <ref-sourcetitle>Arch Gen Psychiatry</ref-sourcetitle> <ref-publicationyear first="1997"/> <ref-volisspag> <voliss volume="54"/> <pagerange first="49" last="55"/> </ref-volisspag> </ref-info> <ref-fulltext>Viguera A. Baldessarini R. Hegarty J. van Kammen D. Tohen M. (1997) Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 54: 49–55.</ref-fulltext> </reference> <reference id="188"> <ref-info> <ref-title> <ref-titletext>Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">71249115194</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>L.</ce:initials> <ce:indexed-name>Waddell L.</ce:indexed-name> <ce:surname>Waddell</ce:surname> </author> <author seq="2"> <ce:initials>M.</ce:initials> <ce:indexed-name>Taylor M.</ce:indexed-name> <ce:surname>Taylor</ce:surname> </author> </ref-authors> <ref-sourcetitle>Br J Psychiatry Suppl</ref-sourcetitle> <ref-publicationyear first="2009"/> <ref-volisspag> <voliss volume="195"/> <pagerange first="s43" last="s50"/> </ref-volisspag> </ref-info> <ref-fulltext>Waddell L. Taylor M. (2009) Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br J Psychiatry Suppl 195: s43–s50.</ref-fulltext> </reference> <reference id="189"> <ref-info> <ref-title> <ref-titletext>Systematic review of patient and nurse attitudes to depot antipsychotic medication</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">0034777239</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>J.</ce:initials> <ce:indexed-name>Walburn J.</ce:indexed-name> <ce:surname>Walburn</ce:surname> </author> <author seq="2"> <ce:initials>R.</ce:initials> <ce:indexed-name>Gray R.</ce:indexed-name> <ce:surname>Gray</ce:surname> </author> <author seq="3"> <ce:initials>K.</ce:initials> <ce:indexed-name>Gournay K.</ce:indexed-name> <ce:surname>Gournay</ce:surname> </author> <author seq="4"> <ce:initials>S.</ce:initials> <ce:indexed-name>Quraishi S.</ce:indexed-name> <ce:surname>Quraishi</ce:surname> </author> <author seq="5"> <ce:initials>A.</ce:initials> <ce:indexed-name>David A.</ce:indexed-name> <ce:surname>David</ce:surname> </author> </ref-authors> <ref-sourcetitle>Br J Psychiatry</ref-sourcetitle> <ref-publicationyear first="2001"/> <ref-volisspag> <voliss volume="179"/> <pagerange first="300" last="307"/> </ref-volisspag> </ref-info> <ref-fulltext>Walburn J. Gray R. Gournay K. Quraishi S. David A. (2001) Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 179: 300–307.</ref-fulltext> </reference> <reference id="190"> <ref-info> <ref-title> <ref-titletext>Design of a long-term antipsychotic in situ forming implant and its release control method and mechanism</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84862826623</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>L.</ce:initials> <ce:indexed-name>Wang L.</ce:indexed-name> <ce:surname>Wang</ce:surname> </author> <author seq="2"> <ce:initials>A.</ce:initials> <ce:indexed-name>Wang A.</ce:indexed-name> <ce:surname>Wang</ce:surname> </author> <author seq="3"> <ce:initials>X.</ce:initials> <ce:indexed-name>Zhao X.</ce:indexed-name> <ce:surname>Zhao</ce:surname> </author> <author seq="4"> <ce:initials>X.</ce:initials> <ce:indexed-name>Liu X.</ce:indexed-name> <ce:surname>Liu</ce:surname> </author> <author seq="5"> <ce:initials>D.</ce:initials> <ce:indexed-name>Wang D.</ce:indexed-name> <ce:surname>Wang</ce:surname> </author> <author seq="6"> <ce:initials>F.</ce:initials> <ce:indexed-name>Sun F.</ce:indexed-name> <ce:surname>Sun</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>Int J Pharm</ref-sourcetitle> <ref-publicationyear first="2012"/> <ref-volisspag> <voliss volume="427"/> <pagerange first="284" last="292"/> </ref-volisspag> </ref-info> <ref-fulltext>Wang L. Wang A. Zhao X. Liu X. Wang D. Sun F. et al. (2012) Design of a long-term antipsychotic in situ forming implant and its release control method and mechanism. Int J Pharm 427: 284–292.</ref-fulltext> </reference> <reference id="191"> <ref-info> <ref-title> <ref-titletext>Understanding and addressing adherence issues in schizophrenia: from theory to practice</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">38349103390</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>P.</ce:initials> <ce:indexed-name>Weiden P.</ce:indexed-name> <ce:surname>Weiden</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="2007"/> <ref-volisspag> <voliss volume="68"/> <pagerange first="14" last="19"/> </ref-volisspag> </ref-info> <ref-fulltext>Weiden P. (2007) Understanding and addressing adherence issues in schizophrenia: from theory to practice. J Clin Psychiatry 68: 14–19.</ref-fulltext> </reference> <reference id="192"> <ref-info> <ref-title> <ref-titletext>The economic burden of schizophrenia in the United States in 2002</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">26644472427</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>E.</ce:initials> <ce:indexed-name>Wu E.</ce:indexed-name> <ce:surname>Wu</ce:surname> </author> <author seq="2"> <ce:initials>H.</ce:initials> <ce:indexed-name>Birnbaum H.</ce:indexed-name> <ce:surname>Birnbaum</ce:surname> </author> <author seq="3"> <ce:initials>L.</ce:initials> <ce:indexed-name>Shi L.</ce:indexed-name> <ce:surname>Shi</ce:surname> </author> <author seq="4"> <ce:initials>D.</ce:initials> <ce:indexed-name>Ball D.</ce:indexed-name> <ce:surname>Ball</ce:surname> </author> <author seq="5"> <ce:initials>R.</ce:initials> <ce:indexed-name>Kessler R.</ce:indexed-name> <ce:surname>Kessler</ce:surname> </author> <author seq="6"> <ce:initials>M.</ce:initials> <ce:indexed-name>Moulis M.</ce:indexed-name> <ce:surname>Moulis</ce:surname> </author> <et-al/> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="2005"/> <ref-volisspag> <voliss volume="66"/> <pagerange first="1122" last="1129"/> </ref-volisspag> </ref-info> <ref-fulltext>Wu E. Birnbaum H. Shi L. Ball D. Kessler R. Moulis M. et al. (2005) The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 66: 1122–1129.</ref-fulltext> </reference> <reference id="193"> <ref-info> <ref-title> <ref-titletext>Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">34249715417</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>L.</ce:initials> <ce:indexed-name>Wunderink L.</ce:indexed-name> <ce:surname>Wunderink</ce:surname> </author> <author seq="2"> <ce:initials>F.</ce:initials> <ce:indexed-name>Nienhuis F.</ce:indexed-name> <ce:surname>Nienhuis</ce:surname> </author> <author seq="3"> <ce:initials>S.</ce:initials> <ce:indexed-name>Sytema S.</ce:indexed-name> <ce:surname>Sytema</ce:surname> </author> <author seq="4"> <ce:initials>C.</ce:initials> <ce:indexed-name>Slooff C.</ce:indexed-name> <ce:surname>Slooff</ce:surname> </author> <author seq="5"> <ce:initials>R.</ce:initials> <ce:indexed-name>Knegtering R.</ce:indexed-name> <ce:surname>Knegtering</ce:surname> </author> <author seq="6"> <ce:initials>D.</ce:initials> <ce:indexed-name>Wiersma D.</ce:indexed-name> <ce:surname>Wiersma</ce:surname> </author> </ref-authors> <ref-sourcetitle>J Clin Psychiatry</ref-sourcetitle> <ref-publicationyear first="2007"/> <ref-volisspag> <voliss volume="68"/> <pagerange first="654" last="661"/> </ref-volisspag> </ref-info> <ref-fulltext>Wunderink L. Nienhuis F. Sytema S. Slooff C. Knegtering R. Wiersma D. (2007) Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 68: 654–661.</ref-fulltext> </reference> <reference id="194"> <ref-info> <ref-title> <ref-titletext>Health resource utilization associated with switching to risperidone long-acting injection</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">33745092184</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>C.</ce:initials> <ce:indexed-name>Young C.</ce:indexed-name> <ce:surname>Young</ce:surname> </author> <author seq="2"> <ce:initials>D.</ce:initials> <ce:indexed-name>Taylor D.</ce:indexed-name> <ce:surname>Taylor</ce:surname> </author> </ref-authors> <ref-sourcetitle>Acta Psychiatr Scand</ref-sourcetitle> <ref-publicationyear first="2006"/> <ref-volisspag> <voliss volume="114"/> <pagerange first="14" last="20"/> </ref-volisspag> </ref-info> <ref-fulltext>Young C. Taylor D. (2006) Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand 114: 14–20.</ref-fulltext> </reference> <reference id="195"> <ref-info> <ref-title> <ref-titletext>Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">84879947404</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>S.</ce:initials> <ce:indexed-name>Zhornitsky S.</ce:indexed-name> <ce:surname>Zhornitsky</ce:surname> </author> <author seq="2"> <ce:initials>E.</ce:initials> <ce:indexed-name>Stip E.</ce:indexed-name> <ce:surname>Stip</ce:surname> </author> </ref-authors> <ref-sourcetitle>Schizophr Res Treatment</ref-sourcetitle> <ref-publicationyear first="2012"/> <ref-volisspag> <voliss volume="2012"/> <pagerange first="1" last="12"/> </ref-volisspag> </ref-info> <ref-fulltext>Zhornitsky S. Stip E. (2012) Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review. Schizophr Res Treatment 2012: 1–12.</ref-fulltext> </reference> <reference id="196"> <ref-info> <ref-title> <ref-titletext>Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia</ref-titletext> </ref-title> <refd-itemidlist> <itemid idtype="SGR">45749101343</itemid> </refd-itemidlist> <ref-authors> <author seq="1"> <ce:initials>B.</ce:initials> <ce:indexed-name>Zhu B.</ce:indexed-name> <ce:surname>Zhu</ce:surname> </author> <author seq="2"> <ce:initials>H.</ce:initials> <ce:indexed-name>Ascher-Svanum H.</ce:indexed-name> <ce:surname>Ascher-Svanum</ce:surname> </author> <author seq="3"> <ce:initials>L.</ce:initials> <ce:indexed-name>Shi L.</ce:indexed-name> <ce:surname>Shi</ce:surname> </author> <author seq="4"> <ce:initials>D.</ce:initials> <ce:indexed-name>Faries D.</ce:indexed-name> <ce:surname>Faries</ce:surname> </author> <author seq="5"> <ce:initials>W.</ce:initials> <ce:indexed-name>Montgomery W.</ce:indexed-name> <ce:surname>Montgomery</ce:surname> </author> <author seq="6"> <ce:initials>S.</ce:initials> <ce:indexed-name>Marder S.</ce:indexed-name> <ce:surname>Marder</ce:surname> </author> </ref-authors> <ref-sourcetitle>Psychiatr Serv</ref-sourcetitle> <ref-publicationyear first="2008"/> <ref-volisspag> <voliss volume="59"/> <pagerange first="315" last="317"/> </ref-volisspag> </ref-info> <ref-fulltext>Zhu B. Ascher-Svanum H. Shi L. Faries D. Montgomery W. Marder S. (2008) Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr Serv 59: 315–317.</ref-fulltext> </reference> </bibliography>
      </tail>
    </bibrecord>
  </item>
</abstracts-retrieval-response>
